10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

OR

[    ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to _____

Commission File Number: 001-32433

PRESTIGE BRANDS HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)

Delaware	20-1297589
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

660 White Plains Road

Tarrytown, New York 10591

(Address of principal executive offices) (Zip Code)

(914) 524-6800

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x      No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  

Large accelerated filer x		Accelerated filer o
Non-accelerated filer o	(Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

As of October 27, 2014, there were 52,172,727 shares of common stock outstanding.

Prestige Brands Holdings, Inc.

Form 10-Q

Index

PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Statements of Income and Comprehensive Income for the three and six months ended September 30, 2014 and 2013 (unaudited)	2
	Consolidated Balance Sheets as of September 30, 2014 (unaudited) and March 31, 2014	3
	Consolidated Statements of Cash Flows for the six months ended September 30, 2014 and 2013 (unaudited)	4
	Notes to Consolidated Financial Statements (unaudited)	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	37
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	61
Item 4.	Controls and Procedures	61
PART II.	OTHER INFORMATION
Item 1A.	Risk Factors	61
Item 6.	Exhibits	67
	Signatures	68

Trademarks and Trade Names

Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Brands Holdings, Inc. or its subsidiaries, as the case may be.  We have italicized our trademarks or trade names when they appear in this Quarterly Report on Form 10-Q.

- 1-

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Prestige Brands Holdings, Inc.

Consolidated Statements of Income and Comprehensive Income

(Unaudited)

	Three Months Ended September 30,						Six Months Ended September 30,
(In thousands, except per share data)	2014			2013			2014			2013
Revenues
Net sales	$	180,005		$	165,507		$	324,546		$	307,149
Other revenues	1,264			1,438			2,425			2,308
Total revenues	181,269			166,945			326,971			309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	78,727			73,723			142,563			133,211
Gross profit	102,542			93,222			184,408			176,246
Operating Expenses
Advertising and promotion	25,044			24,547			44,140			43,228
General and administrative	27,128			11,619			44,134			23,253
Depreciation and amortization	3,852			3,294			6,813			6,562
Total operating expenses	56,024			39,460			95,087			73,043
Operating income	46,518			53,762			89,321			103,203
Other (income) expense
Interest income	(15		)	(25		)	(47		)	(28		)
Interest expense	18,208			16,464			32,893			32,372
Total other expense	18,193			16,439			32,846			32,344
Income before income taxes	28,325			37,323			56,475			70,859
Provision for income taxes	11,862			4,531			23,280			17,375
Net income	$	16,463		$	32,792		$	33,195		$	53,484
Earnings per share:
Basic	$	0.32		$	0.64		$	0.64		$	1.04
Diluted	$	0.31		$	0.63		$	0.63		$	1.03
Weighted average shares outstanding:
Basic	52,088			51,463			52,023			51,343
Diluted	52,594			52,219			52,564			52,130
Comprehensive income, net of tax:
Currency translation adjustments	(10,830		)	1,122			(8,104		)	1,123
Total other comprehensive (loss) income	(10,830		)	1,122			(8,104		)	1,123
Comprehensive income	$	5,633		$	33,914		$	25,091		$	54,607

See accompanying notes.

- 2-

Prestige Brands Holdings, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands)	September 30, 2014			March 31, 2014
Assets
Current assets
Cash and cash equivalents	$	21,748		$	28,331
Accounts receivable, net	98,644			65,050
Inventories	82,875			65,586
Deferred income tax assets	9,171			6,544
Prepaid expenses and other current assets	9,935			11,674
Total current assets	222,373			177,185
Property and equipment, net	12,420			9,597
Goodwill	293,993			190,911
Intangible assets, net	2,163,947			1,394,817
Other long-term assets	32,937			23,153
Total Assets	$	2,725,670		$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Current portion of long term debt	$	7,200		$	—
Accounts payable	58,538			48,286
Accrued interest payable	12,086			9,626
Other accrued liabilities	34,086			26,446
Total current liabilities	111,910			84,358
Long-term debt
Principal amount	1,691,400			937,500
Less unamortized discount	(6,289		)	(3,086		)
Long-term debt, net of unamortized discount	1,685,111			934,414
Deferred income tax liabilities	334,297			213,204
Other long-term liabilities	313			327
Total Liabilities	2,131,631			1,232,303
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None	—			—
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 52,426 shares at September 30, 2014 and 52,021 shares at March 31, 2014	524			520
Additional paid-in capital	421,574			414,387
Treasury stock, at cost - 254 shares at September 30, 2014 and 206 shares at March 31, 2014	(3,034		)	(1,431		)
Accumulated other comprehensive (loss) income, net of tax	(7,365		)	739
Retained earnings	182,340			149,145
Total Stockholders' Equity	594,039			563,360
Total Liabilities and Stockholders' Equity	$	2,725,670		$	1,795,663

 See accompanying notes.

- 3-

Prestige Brands Holdings, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended September 30,
(In thousands)	2014			2013
Operating Activities
Net income	$	33,195		$	53,484
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,815			6,562
Deferred income taxes	11,496			4,355
Amortization of deferred financing costs	2,398			1,975
Stock-based compensation costs	3,403			2,487
Amortization of debt discount	687			798
Loss (Gain) on sale or disposal of property and equipment	56			(3		)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(8,363		)	(5,712		)
Inventories	7,264			821
Prepaid expenses and other current assets	3,114			2,619
Accounts payable	(5,647		)	(1,125		)
Accrued liabilities	2,640			(10,663		)
Net cash provided by operating activities	57,058			55,598
Investing Activities
Purchases of property and equipment	(1,380		)	(2,319		)
Proceeds from the sale of property and equipment	—			3
Proceeds from sale of business	18,500			—
Acquisition of Insight Pharmaceuticals, less cash acquired	(749,666		)	—
Acquisition of the Hydralyte brand	(77,991		)	—
Acquisition of Care Pharmaceuticals, less cash acquired	—			(55,215		)
Net cash used in investing activities	(810,537		)	(57,531		)
Financing Activities
Term loan borrowings	720,000			—
Term loan repayments	(25,000		)	(7,500		)
Repayments under revolving credit agreement	(58,500		)	(35,500		)
Borrowings under revolving credit agreement	124,600			50,000
Payment of deferred financing costs	(16,072		)	(275		)
Proceeds from exercise of stock options	2,757			5,143
Proceeds from restricted stock exercises	57			—
Excess tax benefits from share-based awards	1,030			1,350
Fair value of shares surrendered as payment of tax withholding	(1,660		)	(278		)
Net cash provided by financing activities	747,212			12,940
Effects of exchange rate changes on cash and cash equivalents	(316		)	156
(Decrease) Increase in cash and cash equivalents	(6,583		)	11,163
Cash and cash equivalents - beginning of period	28,331			15,670
Cash and cash equivalents - end of period	$	21,748		$	26,833
Interest paid	$	27,349		$	29,516
Income taxes paid	$	4,716		$	8,468

See accompanying notes.

- 4-

Prestige Brands Holdings, Inc.

Notes to Consolidated Financial Statements (unaudited)

1. Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada), and in Australia and certain other international markets.  Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements.

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31^st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three and six months ended September 30, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.

Revision

We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2014 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

- 5-

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions,

- 6-

as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $9.4 million and $17.1 million for the three and six months ended September 30, 2014, respectively, and $9.1 million and $15.7 million for the three and six months ended September 30, 2013, respectively.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.  

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In August 2014, the FASB issued Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods

- 7-

and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

2. Acquisitions

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed its previously announced acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extends the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading brand in OTC yeast infection treatment. The acquisition also adds brands to the Company's cough/cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.

- 8-

(In thousands)	September 3, 2014
Cash acquired	$	3,507
Accounts receivable	25,784
Inventories	23,559
Deferred income tax assets - current	860
Prepaids and other current assets	1,407
Property, plant and equipment	2,308
Goodwill	103,255
Intangible Assets	724,374
Total assets acquired	885,054
Accounts payable	16,079
Accrued expenses	8,003
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	131,881
Total purchase price	$	753,173

Based on this analysis, we allocated $599.6 million to non-amortizable intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 16.1 years.

We also recorded goodwill of $103.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. Revenues of the acquired Insight operations for the three and six months ended September 30, 2014 were $12.7 million. Net loss for the three and six months ended September 30, 2014 was $2.0 million. On September 3, 2014 we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.

(In thousands, except per share data)	Six Months Ended September 30, 2014
Revenues	$	393,140
Net income	$	37,957
Earnings per share:
Basic	$	0.73
Diluted	$	0.72

- 9-

(In thousands, except per share data)	Six Months Ended September 30, 2013
Revenues	$	389,490
Net income	$	53,511
Earnings per share:
Basic	$	1.04
Diluted	$	1.03

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on the balance sheet and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.

(In thousands)	April 30, 2014
Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041
Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also includes a line of brands for children including, Little Allergies, Little Eyes,

- 10-

and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio and are included in our International OTC Healthcare segment.

The Care Pharma acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.

(In thousands)	July 1, 2013
Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income taxes	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386
Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625
Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 13.1 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

3. Accounts Receivable

Accounts receivable consist of the following:

(In thousands)	September 30, 2014			March 31, 2014
Components of Accounts Receivable
Trade accounts receivable	$	107,943		$	73,632
Other receivables	2,176			1,360
	110,119			74,992
Less allowances for discounts, returns and uncollectible accounts	(11,475		)	(9,942		)
Accounts receivable, net	$	98,644		$	65,050

- 11-

4. Inventories

Inventories consist of the following:

(In thousands)	September 30, 2014		March 31, 2014
Components of Inventories
Packaging and raw materials	$	3,929	$	3,099
Work in process	3,456		—
Finished goods	75,490		62,487
Inventories	$	82,875	$	65,586

Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $4.8 million and $1.1 million at September 30, 2014 and March 31, 2014, respectively, related to obsolete and slow-moving inventory. Following the acquisition of the Hydralyte brand on April 30, 2014, we manufacture certain Hydralyte products in Australia.

5. Property and Equipment

Property and equipment consist of the following:

(In thousands)	September 30, 2014			March 31, 2014
Components of Property and Equipment
Machinery	$	4,245		$	1,927
Computer equipment and software	10,183			8,923
Furniture and fixtures	2,703			1,858
Leasehold improvements	4,823			4,734
	21,954			17,442
Accumulated depreciation	(9,534		)	(7,845		)
Property and equipment, net	$	12,420		$	9,597

We recorded depreciation expense of $0.9 million and $0.5 million for the three months ended September 30, 2014 and September 30, 2013, respectively, and $1.6 million and $1.1 million for the six months ended September 30, 2014 and September 30, 2013, respectively.

6. Goodwill

As described in Note 18 to these Consolidated Financial Statements, we have realigned our reportable segments with how we currently operate, review and evaluate the results of our business. A reconciliation of the activity affecting goodwill by reportable segment is as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare			Household Cleaning		Consolidated
Balance — March 31, 2014	$	160,157	$	23,365		$	7,389	$	190,911
Additions	103,254		1,224			—		104,478
Effects of foreign currency exchange rates	—		(1,396		)	—		(1,396		)
Balance — September 30, 2014	$	263,411	$	23,193		$	7,389	$	293,993

As discussed in Note 2, we completed two acquisitions during the six months ended September 30, 2014. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.3 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.

- 12-

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.

On an annual basis, during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of the values assigned to goodwill and tests for impairment.

At March 31, 2014, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2014. As of September 30, 2014, there have been no triggering events that would indicate potential impairment of goodwill.

The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value that is utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2014, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

7. Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:

(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Totals
Gross Carrying Amounts
Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
Additions	673,180			124,774			797,954
Reductions	—			(17,674		)	(17,674		)
Effects of foreign currency exchange rates	(6,000		)	(95		)	(6,095		)
Balance — September 30, 2014	1,941,058			311,745			2,252,803
Accumulated Amortization
Balance — March 31, 2014	—			83,801			83,801
Additions	—			5,064			5,064
Effects of foreign currency exchange rates	—			(9		)	(9		)
Balance — September 30, 2014	—			88,856			88,856
Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,723,498		$	196,145		$	1,919,643
International OTC Healthcare	97,740			1,449			99,189
Household Cleaning	119,820			25,295			145,115
Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947

As discussed in Note 2, we completed two acquisitions during the six months ended September 30, 2014. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014 we sold one of the brands that we acquired from Insight, for which we allocated $17.7 million to the intangible assets.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the

- 13-

carrying amount.  Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life.  Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.

In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the fourth quarter of fiscal 2014.  We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of September 30, 2014 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the six months ended September 30, 2014.

The weighted average remaining life for finite-lived intangible assets at September 30, 2014 was approximately 14.5 years and the amortization expense for the three and six months ended September 30, 2014 was $2.8 million and $5.1 million, respectively. At September 30, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:

(In thousands)
Year Ending March 31,	Amount
2015 (Remaining six months ending March 31, 2015)	$	7,740
2016	15,554
2017	15,554
2018	15,554
2019	15,554
Thereafter	152,933
	$	222,889

8. Other Accrued Liabilities

Other accrued liabilities consist of the following:

(In thousands)	September 30, 2014		March 31, 2014
Accrued marketing costs	$	16,187	$	11,812
Accrued compensation costs	5,129		6,232
Accrued broker commissions	851		1,019
Income taxes payable	1,186		1,854
Accrued professional fees	2,344		2,002
Deferred rent	1,109		1,258
Accrued production costs	3,364		1,506
Other accrued liabilities	3,916		763
	$	34,086	$	26,446

9. Long-Term Debt

2012 Senior Notes:

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the

- 14-

2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loan"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date.  In addition, Term Loan Amendment No.1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loan") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including but not limited to additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief and (iii) an interest rate on (x) the Term B-1 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin, and (y) the Term B-2 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). Under the Term Loan Amendment No.2, we are required to make quarterly payments each equal to 0.25% of the original principal amount of the Term B-2 Loan, with the balance expected to be due on the seventh anniversary of the closing date. Therefore, we have presented $7.2 million of current portion of long term debt as of September 30, 2014.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%. For the six months ended September 30, 2014, the average interest rate on the 2012 Term Loan was 4.9%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.

On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such

- 15-

borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2014, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 3.7%.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Redemptions and Restrictions:

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At September 30, 2014, we were in compliance with the covenants under our long-term indebtedness.

At September 30, 2014, we had an aggregate of $32.9 million of unamortized debt issuance costs and $6.3 million of unamortized debt discount, the total of which is comprised of $9.4 million related to the 2012 Senior Notes, $6.6 million related to the 2013 Senior Notes, $21.8 million related to the 2012 Term Loan, and $1.4 million related to the 2012 ABL Revolver.

- 16-

During the six months ended September 30, 2014, we borrowed a net amount of $66.1 million against the 2012 ABL Revolver.

Long-term debt consists of the following, as of the dates indicated:

(In thousands, except percentages)	September 30, 2014			March 31, 2014
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	262,500			287,500
2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	720,000			—
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
	1,698,600			937,500
Current portion of long-term debt	7,200			—
	1,691,400			937,500
Less: unamortized discount	(6,289		)	(3,086		)
Long-term debt, net of unamortized discount	$	1,685,111		$	934,414

As of September 30, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:

(In thousands)
Year Ending March 31,	Amount
2015 (remaining six months ending March 31, 2015)	$	3,600
2016	7,200
2017	73,300
2018	7,200
2019	269,700
Thereafter	1,337,600
	$	1,698,600

10. Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

- 17-

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the Term B-1 Loan, Term B-2 Loan, the 2013 Senior Notes, the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At September 30, 2014 and March 31, 2014, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

At September 30, 2014 and March 31, 2014, the carrying value of our 2013 Senior Notes was $400.0 million. The fair value of our 2013 Senior Notes was $377.0 million and $408.5 million at September 30, 2014 and March 31, 2014, respectively.

At September 30, 2014 and March 31, 2014, the carrying value of our 2012 Senior Notes was $250.0 million. The fair value of our 2012 Senior Notes was $266.9 million and $280.6 million at September 30, 2014 and March 31, 2014, respectively.

At September 30, 2014 and March 31, 2014, the carrying value of the Term B-1 Loan was $262.5 million. The fair value of the Term B-1 Loan was $261.2 million and $288.9 million at September 30, 2014 and March 31, 2014, respectively.

At September 30, 2014 the carrying value of the Term B-2 Loan was $720.0 million. The fair value of the Term B-2 Loan was $718.2 million at September 30, 2014. Because the Term B-2 Loan was entered into on September 3, 2014, there were no outstanding loan balances as of March 31, 2014.

At September 30, 2014, the carrying value and fair value of the 2012 ABL Revolver was $66.1 million. There were no outstanding borrowings under the 2012 ABL Revolver at March 31, 2014.

11. Stockholders' Equity

The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends.  No dividends have been declared or paid on the Company's common stock through September 30, 2014.

During the three and six months ended September 30, 2014, we repurchased 13,924 shares and 47,664 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the three and six months ended September 30, 2013, we repurchased zero shares and 10,726 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the six months ended September 30, 2014 and 2013 were at an average price of $33.63 and $25.96, respectively. All of the repurchased shares have been recorded as treasury stock.

12. Accumulated Other Comprehensive (Loss) Income

The table below presents accumulated other comprehensive (loss) income (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.

AOCI consisted of the following at September 30, 2014 and March 31, 2014:

	September 30,			March 31,
(In thousands)	2014			2014
Components of Accumulated Other Comprehensive (Loss) Income
Cumulative translation adjustment	$	(7,365	)	$	739
Total accumulated other comprehensive (loss) income, net of tax	$	(7,365	)	$	739

13. Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding

- 18-

plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:

	Three Months Ended September 30,				Six Months Ended September 30,
(In thousands, except per share data)	2014		2013		2014		2013
Numerator
Net income	$	16,463	$	32,792	$	33,195	$	53,484
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,088		51,463		52,023		51,343
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	506		756		541		787
Denominator for diluted earnings per share	52,594		52,219		52,564		52,130
Earnings per Common Share:
Basic net earnings per share	$	0.32	$	0.64	$	0.64	$	1.04
Diluted net earnings per share	$	0.31	$	0.63	$	0.63	$	1.03

For the three months ended September 30, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

14. Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. On June 19, 2014, the Board of Directors amended the Plan to provide for the grant of an additional 1.8 million shares of the Company's stock, $0.01 par value, pursuant to the Plan, which amendment the Company's stockholders approved on August 5, 2014.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three and six months ended September 30, 2014, pre-tax share-based compensation costs charged against income were $1.5 million and $3.4 million, respectively, and the related income tax benefit recognized was $0.5 million and $1.2 million, respectively. During the three and six months ended September 30, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $2.5 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.7 million, respectively.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets.  The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan.  The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant, unless specified differently on the date of grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

- 19-

On May 12, 2014, the Compensation Committee of our Board of Directors granted 96,638 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 75,638 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 21,000 restricted stock units vest 33.3% per year over three years.

The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the six months ended September 30, 2014 and 2013 was $33.30 and $30.19, respectively.

A summary of the Company's restricted shares granted under the Plan is presented below:

Restricted Shares	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Six months ended September 30, 2013
Vested and nonvested at March 31, 2013	421.3		$	11.01
Granted	120.6		30.19
Vested and issued	(54.7	)	8.11
Forfeited	(3.6	)	13.24
Vested and nonvested at September 30, 2013	483.6		16.11
Vested at September 30, 2013	83.1		9.63
Six months ended September 30, 2014:
Vested and nonvested at March 31, 2014	437.5		$	16.76
Granted	104.4		33.30
Vested and issued	(120.7	)	13.34
Forfeited	(14.4	)	20.78
Vested and nonvested at September 30, 2014	406.8		21.88
Vested at September 30, 2014	76.6		11.62

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted.  Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years.  The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies.  We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors.  Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation.  The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding.  The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option.  On May 12, 2014, the Compensation Committee of our Board of Directors granted stock options to acquire 307,490 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $33.50 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

The weighted-average grant-date fair value of the options granted during the six months ended September 30, 2014 and 2013 was $15.93 and $13.94, respectively.

- 20-

	Six Months Ended September 30,
	2014			2013
Expected volatility	47.3		%	48.0		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	2.2		%	1.3		%

A summary of option activity under the Plan is as follows:

Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Six months ended September 30, 2013:
Outstanding at March 31, 2013	1,386.4		$	10.43
Granted	227.7		29.94
Exercised	(539.4	)	9.54
Forfeited or expired	(8.0	)	13.24
Outstanding at September 30, 2013	1,066.7		15.02		6.5	$	16,110
Exercisable at September 30, 2013	225.5		11.42		7.7	4,216
Six months ended September 30, 2014:
Outstanding at March 31, 2014	994.9		$	15.24
Granted	307.5		33.50
Exercised	(284.4	)	9.70
Forfeited or expired	(32.5	)	25.61
Outstanding at September 30, 2014	985.5		22.19		8.0	$	10,364
Exercisable at September 30, 2014	416.0		14.31		6.8	7,514

The aggregate intrinsic value of options exercised in the six months ended September 30, 2014 was $7.1 million.

At September 30, 2014, there were $7.4 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest.  We expect to recognize such costs over a weighted-average period of 1.0 year.  The total fair value of options and restricted shares vested during the six months ended September 30, 2014 and 2013 was $4.2 million and $3.2 million, respectively.  For the six months ended September 30, 2014 and 2013, cash received from the exercise of stock options was $2.8 million and $5.1 million, respectively, and we realized $1.8 million and $1.7 million, respectively, in tax benefits from the tax deductions resulting from these option exercises. At September 30, 2014, there were 1.2 million shares available for issuance under the Plan.

15. Income Taxes

Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur.  The effective tax rates used in the calculation of income taxes were 41.9% and 12.1% for the three months ended September 30, 2014 and September 30, 2013, respectively. The effective tax rates used in the calculation of income taxes were 41.2% and 24.5%, for the six months ended September 30, 2014 and September 30, 2013, respectively. The increase in the effective tax rate for the three and six months ended September 30, 2014 was primarily due to the impact of certain non-deductible items related to acquisitions and state tax adjustments and a one-time benefit of $9.1 million to adjust our current and deferred tax balances as of September 30, 2013 for lower state income taxes. This benefit was primarily related to a law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only.

At September 30, 2014, wholly-owned subsidiaries of the Company had net operating loss carryforwards of approximately $78.2 million, which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020.  The net

- 21-

operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire.

We had no change in our uncertain tax liability during the six months ended September 30, 2014. Therefore, the balance in our uncertain tax liability was $1.2 million at September 30, 2014 and March 31, 2014. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense.  We did not incur any material interest or penalties related to income taxes in any of the periods presented.

16. Commitments and Contingencies

We are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. We required additional office space as a result of the closing of the acquisition of Insight. Therefore, in the first quarter of fiscal 2015, we amended our existing New York office lease to include an additional 15,470 square feet beginning October 2014 and extended the expiration of the combined lease through September 2020. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases as of September 30, 2014:

(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2015 (Remaining six months ending March 31, 2015)	$	859	$	344	$	1,203
2016	1,612		311		1,923
2017	1,772		77		1,849
2018	1,856		—		1,856
2019	1,864		—		1,864
Thereafter	2,465		—		2,465
	$	10,428	$	732	$	11,160

Rent expense for each of the three months ended September 30, 2014 and 2013 was $0.3 million and $0.5 million, respectively, while rent expense for each of the six months ended September 30, 2014 and 2013 was $0.7 million and $0.8 million, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products.  Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.

- 22-

(In thousands)
Year Ending March 31,	Amount
2015 (Remaining six months ending March 31, 2015)	$	549
2016	1,074
2017	1,044
2018	1,013
2019	982
Thereafter	560
	$	5,222

17. Concentrations of Risk

Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products.  We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores.  During the three and six months ended September 30, 2014, approximately 40.6% and 41.2%, respectively, of our total revenues were derived from our five top selling brands.  During the three and six months ended September 30, 2013, approximately 41.8% and 43.0%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 17.0% and 18.0%, respectively, of our gross revenues for the three and six months ended September 30, 2014, and approximately 19.2% and 20.4%, respectively, of our gross revenues for the three and six months ended September 30, 2013. At September 30, 2014, approximately 21.5% of accounts receivable were owed by the same customer.

We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri.  A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost.  We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels.  As a result, any such disruption could have a material adverse effect on our business, sales and profitability.

At September 30, 2014, we had relationships with 101 third-party manufacturers.  Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 77.4% of gross sales for the six months ended September 30, 2014. At September 30, 2013, we had relationships with 50 third-party manufacturers.  Of those, we had long-term contracts with 22 manufacturers that produced items that accounted for approximately 77.9% of gross sales for the six months ended September 30, 2013. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

18. Business Segments

Beginning April 1, 2014, we began managing and reporting certain of our businesses separately and have therefore realigned our reportable segments to align with how we manage and evaluate the results of our business. These reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. The results of our previously reported OTC Healthcare segment is now separated into two reporting segments, the North American OTC Healthcare segment and the International OTC Healthcare segment, largely to reflect our international expansion due to recent acquisitions. Prior year amounts were reclassified to conform to the current reportable segments discussed above. Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

- 23-

The tables below summarize information about our reportable segments.

	Three Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	138,138		$	17,331	$	25,246	$	180,715
Elimination of intersegment revenues	(710		)	—		—		(710		)
Third-party segment revenues	137,428			17,331		25,246		180,005
Other revenues	150			23		1,091		1,264
Total segment revenues	137,578			17,354		26,337		181,269
Cost of sales	52,185			6,595		19,947		78,727
Gross profit	85,393			10,759		6,390		102,542
Advertising and promotion	21,442			3,035		567		25,044
Contribution margin	$	63,951		$	7,724	$	5,823	77,498
Other operating expenses								30,980
Operating income								46,518
Other expense								18,193
Income before income taxes								28,325
Provision for income taxes								11,862
Net income								$	16,463

	Six Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	249,112		$	31,022	$	45,839	$	325,973
Elimination of intersegment revenues	(1,427		)	—		—		(1,427		)
Third-party segment revenues	247,685			31,022		45,839		324,546
Other revenues	327			58		2,040		2,425
Total segment revenues	248,012			31,080		47,879		326,971
Cost of sales	94,526			11,679		36,358		142,563
Gross profit	153,486			19,401		11,521		184,408
Advertising and promotion	37,794			5,375		971		44,140
Contribution margin	$	115,692		$	14,026	$	10,550	140,268
Other operating expenses								50,947
Operating income								89,321
Other expense								32,846
Income before income taxes								56,475
Provision for income taxes								23,280
Net income								$	33,195

- 24-

	Three Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	132,944		$	9,008	$	24,374	$	166,326
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	132,125			9,008		24,374		165,507
Other revenues	150			7		1,281		1,438
Total segment revenues	132,275			9,015		25,655		166,945
Cost of sales	50,987			4,338		18,398		73,723
Gross profit	81,288			4,677		7,257		93,222
Advertising and promotion	22,547			1,446		554		24,547
Contribution margin	$	58,741		$	3,231	$	6,703	68,675
Other operating expenses								14,913
Operating income								53,762
Other expense								16,439
Income before income taxes								37,323
Provision for income taxes								4,531
Net income								$	32,792

	Six Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	251,880		$	12,422	$	43,666	$	307,968
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	251,061			12,422		43,666		307,149
Other revenues	300			14		1,994		2,308
Total segment revenues	251,361			12,436		45,660		309,457
Cost of sales	94,533			5,803		32,875		133,211
Gross profit	156,828			6,633		12,785		176,246
Advertising and promotion	40,097			1,710		1,421		43,228
Contribution margin	$	116,731		$	4,923	$	11,364	133,018
Other operating expenses								29,815
Operating income								103,203
Other expense								32,344
Income before income taxes								70,859
Provision for income taxes								17,375
Net income								$	53,484

- 25-

The tables below summarize information about our segment revenues from similar product groups.

	Three Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,072	$	792	$	—	$	29,864
Cough & Cold	24,771		5,460		—		30,231
Women's Health	9,119		658		—		9,777
Gastrointestinal	20,896		5,598		—		26,494
Eye & Ear Care	21,405		4,028		—		25,433
Dermatologicals	17,459		687		—		18,146
Oral Care	12,934		127		—		13,061
Other OTC	1,922		4		—		1,926
Household Cleaning	—		—		26,337		26,337
Total segment revenues	$	137,578	$	17,354	$	26,337	$	181,269

	Six Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	54,103	$	1,457	$	—	$	55,560
Cough & Cold	44,814		10,259		—		55,073
Women's Health	9,487		1,176				10,663
Gastrointestinal	41,534		8,096		—		49,630
Eye & Ear Care	42,130		8,670		—		50,800
Dermatologicals	29,720		1,229		—		30,949
Oral Care	23,121		189		—		23,310
Other OTC	3,103		4		—		3,107
Household Cleaning	—		—		47,879		47,879
Total segment revenues	$	248,012	$	31,080	$	47,879	$	326,971

	Three Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,343	$	698	$	—	$	30,041
Cough & Cold	28,695		5,023		—		33,718
Women's Health	501		633		—		1,134
Gastrointestinal	21,695		301		—		21,996
Eye & Ear Care	19,378		1,625		—		21,003
Dermatologicals	17,716		605		—		18,321
Oral Care	13,028		130		—		13,158
Other OTC	1,919		—		—		1,919
Household Cleaning	—		—		25,655		25,655
Total segment revenues	$	132,275	$	9,015	$	25,655	$	166,945

- 26-

	Six Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	57,479	$	727	$	—	$	58,206
Cough & Cold	49,193		6,006		—		55,199
Women's Health	988		633		—		1,621
Gastrointestinal	43,453		312		—		43,765
Eye & Ear Care	39,710		3,885		—		43,595
Dermatologicals	32,347		696		—		33,043
Oral Care	24,114		177		—		24,291
Other OTC	4,077		—		—		4,077
Household Cleaning	—		—		45,660		45,660
Total segment revenues	$	251,361	$	12,436	$	45,660	$	309,457

During the three months ended September 30, 2014 and September 30, 2013, approximately 82.7% and 86.9%, respectively of our total segment revenues were from customers in the United States. During the six months ended September 30, 2014 and September 30, 2013, approximately 83.5% and 87.8%, respectively of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended September 30, 2014, our Canada and Australia sales accounted for approximately 7.4% and 8.1%, respectively, of our total segment revenues, while during the three months ended September 30, 2013, approximately 7.2% of our total segment revenues was attributable to sales to Canada. During the six months ended September 30, 2014, our Canada and Australia sales accounted for approximately 6.6% and 7.6%, respectively, of our total segment revenues, while during the six months ended September 30, 2013, approximately 7.6% of our total segment revenues was attributable to sales to Canada.

At September 30, 2014, approximately 95.0% of our consolidated goodwill and intangible assets were located in the United States and approximately 5.0% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	23,193	$	7,389	$	293,993
Intangible assets
Indefinite-lived	1,723,498		97,740		119,820		1,941,058
Finite-lived	196,145		1,449		25,295		222,889
Intangible assets, net	1,919,643		99,189		145,115		2,163,947
Total	$	2,183,054	$	122,382	$	152,504	$	2,457,940

- 27-

19. Condensed Consolidating Financial Statements

As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of September 30, 2014 and March 31, 2014, Condensed Consolidating Statements of Income and Comprehensive Income for the three and six months ended September 30, 2014 and 2013, and Condensed Consolidating Statements of Cash Flows for the six months ended September 30, 2014 and 2013. Such consolidating information includes separate columns for:

a)  Prestige Brands Holdings, Inc., the parent,

b)  Prestige Brands, Inc., the issuer or the borrower,

c)  Combined Subsidiary Guarantors,

d)  Combined Non-Guarantor Subsidiaries, and

e)  Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.

In the third quarter of fiscal 2014, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the second quarter of fiscal 2014. This resulted in an understatement of equity in earnings of subsidiaries for Prestige Brands, Inc. of $48.1 million, an overstatement of $0.6 million for Prestige Brands Holdings, Inc. and a net understatement of equity in earnings of subsidiaries for the eliminations of $47.5 million for each of the three and six month periods ended September 30, 2013. These items also resulted in corresponding adjustments to the investments in subsidiaries on the balance sheet as of September 30, 2013 and adjustments to net income (loss) and equity in income of subsidiaries in the statement of cash flows, although net cash provided by operating activities for the six months ended September 30, 2013 remained unchanged. Revisions were also made to increase the cumulative translation adjustment of the Issuer and subsidiary guarantors by approximately $1 million each, with corresponding adjustments to the investment in subsidiaries and stockholders' equity balances.

The Company assessed the materiality of these items on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the revisions were not material to the consolidated financial statements. The Company disclosed the impact of the revisions on previously reported amounts and accordingly revised the Condensed Consolidating Financial Statements relating to the second quarter of fiscal 2014. There were no changes to any of the Company's Consolidated Financial Statements.

- 28-

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	27,167		$	138,336		$	15,212		$	(710	)	$	180,005
Other revenues	—			95			1,241			436			(508		)	1,264
Total revenues	—			27,262			139,577			15,648			(1,218		)	181,269
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,426			64,812			5,767			(2,278		)	78,727
Gross profit	—			16,836			74,765			9,881			1,060			102,542
Operating Expenses
Advertising and promotion	—			2,699			19,311			3,034			—			25,044
General and administrative	1,109			3,441			20,329			2,249			—			27,128
Depreciation and amortization	870			145			2,729			108			—			3,852
Total operating expenses	1,979			6,285			42,369			5,391			—			56,024
Operating income (loss)	(1,979		)	10,551			32,396			4,490			1,060			46,518
Other (income) expense
Interest income	(12,245		)	(16,719		)	(1,760		)	(11		)	30,720			(15		)
Interest expense	8,629			18,208			20,333			1,758			(30,720		)	18,208
Equity in (income) loss of subsidiaries	(17,577		)	(9,825		)	(1,870		)	—			29,272			—
Total other (income) expense	(21,193		)	(8,336		)	16,703			1,747			29,272			18,193
Income before income taxes	19,214			18,887			15,693			2,743			(28,212		)	28,325
Provision for income taxes	2,751			3,262			4,976			873			—			11,862
Net income (loss)	$	16,463		$	15,625		$	10,717		$	1,870		$	(28,212	)	$	16,463
Comprehensive income, net of tax:
Currency translation adjustments	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
Total other comprehensive (loss) income	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
Comprehensive income (loss)	$	5,633		$	4,795		$	(113	)	$	(8,960	)	$	4,278		$	5,633

- 29-

Condensed Consolidating Statements of Income and Comprehensive Income

Six Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	52,577		$	247,234		$	26,163		$	(1,428	)	$	324,546
Other revenues	—			225			2,340			838			(978		)	2,425
Total revenues	—			52,802			249,574			27,001			(2,406		)	326,971
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			19,874			115,327			9,790			(2,428		)	142,563
Gross profit	—			32,928			134,247			17,211			22			184,408
Operating Expenses
Advertising and promotion	—			5,388			33,377			5,375			—			44,140
General and administrative	2,254			5,914			29,319			6,647			—			44,134
Depreciation and amortization	1,512			290			4,818			193			—			6,813
Total operating expenses	3,766			11,592			67,514			12,215			—			95,087
Operating income (loss)	(3,766		)	21,336			66,733			4,996			22			89,321
Other (income) expense
Interest income	(24,378		)	(30,944		)	(2,522		)	(40		)	57,837			(47		)
Interest expense	17,177			32,893			38,138			2,522			(57,837		)	32,893
Equity in (income) loss of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Total other (income) expense	(40,457		)	(18,774		)	34,705			2,482			54,890			32,846
Income before income taxes	36,691			40,110			32,028			2,514			(54,868		)	56,475
Provision (benefit) for income taxes	3,496			6,979			11,202			1,603			—			23,280
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Comprehensive income, net of tax:
Currency translation adjustments	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Total other comprehensive (loss) income	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Comprehensive income (loss)	$	25,091		$	25,027		$	12,722		$	(7,193	)	$	(30,556	)	$	25,091

- 30-

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,237		$	132,821		$	7,449		$	—		$	165,507
Other revenues	—			67			1,431			668			(728		)	1,438
Total revenues	—			25,304			134,252			8,117			(728		)	166,945
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
Gross profit	—			15,966			72,739			4,517			—			93,222
Operating Expenses
Advertising and promotion	—			3,594			19,556			1,397			—			24,547
General and administrative	891			1,481			8,358			889			—			11,619
Depreciation and amortization	517			143			2,589			45			—			3,294
Total operating expenses	1,408			5,218			30,503			2,331			—			39,460
Operating income (loss)	(1,408		)	10,748			42,236			2,186			—			53,762
Other (income) expense
Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
Equity in (income) loss of subsidiaries	(30,344		)	(20,599		)	(1,189		)	—			52,132			—
Total other (income) expense	(34,435		)	(18,140		)	16,194			688			52,132			16,439
Income (loss) before income taxes	33,027			28,888			26,042			1,498			(52,132		)	37,323
Provision for income taxes	235			1,064			2,922			310			—			4,531
Net income (loss)	$	32,792		$	27,824		$	23,120		$	1,188		$	(52,132	)	$	32,792
Comprehensive income, net of tax:
Currency translation adjustments	1,122			1,122			1,122			1,122			(3,366		)	1,122
Total other comprehensive income (loss)	1,122			1,122			1,122			1,122			(3,366		)	1,122
Comprehensive income (loss)	$	33,914		$	28,946		$	24,242		$	2,310		$	(55,498	)	$	33,914

- 31-

Condensed Consolidating Statements of Income and Comprehensive Income

Six Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	49,386		$	249,091		$	8,672		$	—		$	307,149
Other revenues	—			135			2,294			1,102			(1,223		)	2,308
Total revenues	—			49,521			251,385			9,774			(1,223		)	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
Gross profit	—			30,725			139,883			5,638			—			176,246
Operating Expenses
Advertising and promotion	—			6,924			34,700			1,604			—			43,228
General and administrative	2,390			3,124			16,815			924			—			23,253
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Total operating expenses	3,424			10,333			56,699			2,587			—			73,043
Operating income (loss)	(3,424		)	20,392			83,184			3,051			—			103,203
Other (income) expense
Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
Equity in (income) loss of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Total other (income) expense	(57,896		)	(31,108		)	33,443			686			87,219			32,344
Income (loss) before income taxes	54,472			51,500			49,741			2,365			(87,219		)	70,859
Provision for income taxes	988			4,151			11,738			498			—			17,375
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Comprehensive income, net of tax:
Currency translation adjustments	1,123			1,123			1,123			1,123			(3,369		)	1,123
Total other comprehensive income (loss)	1,123			1,123			1,123			1,123			(3,369		)	1,123
Comprehensive income (loss)	$	54,607		$	48,472		$	39,126		$	2,990		$	(90,588	)	$	54,607

- 32-

Condensed Consolidating Balance Sheet

September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
Accounts receivable, net	7			14,352			76,165			8,120			—			98,644
Inventories	—			9,666			67,420			6,777			(988		)	82,875
Deferred income tax assets	1,139			823			6,743			466			—			9,171
Prepaid expenses and other current assets	2,841			354			6,023			717			—			9,935
Total current assets	14,452			25,195			161,385			22,329			(988		)	222,373
Property and equipment, net	8,580			90			2,297			1,453			—			12,420
Goodwill	—			66,007			204,794			23,192			—			293,993
Intangible assets, net	—			192,593			1,871,933			99,421			—			2,163,947
Other long-term assets	—			32,937			—			—			—			32,937
Intercompany receivables	1,203,499			2,688,676			599,886			10,045			(4,502,106		)	—
Investment in subsidiary	1,519,129			1,213,732			79,877			—			(2,812,738		)	—
Total Assets	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
Liabilities and Stockholders' Equity
Current liabilities
Current portion of long term debt	—			7,200			—			—			—			7,200
Accounts payable	2,084			9,508			42,634			4,312			—			58,538
Accrued interest payable	—			12,086			—			—			—			12,086
Other accrued liabilities	6,407			2,970			20,746			3,963			—			34,086
Total current liabilities	8,491			31,764			63,380			8,275			—			111,910
Long-term debt
Principal amount	—			1,691,400			—			—			—			1,691,400
Less unamortized discount	—			(6,289		)	—			—			—			(6,289		)
Long-term debt, net of unamortized discount	—			1,685,111			—			—			—			1,685,111
Deferred income tax liabilities	—			58,076			276,180			41			—			334,297
Other long-term liabilities	—			—			—			313			—			313
Intercompany payables	2,143,130			995,186			1,295,207			68,583			(4,502,106		)	—
Total Liabilities	2,151,621			2,770,137			1,634,767			77,212			(4,502,106		)	2,131,631
Stockholders' Equity
Preferred share rights	—			—			—			—			—			—
Common stock	524			—			—			—			—			524
Additional paid-in capital	421,574			1,280,948			1,131,578			74,031			(2,486,557		)	421,574
Treasury stock, at cost - 254 shares	(3,034		)	—			—			—			—			(3,034		)
Accumulated other comprehensive (loss) income, net of tax	(7,365		)	(7,365		)	(7,365		)	(7,365		)	22,095			(7,365		)
Retained earnings (accumulated deficit)	182,340			175,510			161,192			12,562			(349,264		)	182,340
Total Stockholders' Equity	594,039			1,449,093			1,285,405			79,228			(2,813,726		)	594,039
Total Liabilities and Stockholders' Equity	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670

- 33-

Condensed Consolidating Balance Sheet

March 31, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185
Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358
Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414
Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

- 34-

Condensed Consolidating Statement of Cash Flows

Six Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,512			290			4,818			195			—			6,815
Deferred income taxes	(879		)	1,351			11,084			(60		)	—			11,496
Amortization of deferred financing costs				2,398												2,398
Stock-based compensation costs	3,403															3,403
Amortization of debt discount				687												687
Loss on sale of assets							—			56						56
Equity in income of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	466			(107		)	(4,496		)	(4,226		)	—			(8,363		)
Inventories	—			4,691			1,857			738			(22		)	7,264
Prepaid expenses and other current assets	5,163			(241		)	(1,718		)	(90		)	—			3,114
Accounts payable	(2,332		)	1,850			(6,997		)	1,832			—			(5,647		)
Accrued liabilities	(1,321		)	3,313			(701		)	1,349			—			2,640
Net cash provided by operating activities	5,951			26,640			23,762			705			—			57,058
Investing Activities
Purchases of property and equipment	(1,127		)				(87		)	(166		)				(1,380		)
Proceeds from the sale of business	—			—			18,500			—			—			18,500
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)				—			(749,666		)
Acquisition of Hydralyte	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net				(809,157		)	731,166			77,991						—
Net cash used in investing activities	(1,127		)	(809,157		)	(87		)	(166		)	—			(810,537		)
Financing Activities
Term loan borrowings				720,000												720,000
Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	2,757			—			—			—			—			2,757
Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
Fair value of shares surrendered as payment of tax withholding	(1,660		)	—			—			—			—			(1,660		)
Intercompany activity, net	(21,187		)	37,489			(18,641		)	2,339			—			—
Net cash provided by (used in) financing activities	(19,003		)	782,517			(18,641		)	2,339			—			747,212
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(316		)	—			(316		)
(Decrease) increase in cash and cash equivalents	(14,179		)	—			5,034			2,562			—			(6,583		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748

- 35-

Condensed Consolidating Statement of Cash Flows

Six Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Deferred income taxes	(14		)	(642		)	5,011			—			—			4,355
Amortization of deferred financing costs	—			1,975			—			—			—			1,975
Stock-based compensation costs	2,487			—			—			—			—			2,487
Amortization of debt discount	—			798			—			—			—			798
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(112		)	996			(5,323		)	(1,273		)	—			(5,712		)
Inventories	—			(1,975		)	3,073			(277		)	—			821
Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
Net cash provided by operating activities	2,601			12,368			38,806			1,823			—			55,598
Investing Activities
Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
Financing Activities
Term loan repayments	—			(7,500		)	—			—			—			(7,500		)
Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	2,347			36,122			(38,809		)	340			—			—
Net cash provided by (used in) financing activities	8,562			42,847			(38,809		)	340			—			12,940
Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
Increase in cash and cash equivalents	8,947			—			—			2,216			—			11,163
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	23,667		$	—		$	—		$	3,166		$	—		$	26,833

- 36-

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with the Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.  This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties.  Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014, as well as those described in Part II, Item 1A., "Risk Factors" in this Quarterly Report on Form 10-Q and in future reports filed with the Securities and Exchange Commission (the "SEC").

See also “Cautionary Statement Regarding Forward-Looking Statements” on page 60 of this Quarterly Report on Form 10-Q.

General

We are engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada), and in Australia and certain other international markets.  We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to grow our presence in these categories and, as a result, grow our sales and profits.

We have grown our product portfolio both organically and through acquisitions. We develop our core brands by investing in new product lines, brand extensions and providing advertising support. Acquisitions of OTC brands have also been an important part of our growth strategy. We have acquired well-recognized brands from consumer products and pharmaceutical companies. While many of these brands have long histories of brand development and investment, we believe that, at the time we acquired them, most were considered “non-core” by their previous owners. As a result, these acquired brands did not benefit from adequate management focus and marketing support during the period prior to their acquisition, which created significant opportunities for us to reinvigorate these brands and improve their performance post-acquisition. After adding a brand to our portfolio, we seek to increase its sales, market share and distribution in both existing and new channels through our established retail distribution network.  This is achieved through increased spending on advertising and promotional support, new sales and marketing strategies, improved packaging and formulations and innovative development of brand extensions.

Acquisitions and Divestitures

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed its previously announced acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extends the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading brand in OTC yeast infection treatment. The acquisition also adds brands to the Company's cough/cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.

- 37-

(In thousands)	September 3, 2014
Cash acquired	$	3,507
Accounts receivable	25,784
Inventories	23,559
Deferred income tax assets - current	860
Prepaids and other current assets	1,407
Property, plant and equipment	2,308
Goodwill	103,255
Intangible Assets	724,374
Total assets acquired	885,054
Accounts payable	16,079
Accrued expenses	8,003
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	131,881
Total purchase price	$	753,173

Based on this analysis, we allocated $599.6 million to non-amortizable intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 16.1 years.

We also recorded goodwill of $103.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. Revenues of the acquired Insight operations for the three and six months ended September 30, 2014 were $12.7 million. Net loss for the three and six months ended September 30, 2014 was $2.0 million. On September 3, 2014 we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.

(In thousands, except per share data)	Six Months Ended September 30, 2014
Revenues	$	393,140
Net income	$	37,957
Earnings per share:
Basic	$	0.73
Diluted	$	0.72

- 38-

(In thousands, except per share data)	Six Months Ended September 30, 2013
Revenues	$	389,490
Net income	$	53,511
Earnings per share:
Basic	$	1.04
Diluted	$	1.03

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on the balance sheet and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.

(In thousands)	April 30, 2014
Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041
Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the

- 39-

Fab line of nutritional supplements. Care Pharma also includes a line of brands for children including, Little Allergies, Little Eyes,and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio and are included in our International OTC Healthcare segment.

The Care Pharma acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.

(In thousands)	July 1, 2013
Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income taxes	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386
Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625
Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 13.1 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

- 40-

Results of Operations

Three Months Ended September 30, 2014 compared to the Three Months Ended September 30, 2013

Total Segment Revenues

	Three Months Ended September 30,
(In thousands)	2014		%	2013		%	Increase (Decrease)			%
North American OTC Healthcare
Analgesics	$	29,072	16.0	$	29,343	17.6	$	(271	)	(0.9	)
Cough & Cold	24,771		13.7	28,695		17.2	(3,924		)	(13.7	)
Women's Health	9,119		5.0	501		0.3	8,618			(*)
Gastrointestinal	20,896		11.5	21,695		13.0	(799		)	(3.7	)
Eye & Ear Care	21,405		11.8	19,378		11.6	2,027			10.5
Dermatologicals	17,459		9.6	17,716		10.6	(257		)	(1.5	)
Oral Care	12,934		7.1	13,028		7.8	(94		)	(0.7	)
Other OTC	1,922		1.2	1,919		1.1	3			0.2
Total North American OTC Healthcare	137,578		75.9	132,275		79.2	5,303			4.0
International OTC Healthcare
Analgesics	792		0.4	698		0.4	94			13.5
Cough & Cold	5,460		3.0	5,023		3.0	437			8.7
Women's Health	658		0.4	633		0.4	25			3.9
Gastrointestinal	5,598		3.1	301		0.2	5,297			(*)
Eye & Ear Care	4,028		2.2	1,625		1.0	2,403			147.9
Dermatologicals	687		0.4	605		0.3	82			13.6
Oral Care	127		0.1	130		0.1	(3		)	(2.3	)
Other OTC	4		—	—		—	4			(*)
Total International OTC Healthcare	17,354		9.6	9,015		5.4	8,339			92.5
Total OTC Healthcare	154,932		85.5	141,290		84.6	13,642			9.7
Household Cleaning	26,337		14.5	25,655		15.4	682			2.7
Total Consolidated	$	181,269	100.0	$	166,945	100.0	$	14,324		8.6

(*) not meaningful

Total segment revenues for the three months ended September 30, 2014 were $181.3 million, an increase of $14.3 million, or 8.6% versus the three months ended September 30, 2013. This increase was primarily related to an increase in the International OTC Healthcare segment due to the acquisition of the Hydralyte brand, and an increase in the North American OTC Healthcare segment due to the acquisition of Insight, partially offset by a decline in the North American OTC Healthcare legacy brands.

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment increased $5.3 million, or 4.0%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. 

This increase was primarily due to the acquisition of Insight, which contributed $12.7 million to the segment overall, with $8.8 million to the women’s health care product group, partially offset by a decrease of $0.2 million in the women's health care product group from the legacy North American OTC healthcare brands. This increase was also attributable to a $2.0 million increase in the eye & ear care product group. This was partially offset by declines of approximately $3.9 million and $0.8 million in the cough & cold and gastroinstestinal product groups, respectively, from the legacy North American OTC Healthcare brands. The decrease in the cough & cold product group revenues was due largely to a decrease in revenues for Pediacare, which continues to experience losses due to return of competitive products to the market and an inventory build that occurred in 2013 for a new

- 41-

product launch. The decrease in the dermatologicals product group revenues was caused primarily by decreases in revenues for Compound W due to overall category declines and competition from private label products.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $8.3 million during the three months ended September 30, 2014 versus the three months ended September 30, 2013. This increase was primarily attributable to increases of $5.3 million and $2.4 million in the gastrointestinal and eye & ear care product groups, respectively, resulting from the acquisition of Hydralyte and increased sales of Murine Tears.

Household Cleaning Segment

Revenues for the Household Cleaning segment increased by $0.7 million, or 2.7%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. The increase was primarily due to increased sales in the dollar channel for Comet.

Cost of Sales

The following table presents our cost of sales and cost of sales as a percentage of total segment revenues, by segment for each of the periods presented.

	Three Months Ended September 30,
(Amounts in thousands)							Increase (Decrease)
Cost of Sales	2014		%	2013		%	Amount		%
North American OTC Healthcare	$	52,185	37.9	$	50,987	38.5	$	1,198	2.3
International OTC Healthcare	6,595		38.0	4,338		48.1	2,257		52.0
Household Cleaning	19,947		75.7	18,398		71.7	1,549		8.4
	$	78,727	43.4	$	73,723	44.2	$	5,004	6.8

Cost of sales increased $5.0 million, or 6.8%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. This increase was largely due to increased volume. As a percentage of total revenue, cost of sales decreased to 43.4% in the three months ended September 30, 2014 from 44.2% in the three months ended September 30, 2013. This decrease in cost of sales as a percentage of revenues was primarily due to favorable impact from lower cost of sales as a percentage of revenue of the International OTC Healthcare segment.

North American OTC Healthcare Segment

Cost of sales for the North American OTC Healthcare segment increased $1.2 million, or 2.3%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013.  This increase is due to increased sales volume from the acquisition of Insight, partially offset by a decrease in cost of sales in the North American OTC Healthcare legacy brands. As a percentage of North American OTC Healthcare revenues, cost of sales in the North American OTC Healthcare segment decreased to 37.9% in the three months ended September 30, 2014 from 38.5% during the three months ended September 30, 2013. This decrease in cost of sales as a percentage of revenues was primarily due to a favorable product mix in the North American OTC Healthcare segment.

International OTC Healthcare Segment

Cost of sales for the International OTC Healthcare segment increased $2.3 million, or 52.0%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. This increase was due to the acquisition of Hydralyte and increased overall sales volume. As a percentage of International OTC Healthcare revenues, cost of sales in the International OTC Healthcare segment decreased to 38.0% in the three months ended September 30, 2014 from 48.1% during the three months ended September 30, 2013. This decrease in cost of sales as a percentage of revenues was primarily due to a favorable product mix in the International OTC Healthcare segment.

Household Cleaning Segment

Cost of sales for the Household Cleaning segment increased $1.5 million, or 8.4%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013.  As a percentage of Household Cleaning revenues, cost of sales increased to 75.7% during the three months ended September 30, 2014 from 71.7% during the three months ended September 30, 2013. This increase in cost of sales as a percentage of revenues was primarily attributable to an unfavorable product mix resulting from higher sales volumes at lower prices through the dollar channel.

- 42-

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.

	Three Months Ended September 30,
(Amounts in thousands)							Increase (Decrease)
Gross Profit	2014		%	2013		%	Amount			%
North American OTC Healthcare	$	85,393	62.1	$	81,288	61.5	$	4,105		5.0
International OTC Healthcare	10,759		62.0	4,677		51.9	6,082			130.0
Household Cleaning	6,390		24.3	7,257		28.3	(867		)	(11.9	)
	$	102,542	56.6	$	93,222	55.8	$	9,320		10.0

Gross profit for the three months ended September 30, 2014 increased $9.3 million, or 10.0%, when compared with the three months ended September 30, 2013.  As a percentage of total revenues, gross profit increased to 56.6% in the three months ended September 30, 2014 from 55.8% in the three months ended September 30, 2013. The increase in gross profit as a percentage of revenues was primarily the result of higher gross margins recognized in the International OTC Healthcare segment.

North American OTC Healthcare Segment

Gross profit for the North American OTC Healthcare segment increased $4.1 million, or 5.0%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013.  As a percentage of North American OTC Healthcare revenues, gross profit increased to 62.1% during the three months ended September 30, 2014 from 61.5% during the three months ended September 30, 2013. The increase in gross profit as a percentage of revenues was primarily the result of a favorable product group mix with higher gross margins.

International OTC Healthcare Segment

Gross profit for the International OTC Healthcare segment increased $6.1 million, or 130.0%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. As a percentage of International OTC Healthcare revenues, gross profit increased to 62.0% during the three months ended September 30, 2014 from 51.9% during the three months ended September 30, 2013. The increase in gross profit as a percentage of revenues was primarily the result of the higher gross margins associated with Murine Tears andthe recently acquired Hydralyte brand.

Household Cleaning Segment

Gross profit for the Household Cleaning segment decreased $0.9 million, or 11.9%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013.  As a percentage of Household Cleaning revenue, gross profit decreased to 24.3% during the three months ended September 30, 2014 from 28.3% during the three months ended September 30, 2013. The decrease in gross profit as a percentage of revenues was primarily attributable to an unfavorable customer mix resulting from higher sales through the dollar and club channels, which have lower gross margins.

Contribution Margin

The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.

	Three Months Ended September 30,
(Amounts in thousands)							Increase (Decrease)
Contribution Margin	2014		%	2013		%	Amount			%
North American OTC Healthcare	$	63,951	46.5	$	58,741	44.4	$	5,210		8.9
International OTC Healthcare	7,724		44.5	3,231		35.8	4,493			139.1
Household Cleaning	5,823		22.1	6,703		26.1	(880		)	(13.1	)
	$	77,498	42.8	$	68,675	41.1	$	8,823		12.8

Contribution margin is the financial measure that we use as a primary measure for evaluating segment performance, which is defined as gross profit less advertising and promotional expenses. Contribution margin increased $8.8 million, or 12.8%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013.  The contribution margin increase

- 43-

was primarily the result of the previously discussed impact of the acquisitions and lower advertising and promotional expenses by the North American OTC Healthcare legacy brands.

North American OTC Healthcare Segment

Contribution margin for the North American OTC Healthcare segment increased $5.2 million, or 8.9%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. The contribution margin increase was primarily the result of the Insight acquisition and lower advertising and promotional expenses associated with the legacy North American OTC Healthcare segment brands. Advertising and promotional spending decreased $1.1 million, or 4.9%, due primarily to BC and Goody's new product launches in the prior year. This was partially offset by increases associated with the recently acquired Insight brands. As a percentage of North American OTC Healthcare revenues, contribution margin for the North American OTC Healthcare segment increased to 46.5% during the three months ended September 30, 2014 from 44.4% during the three months ended September 30, 2013.

International OTC Healthcare Segment

Contribution margin for the International OTC Healthcare segment increased $4.5 million, or 139.1%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013. As a percentage of International OTC Healthcare revenues, contribution margin from the International OTC Healthcare segment increased to 44.5% during the three months ended September 30, 2014 from 35.8% during the three months ended September 30, 2013. This increase was primarily related to the increased gross profit from the recent acquisition of the Hydralyte brand.

Household Cleaning Segment

Contribution margin for the Household Cleaning segment decreased $0.9 million, or 13.1%, during the three months ended September 30, 2014 versus the three months ended September 30, 2013.  As a percentage of Household Cleaning revenues, contribution margin from the Household Cleaning segment decreased to 22.1% during the three months ended September 30, 2014 from 26.1% during the three months ended September 30, 2013. The contribution margin decrease was the result of the gross profit decrease discussed above.

General and Administrative

General and administrative expenses were $27.1 million for the three months ended September 30, 2014 versus $11.6 million for the three months ended September 30, 2013. The increase in general and administrative expenses was primarily due to $8.0 million of acquisition costs mainly related to the purchase of Insight, increased compensation costs of $5.4 million and higher legal and other professional costs of $0.9 million.

Depreciation and Amortization

Depreciation and amortization expense was $3.9 million and $3.3 million for the three months ended September 30, 2014 and September 30, 2013, respectively. The increase in depreciation and amortization expense was due to slightly lower intangible asset amortization in the current period.

Interest Expense

Net interest expense was $18.2 million during the three months ended September 30, 2014 versus $16.5 million during the three months ended September 30, 2013. The increase in interest expense was primarily the result of a higher level of indebtedness. The average indebtedness outstanding increased from $1.0 billion during the three months ended September 30, 2013 to $1.2 billion during the three months ended September 30, 2014. The increase in average indebtedness outstanding is the result of additional borrowings under our 2012 Term Loan and 2012 ABL Revolver to fund our acquisition of Insight, partially offset by the higher repayments during the three months ended September 30, 2014. This increase was primarily due to higher borrowings under our 2012 Term Loan and 2012 ABL Revolver. The average cost of borrowing decreased to 6.0% for the three months ended September 30, 2014, from 6.7% for the three months ended September 30, 2013, which is attributed to the refinancing of debt in September 2014.

Income Taxes

The provision for income taxes during the three months ended September 30, 2014 was $11.9 million versus $4.5 million during the three months ended September 30, 2013.  The effective tax rate during the three months ended September 30, 2014 was 41.9% versus 12.1% during the three months ended September 30, 2013.  The increase in the effective tax rate was primarily due to certain non-deductible items related to acquisitions and state tax adjustments. The estimated effective tax rate for the remaining quarters of the fiscal year ending March 31, 2015 is expected to be approximately 35.8%, excluding the impact of acquisitions and discrete items that may occur.

- 44-

Results of Operations

Six Months Ended September 30, 2014 compared to the Six Months Ended September 30, 2013

Total Segment Revenues

	Six Months Ended September 30,
(In thousands)	2014		%	2013		%	Increase (Decrease)			%
North American OTC Healthcare
Analgesics	$	54,103	16.5	$	57,479	18.6	$	(3,376	)	(5.9	)
Cough & Cold	44,814		13.7	49,193		15.9	(4,379		)	(8.9	)
Women's Health	9,487		2.9	988		0.3	8,499			(*)
Gastrointestinal	41,534		12.7	43,453		14.0	(1,919		)	(4.4	)
Eye & Ear Care	42,130		12.9	39,710		12.8	2,420			6.1
Dermatologicals	29,720		9.1	32,347		10.5	(2,627		)	(8.1	)
Oral Care	23,121		7.1	24,114		7.8	(993		)	(4.1	)
Other OTC	3,103		1.0	4,077		1.3	(974		)	(23.9	)
Total North American OTC Healthcare	248,012		75.9	251,361		81.2	(3,349		)	(1.3	)
International OTC Healthcare
Analgesics	1,457		0.4	727		0.2	730			100.4
Cough & Cold	10,259		3.1	6,006		1.9	4,253			70.8
Women's Health	1,176		0.4	633		0.2	543			85.8
Gastrointestinal	8,096		2.5	312		0.1	7,784			(*)
Eye & Ear Care	8,670		2.6	3,885		1.3	4,785			123.2
Dermatologicals	1,229		0.4	696		0.2	533			76.6
Oral Care	189		0.1	177		0.1	12			6.8
Other OTC	4		—	—		—	4			(*)
Total International OTC Healthcare	31,080		9.5	12,436		4.0	18,644			149.9
Total OTC Healthcare	279,092		85.4	263,797		85.2	15,295			5.8
Household Cleaning	47,879		14.6	45,660		14.8	2,219			4.9
Total Consolidated	$	326,971	100.0	$	309,457	100.0	$	17,514		5.7

(*) not meaningful

Total segment revenues for the six months ended September 30, 2014 were $327.0 million, an increase of $17.5 million, or 5.7%, versus the six months ended September 30, 2013. This increase was primarily related to the increase in the International OTC Healthcare segment, which resulted primarily from the recent acquisitions of Care Pharma and the Hydralyte brand, and to an increase in the Household Cleaning segment. This was offset by a decline in the North American legacy OTC Healthcare brands, partially offset by an increase from brands acquired from the recent Insight acquisition.

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment decreased $3.3 million, or 1.3%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013. 

This decrease was primarily due to a decline in the cough & cold, analgesics, dermatological, and gastrointestinal product groups, in the amount of $4.4 million, $3.4 million, $2.6 million and $1.9 million, respectively. The decrease in the analgesics product group revenues was due largely to a decrease in revenues for the BC and Goody’s brands, which benefited from new product launches in fiscal 2013. The decrease in the dermatologicals product group revenues was primarily due to declines in revenue from Compound W and Dermoplast. The decrease in the gastrointestinal product group revenues was caused primarily by decreases in revenues for both the Beano and Fiber Choice brands. The remaining decrease reflects an aggregate decline in other product

- 45-

groups within the North American OTC Healthcare Segment, partially offset by increases in the eye & ear care and women’s health product groups.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $18.6 million during the six months ended September 30, 2014 versus the six months ended September 30, 2013. The increase was primarily due to the acquisition of the Hydralyte brand in April 2014 and increased sales of Murine Tears in the eye & ear care product group.

Household Cleaning Segment

Revenues for the Household Cleaning segment increased by $2.2 million, or 4.9%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013. The increase was primarily due to increased sales in the dollar channel for Comet.

Cost of Sales

The following table presents our cost of sales and cost of sales as a percentage of total segment revenues, by segment for each of the periods presented.

	Six Months Ended September 30,
(Amounts in thousands)							Increase (Decrease)
Cost of Sales	2014		%	2013		%	Amount			%
North American OTC Healthcare	$	94,526	38.1	$	94,533	37.6	$	(7	)	—
International OTC Healthcare	11,679		37.6	5,803		46.7	5,876			101.3
Household Cleaning	36,358		75.9	32,875		72.0	3,483			10.6
	$	142,563	43.6	$	133,211	43.0	$	9,352		7.0

Cost of sales increased $9.4 million, or 7.0%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013. This increase was largely due to the products acquired in the Care Pharma ,the Hydralyte brand, and Insight acquisitions. As a percentage of total revenue, cost of sales increased to 43.6% in the six months ended September 30, 2014 from 43.0% in the six months ended September 30, 2013. This increase in cost of sales as a percentage of revenues was primarily due to higher volumes at lower prices through the dollar channel, which affected the Household Cleaning segment and an unfavorable product mix in the North American OTC Healthcare segment. This was offset by favorable product mix changes in the International OTC Healthcare segment due to the acquisitions of Care Pharma and the Hydralyte brand.

North American OTC Healthcare Segment

Cost of sales for the North American OTC Healthcare segment was consistent at $94.5 million for the six months ended September 30, 2014 and the six months ended September 30, 2013.  As a percentage of North American OTC Healthcare revenues, cost of sales in the North American OTC Healthcare segment increased to 38.1% in the six months ended September 30, 2014 from 37.6% during the six months ended September 30, 2013. This increase in cost of sales as a percentage of revenues was primarily due to an unfavorable product mix in the North American OTC Healthcare segment.

International OTC Healthcare Segment

Cost of sales for the International OTC Healthcare segment increased $5.9 million during the six months ended September 30, 2014 versus the six months ended September 30, 2013. This increase was due to higher volumes in the products acquired from the acquisition of Care Pharma and the Hydralyte brand. As a percentage of International OTC Healthcare revenues, cost of sales in the International OTC Healthcare segment decreased to 37.6% in the six months ended September 30, 2014 from 46.7% during the six months ended September 30, 2013. This decrease in cost of sales as a percentage of revenues was primarily due to a favorable product mix in the International OTC Healthcare segment.

Household Cleaning Segment

Cost of sales for the Household Cleaning segment increased $3.5 million, or 10.6%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013.  As a percentage of Household Cleaning revenues, cost of sales increased to 75.9% during the six months ended September 30, 2014 from 72.0% during the six months ended September 30, 2013. The increase in the cost of sales as a percentage of revenues was primarily attributable to an unfavorable product mix resulting from higher sales volumes at lower prices through the dollar and club channels.

- 46-

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.

	Six Months Ended September 30,
(Amounts in thousands)							Increase (Decrease)
Gross Profit	2014		%	2013		%	Amount			%
North American OTC Healthcare	$	153,486	61.9	$	156,828	62.4	$	(3,342	)	(2.1	)
International OTC Healthcare	19,401		62.4	6,633		53.3	12,768			192.5
Household Cleaning	11,521		24.1	12,785		28.0	(1,264		)	(9.9	)
	$	184,408	56.4	$	176,246	57.0	$	8,162		4.6

Gross profit for the six months ended September 30, 2014 increased $8.2 million, or 4.6%, when compared with the six months ended September 30, 2013.  As a percentage of total revenues, gross profit decreased to 56.4% in the six months ended September 30, 2014 from 57.0% in the six months ended September 30, 2013. The decrease in gross profit percentage was primarily due to higher costs as as percentage of total segment revenues in the North American OTC Healthcare and the Household Cleaning segment. This was partially offset by the higher gross profit percentages from the recently acquired Care Pharma and Hydralyte brands.

North American OTC Healthcare Segment

Gross profit for the North American OTC Healthcare segment decreased $3.3 million, or 2.1%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013.  As a percentage of North American OTC Healthcare revenues, gross profit decreased slightly to 61.9% during the six months ended September 30, 2014 from 62.4% during the six months ended September 30, 2013.

International OTC Healthcare Segment

Gross profit for the International OTC Healthcare segment increased $12.8 million during the six months ended September 30, 2014 versus the six months ended September 30, 2013. As a percentage of International OTC Healthcare revenues, gross profit increased to 62.4% during the six months ended September 30, 2014 from 53.3% during the six months ended September 30, 2013. The increase was due to the higher gross profit percentage from the recently acquired Care Pharma and Hydralyte brands.

Household Cleaning Segment

Gross profit for the Household Cleaning segment decreased $1.3 million, or 9.9%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013.  As a percentage of Household Cleaning revenue, gross profit decreased to 24.1% during the six months ended September 30, 2014 from 28.0% during the six months ended September 30, 2013. The decrease was primarily attributable to an unfavorable product mix resulting from higher sales through the dollar channel, which have lower gross margins.

Contribution Margin

The following table presents our contribution margin and contribution margin as a percentage of total segment revenues, by segment for each of the periods presented.

	Six Months Ended September 30,
(Amounts in thousands)							Increase (Decrease)
Contribution Margin	2014		%	2013		%	Amount			%
North American OTC Healthcare	$	115,692	46.6	$	116,731	46.4	$	(1,039	)	(0.9	)
International OTC Healthcare	14,026		45.1	4,923		39.6	9,103			184.9
Household Cleaning	10,550		22.0	11,364		24.9	(814		)	(7.2	)
	$	140,268	42.9	$	133,018	43.0	$	7,250		5.5

Contribution margin is the financial measure that we use as a primary measure for evaluating segment performance, which is defined as gross profit less advertising and promotional expenses. Contribution margin increased $7.3 million, or 5.5%, during

- 47-

the six months ended September 30, 2014 versus the six months ended September 30, 2013.  The contribution margin increase was primarily the result of the effects of higher gross profit discussed above as well as lower advertising and promotional expenses.

North American OTC Healthcare Segment

Contribution margin for the North American OTC Healthcare segment decreased $1.0 million, or 0.9%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013. The contribution margin decline was primarily the result of the effects of lower sales volumes and higher costs and resulting lower gross profit, slightly offset by lower advertising and promotional spending. As a percentage of North American OTC Healthcare revenues, contribution margin for the North American OTC Healthcare segment increased to 46.6% during the six months ended September 30, 2014 from 46.4% during the six months ended September 30, 2013. Advertising and promotional spending decreased due primarily to BC,Goody's and Pediacare new product launches in the prior year, partially offset by the Insight acquisition.

International OTC Healthcare Segment

Contribution margin for the International OTC Healthcare segment increased $9.1 million during the six months ended September 30, 2014 versus the six months ended September 30, 2013. As a percentage of International OTC Healthcare revenues, contribution margin for the International OTC Healthcare segment increased to 45.1% during the six months ended September 30, 2014 from 39.6% during the six months ended September 30, 2013. This increase was primarily related to increased gross profit from the recent acquisitions of the Care Pharma and the Hydralyte brand discussed above.

Household Cleaning Segment

Contribution margin for the Household Cleaning segment decreased $0.8 million, or 7.2%, during the six months ended September 30, 2014 versus the six months ended September 30, 2013.  As a percentage of Household Cleaning revenues, contribution margin for the Household Cleaning segment decreased to 22.0% during the six months ended September 30, 2014 from 24.9% during the six months ended September 30, 2013. The contribution margin decrease was the result of gross profit changes discussed above, partially offset by lower advertising and promotion spending.

General and Administrative

General and administrative expenses were $44.1 million for the six months ended September 30, 2014 versus $23.3 million for the six months ended September 30, 2013. The increase in general and administrative expenses was primarily due to $12.1 million of acquisition costs related to the purchases of Insight and Hydralyte, increased compensation costs of $5.7 million and higher legal and other professional costs of $1.6 million.

Depreciation and Amortization

Depreciation and amortization expense was $6.8 million for the six months ended September 30, 2014 versus $6.6 million for the six months ended September 30, 2013.  The increase in depreciation and amortization expense was due to slightly higher intangible asset amortization in the current period.

Interest Expense

Net interest expense was $32.9 million during the six months ended September 30, 2014 versus $32.3 million during the six months ended September 30, 2013. The increase in interest expense was primarily the result of a higher level of indebtedness. The average indebtedness outstanding increased from $1.0 billion during the six months ended September 30, 2013 to $1.1 billion during the six months ended September 30, 2014. The increase in average indebtedness outstanding is the result of additional borrowings under our 2012 Term B-2 Loan and 2012 ABL Revolver to fund our acquisition of the Hydralyte brand and Insight, partially offset by the higher repayments during the six months ended September 30, 2014. The average cost of borrowing decreased to 6.0% for the six months ended September 30, 2014, from 6.6% for the six months ended September 30, 2013, which is attributed to the refinancing of debt in September 2014.

Income Taxes

The provision for income taxes during the six months ended September 30, 2014 was $23.3 million versus $17.4 million during the six months ended September 30, 2013.  The effective tax rate during the six months ended September 30, 2014 was 41.2% versus 24.5% during the six months ended September 30, 2013.  The increase in the effective tax rate was primarily due to certain non-deductible items related to acquisitions and state tax adjustments. The estimated effective tax rate for the remaining quarters of the fiscal year ending March 31, 2015 is expected to be approximately 35.8%, excluding the impact of additional acquisitions and discrete items that may occur.

- 48-

Liquidity and Capital Resources

Liquidity

Our primary source of cash comes from our cash flow from operations. In the past, we have supplemented this source of cash with various debt facilities, primarily in connection with acquisitions. We have financed, and expect to continue to finance our operations over the next twelve months, with a combination of borrowings and funds generated from operations.  Our principal uses of cash are for operating expenses, debt service, acquisitions, working capital and capital expenditures.

The following table summarizes our cash provided by (used in) operating activities, investing activities and financing activities as reported in our consolidated statements of cash flows in the accompanying Consolidated Financial Statements.

	Six Months Ended September 30,
(In thousands)	2014			2013
Cash provided by (used in):
Operating Activities	$	57,058		$	55,598
Investing Activities	(810,537		)	(57,531		)
Financing Activities	747,212			12,940

Operating Activities

Net cash provided by operating activities was $57.1 million for the six months ended September 30, 2014 compared to $55.6 million for the six months ended September 30, 2013. The $1.5 million increase in net cash provided by operating activities was primarily due to a decrease in working capital of $13.1 million and higher non-cash charges of $8.7 million, offset by a decrease in net income of $20.3 million.

Working capital is defined as current assets (excluding cash and cash equivalents) minus current liabilities. Working capital decreased primarily due to decreases in inventories of $6.4 million, prepaid expenses of $0.5 million, and an increase in accrued liabilities of $13.3 million. This was offset by increases in accounts receivable of $2.7 million and a decrease in accounts payable of $4.5 million.

Non-cash charges increased $8.7 million primarily due to an increase in stock based compensation charges of $0.9 million and deferred income tax charges of $7.1 million, and amortization of deferred financing costs of $0.4 million.

Investing Activities

Net cash used in investing activities was $810.5 million for the six months ended September 30, 2014 compared to $57.5 million for the six months ended September 30, 2013. The increase in net cash used in investing activities for the six months ended September 30, 2014 was primarily due to the use of cash for the acquisition of Insight Pharmaceuticals in September 2014 of $749.7 and for the acquisition of the Hydralyte brand in April 2014 of $78.0 million slightly offset by proceeds from sale of business assets of $18.5 million.

Financing Activities

Net cash provided by financing activities was $747.2 million for the six months ended September 30, 2014 compared to net cash provided by financing activities of $12.9 million for the six months ended September 30, 2013.  The increase in cash provided by financing activities was primarily due to the net borrowings of $720.0 million under the 2012 term loan and $66.1 million under the 2012 ABL Revolver in the six months ended September 30, 2014, while the prior year period resulted in net borrowings under the 2012 ABL Revolver of $14.5 million. We utilized $65.0 million of borrowings under the ABL Revolver for the acquisition of the Hydralyte brand and repaid $58.5 million during the six months ended September 30, 2014. Due to the net borrowing under the 2012 ABL Revolver and 2012 Term Loan, our outstanding indebtedness increased to $1,698.6 million at September 30, 2014 from $937.5 million at March 31, 2014.

Capital Resources

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") (i) issued the 2012 Senior Notes in an aggregate principal amount of $250.0 million, (ii) entered into the 2012 Term Loan with a seven-year maturity and the 2012 ABL Revolver with a five-year maturity, and (iii) repaid in full and canceled its then-existing credit facility. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In addition to the discount, we incurred $33.3 million in issuance costs, which were capitalized as deferred financing costs and are being amortized over the terms of the related loans and notes. The Borrower may redeem some or all of the 2012 Senior Notes at

- 49-

redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to Prestige Brands, Inc. or Prestige Brands Holdings, Inc.

On February 21, 2013, the Borrower entered into an amendment to the 2012 Term Loan ("Term Loan Amendment No. 1"). The Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loan"). The interest rate on the Term B-1 Loans under Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate, plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date.  In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans in an aggregate principal amount of $720.0 million (the "Term B-2 Loan"), (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief and (iii) an interest rate on (x) the Term B-1 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin, and (y) the Term B-2 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provides for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii)increased flexibility under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2014, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 3.7%.

On December 17, 2013, the Borrower issued $400.0 million of the 2013 Senior Notes. The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or Prestige Brands Holdings, Inc. As a result of this issuance, in December 2013, we redeemed $201.7 million of our 8.25% senior notes due 2018 and the balance of $48.3 million in January 2014 and repaid approximately $120.0 million toward our 2012 Term Loan.

- 50-

As of September 30, 2014, we had an aggregate of $1,698.6 million of outstanding indebtedness, which consisted of the following:

• $250.0 million of 8.125% 2012 Senior Notes due 2020;

• $400.0 million of 5.375% 2013 Senior Notes due 2021;

• $262.5 million of borrowings under the 2012 Term B-1 Loan;

• $720.0 million of borrowings under the 2012 Term B-2 Loan; and

• $66.1 million of borrowings under the 2012 ABL Revolver.

As ofSeptember 30, 2014, we had$68.9 millionof borrowing capacity underthe 2012 ABL Revolver.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%.

Borrowings under the 2012 ABL Revolver bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments in an amount set forth in the credit agreement covering the 2012 ABL Revolver.

As we deem appropriate, we may from time to time utilize derivative financial instruments to mitigate the impact of changing interest rates associated with our long-term debt obligations or other derivative financial instruments.  While we have utilized derivative financial instruments in the past, we did not have any significant derivative financial instruments outstanding at either September 30, 2014 or March 31, 2014 or during any of the periods presented. We have not entered into derivative financial instruments for trading purposes; all of our derivatives were over-the-counter instruments with liquid markets.  

Our debt facilities contain various financial covenants, including provisions that require us to maintain certain leverage, interest coverage and fixed charge ratios.  The credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 and 2013 Senior Notes contain provisions that accelerate our indebtedness on certain changes in control and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payment of dividends and other specified payments, repurchasing our equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transaction with affiliates. Specifically, we must:

• Have a leverage ratio of less than 8.00 to 1.0 for the quarter ended September 30, 2014 (defined as, with certain adjustments, the ratio of our consolidated total net debt as of the last day of the fiscal quarter to our trailing twelve month consolidated net income before interest, taxes, depreciation, amortization, non-cash charges and certain other items (“EBITDA”)). Our leverage ratio requirement decreases over time to 3.75 to 1.0 for the quarter ending June 30, 2016 and remains level thereafter;

• Have an interest coverage ratio of greater than 2.25 to 1.0 for the quarter ended September 30, 2014 (defined as, with certain adjustments, the ratio of our consolidated EBITDA to our trailing twelve month consolidated cash interest expense). Our interest coverage requirement increases over time to 3.50 to 1.0 for the quarter ending June 30, 2016 and remains level thereafter; and

• Have a fixed charge ratio of greater than 1.0 to 1.0 for the quarter ended September 30, 2014 (defined as, with certain adjustments, the ratio of our consolidated EBITDA minus capital expenditures to our trailing twelve month consolidated interest paid, taxes paid and other specified payments). Our fixed charge requirement remains level throughout the term of the agreement.

- 51-

At September 30, 2014, we were in compliance with the applicable financial and restrictive covenants under the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. Additionally, management anticipates that in the normal course of operations, we will be in compliance with the financial and restrictive covenants during 2015. During the years ended March 31, 2014, 2013 and 2012, we made voluntary principal payments against outstanding indebtedness of $157.5 million, $190.0 million and $25.0 million, respectively, under the 2012 Term Loan. Under the Term Loan Amendment No.2, we are required to make quarterly payments each equal to 0.25% of the original principal amount of the Term B-2 Loan, with the balance expected to be due on the seventh anniversary of the closing date. Therefore, we have presented $7.2 million of current portion of long term debt as of September 30, 2014.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements or financing activities with special-purpose entities.

Inflation

Inflationary factors such as increases in the costs of raw materials, packaging materials, purchased product and overhead may adversely affect our operating results.  Although we do not believe that inflation has had a material impact on our financial condition or results from operations for the three and six month periods ended September 30, 2014, a high rate of inflation in the future could have a material adverse effect on our financial condition or results from operations.  The recent volatility in crude oil prices has had an adverse impact on transportation costs, as well as certain petroleum based raw materials and packaging material.  Although we make efforts to minimize the impact of inflationary factors, including raising prices to our customers, a high rate of pricing volatility associated with crude oil supplies or other raw materials used in our products may have an adverse effect on our operating results.

- 52-

Critical Accounting Policies and Estimates

Our significant accounting policies are described in the notes to the unaudited Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q, as well as in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.  While all significant accounting policies are important to our Consolidated Financial Statements, certain of these policies may be viewed as being critical.  Such policies are those that are both most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, or the related disclosure of contingent assets and liabilities.  These estimates are based upon our historical experience and on various other assumptions that we believe to be reasonable under the circumstances.  Actual results may differ materially from these estimates under different conditions.  The most critical accounting estimates are described below.

Revenue Recognition

We recognize revenue when the following revenue recognition criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Direct reimbursements of advertising costs are reflected as a reduction of advertising costs in the periods in which the reimbursement criteria are achieved. We do not provide incentives to customers for the acquisition of product in excess of normal inventory quantities, because such incentives increase the potential for future returns, as well as reduce sales in the subsequent fiscal periods. Estimates of costs of promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of the promotional program, the estimated amounts are adjusted to actual results.  Our related promotional expense for the fiscal year ended March 31, 2014 was $33.4 million. For the three and six months ended September 30, 2014, our related promotional expense was $12.3 million and $21.1 million, respectively. We believe that the estimation methodologies employed, combined with the nature of the promotional campaigns, make the likelihood remote that our obligation would be misstated by a material amount. However, for illustrative purposes, had we underestimated the promotional program rate by 10% for the fiscal year ended March 31, 2014, our sales and operating income would have been adversely affected by approximately $3.3 million.  Net income would have been adversely affected by approximately $2.1 million.  Similarly, had we underestimated the promotional program rate by 10% for the three and six months ended September 30, 2014, our sales and operating income would have been adversely affected by approximately $1.2 million and $2.1 million, respectively.  Net income would have been adversely affected by approximately $0.8 million and $1.3 million, respectively, for the three and six months ended September 30, 2014.

We also periodically run coupon programs in Sunday newspaper inserts, on our product website or as on-package instant redeemable coupons.  We utilize a national clearinghouse to process coupons redeemed by customers.  At the time a coupon is distributed, a provision is made based upon historical redemption rates for that particular product, information provided as a result of the clearinghouse's experience with coupons of similar dollar value, the length of time the coupon is valid, and the seasonality of the coupon drop, among other factors.  For the fiscal year ended March 31, 2014, we had 225 coupon events.  The amount recorded against revenues and accrued for these events during 2014 was $5.6 million. Cash settlement of coupon redemptions during 2014 was $3.8 million.  During the three and six months ended September 30, 2014, we had 66 and 128 coupon events, respectively.  The amount recorded against revenue and accrued for these events during the three and six months ended September 30, 2014 was $0.8 million and $2.6 million, respectively. Cash settlement of coupon redemptions during the three and six months ended September 30, 2014 was $0.8 million and $1.3 million, respectively.

Allowances for Product Returns

Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with the recording of sales.  Such estimates are made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

- 53-

We construct our returns analysis by looking at the previous year's return history for each brand.  Subsequently, each month, we estimate our current return rate based upon a rolling twelve month average return rate and review that calculated rate for reasonableness, giving consideration to the other factors described above.  Our historical return rate has been relatively stable; for example, for the fiscal years ended March 31, 2014, 2013 and 2012, returns represented 2.2%, 2.9% and 2.9%, respectively, of gross sales.  For the three and six months September 30, 2014, product returns represented 4.2% and 4.1% of gross sales, respectively.  At September 30, 2014 and March 31, 2014, the allowance for sales returns and cash discounts was $10.0 million and $7.0 million, respectively.

While we utilize the methodology described above to estimate product returns, actual results may differ materially from our estimates, causing our future financial results to be adversely affected.  Among the factors that could cause a material change in the estimated return rate would be significant unexpected returns with respect to a product or products that comprise a significant portion of our revenues.  Based upon the methodology described above and our actual returns experience, management believes the likelihood of such an event remains remote.  Over the last three years, our actual product return rate has stayed within a range of 2.2% to 2.9% of gross sales.  However, a hypothetical increase of 0.1% in our estimated return rate as a percentage of gross sales would have adversely affected our reported sales and operating income for the fiscal year ended March 31, 2014 by approximately $0.7 million.  Net income would have been reduced by approximately $0.4 million.  A hypothetical increase of 0.1% in our estimated return rate as a percentage of gross sales for the three and six months ended September 30, 2014 would have reduced our reported sales and operating income by approximately $0.2 million and $0.4 million, respectively, while our net income would have been reduced by approximately $0.1 million and $0.2 million, respectively.

Lower of Cost or Market for Obsolete and Damaged Inventory

We value our inventory at the lower of cost or market value.  Accordingly, we reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Many of our products are subject to expiration dating.  As a general rule, our customers will not accept goods with expiration dating of less than 12 months from the date of delivery.  To monitor this risk, management utilizes a detailed compilation of inventory with expiration dating between zero and 15 months and reserves for 100% of the cost of any item with expiration dating of 12 months or less.  Inventory obsolescence costs charged to operations were $2.5 million for the fiscal year ended March 31, 2014, while for the three and six months ended September 30, 2014, we recorded obsolescence costs of $1.3 million and $2.6 million, respectively.  A hypothetical increase of 1.0% in our allowance for obsolescence at March 31, 2014 would have adversely affected our reported operating income and net income for the fiscal year ended March 31, 2014 by approximately $0.1 million.  Similarly, a hypothetical increase of 1.0% in our obsolescence allowance for the three and six months ended September 30, 2014 would have adversely affected each of our reported operating income and net income by less than approximately $0.1 million and $0.1 million, respectively.

Allowance for Doubtful Accounts

In the ordinary course of business, we grant non-interest bearing trade credit to our customers on normal credit terms.  We maintain an allowance for doubtful accounts receivable, which is based upon our historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce our credit risk, we (i) establish credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of our customers' financial condition, (iii) monitor the payment history and aging of our customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

We establish specific reserves for those accounts that file for bankruptcy, have no payment activity for 180 days or have reported major negative changes to their financial condition.  The allowance for bad debts amounted to 1.4% and 1.6% of accounts receivable at September 30, 2014 and March 31, 2014, respectively.  Bad debt expense for the fiscal year ended March 31, 2014 was $0.1 million, while during the three and six months ended September 30, 2014, we recorded bad debt expense of less than $0.1 million.

While management believes that it is diligent in its evaluation of the adequacy of the allowance for doubtful accounts, an unexpected event, such as the bankruptcy filing of a major customer, could have an adverse effect on our future financial results.  A hypothetical increase of 0.1% in our bad debt expense as a percentage of net sales during the fiscal year ended March 31, 2014 would have resulted in a decrease in each of reported operating income and reported net income of approximately $0.1 million.  Similarly, a hypothetical increase of 0.1% in our bad debt expense as a percentage of sales for the three and six months ended September 30, 2014 would have resulted in a decrease in each of reported operating income and reported net income of less than $0.1 million.

- 54-

Valuation of Intangible Assets and Goodwill

Goodwill and intangible assets amounted to $2,457.9 million and $1,585.7 million at September 30, 2014 and March 31, 2014, respectively.  At September 30, 2014, goodwill and intangible assets were apportioned among our three operating segments as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	23,193	$	7,389	$	293,993
Intangible assets, net
Indefinite-lived:
Analgesics	341,122		2,356		—		343,478
Cough & Cold	185,453		21,904		—		207,357
Women's Health	532,301		1,920		—		534,221
Gastrointestinal	213,639		69,291		—		282,930
Eye & Ear Care	172,318		—		—		172,318
Dermatologicals	217,227		2,269		—		219,496
Oral Care	61,438		—		—		61,438
Household Cleaning	—				119,820		119,820
Total indefinite-lived intangible assets, net	1,723,498		97,740		119,820		1,941,058
Finite-lived:
Analgesics	10,442		—		—		10,442
Cough & Cold	34,012		806		—		34,818
Women's Health	39,162		381		—		39,543
Gastrointestinal	21,642		262		—		21,904
Eye & Ear Care	31,072		—		—		31,072
Dermatologicals	27,191		—		—		27,191
Oral Care	16,521		—		—		16,521
Other OTC	16,103		—		—		16,103
Household Cleaning	—		—		25,295		25,295
Total finite-lived intangible assets, net	196,145		1,449		25,295		222,889
Total intangible assets, net	1,919,643		99,189		145,115		2,163,947
Total goodwill and intangible assets, net	$	2,183,054	$	122,382	$	152,504	$	2,457,940

Our Chloraseptic, Clear Eyes, Compound W,Dramamine, Efferdent, Luden's, PediaCare, BC, Goody's, Ecotrin, Beano, Gaviscon, Tagamet, Fiber Choice, Sominex and Debrox brands comprise the majority of the value of the intangible assets within the North American OTC Healthcare segment. Our Fess and Hydralyte brands comprise the majority of the value of the intangible assets within the International OTC Healthcare segment.  The Chore Boy, Comet, and Spic and Span brands comprise substantially all of the intangible asset value within the Household Cleaning segment.

On September 3, 2014, we completed the acquisition of Insight. In connection with this acquisition, we allocated $724.4 million to intangible assets based on our preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of the acquisition.

In connection with the acquisition of Insight, we also recorded goodwill based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

On April 30, 2014, we completed the acquisition of the Hydralyte brand. In connection with this acquisition, we allocated $73.6 million to intangible assets based on our preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition.

- 55-

In connection with the acquisition of the Hydralyte brand, we also recorded goodwill based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

Goodwill and intangible assets comprise substantially all of our assets.  Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a purchase business combination.  Intangible assets generally represent our trademarks, brand names and patents.  When we acquire a brand, we are required to make judgments regarding the value assigned to the associated intangible assets, as well as their respective useful lives.  Management considers many factors both prior to and after the acquisition of an intangible asset in determining the value, as well as the useful life, assigned to each intangible asset that we acquire or continue to own and promote.  

The most significant factors are:

• Brand History

A brand that has been in existence for a long period of time (e.g.,25, 50 or 100 years) generally warrants a higher valuation and longer life (sometimes indefinite) than a brand that has been in existence for a very short period of time.  A brand that has been in existence for an extended period of time generally has been the subject of considerable investment by its previous owner(s) to support product innovation and advertising and promotion.

• Market Position

Consumer products that rank number one or two in their respective market generally have greater name recognition and are known as quality product offerings, which warrant a higher valuation and longer life than products that lag in the marketplace.

• Recent and Projected Sales Growth

Recent sales results present a snapshot as to how the brand has performed in the most recent time periods and represent another factor in the determination of brand value.  In addition, projected sales growth provides information about the strength and potential longevity of the brand.  A brand that has both strong current and projected sales generally warrants a higher valuation and a longer life than a brand that has weak or declining sales.  Similarly, consideration is given to the potential investment, in the form of advertising and promotion, that is required to reinvigorate a brand that has fallen from favor.

• History of and Potential for Product Extensions

Consideration also is given to the product innovation that has occurred during the brand's history and the potential for continued product innovation that will determine the brand's future.  Brands that can be continually enhanced by new product offerings generally warrant a higher valuation and longer life than a brand that has always “followed the leader”.

After consideration of the factors described above, as well as current economic conditions and changing consumer behavior, management prepares a determination of the intangible assets' values and useful lives based on its analysis.  Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.  In a similar manner, indefinite-lived assets are no longer amortized.  They are also subject to an annual impairment test, or more frequently if events or changes in circumstances indicate that the asset's carrying value more likely than not exceeds its fair market value.  Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life.  Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to goodwill and intangible assets and tests for impairment.

We report goodwill and indefinite-lived intangible assets in each of our three reportable segments: North American OTC Healthcare, International OTC Healthcare and Household Cleaning.  We identify our reporting units in accordance with the FASB ASC Subtopic 280-10, which is at the brand level and one level below the operating segment level. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on the key assumptions and valuation methodologies previously discussed.  As a result, any material changes to these assumptions could require us to record additional impairment in the future. We have experienced declines in revenue of certain brands in the North American OTC Healthcare segment during the three and six months ended September 30, 2014, compared to the same periods during the prior year. Sustained or significant future declines

- 56-

in revenue, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair values of certain brands could indicate that fair value no longer exceeds the carrying value in which case a non-cash impairment charge may be recorded in future periods. For example, we have experienced increased competitive pressures in our pediatric cough and cold and gastroinstestinal product groups. If these conditions persist, or if our performance during future cough & cold seasons is weaker than projections used in the valuation calculations, the value of brands that treat these ailments may become impaired. We will continue to assess intangible assets at the brand level to identify conditions that indicate the carrying value may not be recoverable, and perform impairment analysis as deemed prudent.

Goodwill

As of March 31, 2014, we had 20 reporting units with goodwill, including six reporting units resulting from the acquisition of the 17 brands from GlaxoSmithKline plc in 2012, and five reporting units resulting from the acquisition of the Care Pharma brands. The aggregate fair value exceeded the carrying value by 53.1%. One individual reporting unit's fair value exceeded its carrying value by less than 10.0%. The reporting unit's associated carrying value of goodwill and intangible assets amounted to $0.8 million at March 31, 2014. Additionally, certain brands, including certain of our Household Cleaning brands, have experienced recent revenue declines. While certain reporting units' fair value exceeded their carrying value by less than 10.0%, should such revenue declines continue, the fair value of the corresponding reporting units may no longer exceed their carrying value and we would be required to record an impairment charge. As part of our annual test for impairment of goodwill, management estimates the discounted cash flows of each reporting unit, which is at the brand level and one level below the operating segment level, to estimate their respective fair values. In performing this analysis, management considers the same types of information as listed below with regard to finite-lived intangible assets. In the event that the carrying amount of the reporting unit exceeds the fair value, management would then be required to allocate the estimated fair value of the assets and liabilities of the reporting unit as if the unit was acquired in a business combination, thereby revaluing the carrying amount of goodwill. Future events, such as competition, technological advances, sustained or significant adverse changes in operating results of certain brands, and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions, and we may be required to record additional impairment charges in the future. No impairment charge was recorded during the six months ended September 30, 2014.

Indefinite-Lived Intangible Assets

In a manner similar to finite-lived intangible assets, at each reporting period, management analyzes current events and circumstances to determine whether the indefinite life classification for a trademark or trade name continues to be valid. If circumstances warrant a change to a finite life, the carrying value of the intangible asset would then be amortized prospectively over the estimated remaining useful life.

Management tests the indefinite-lived intangible assets for impairment by comparing the carrying value of the intangible asset to its estimated fair value. Since quoted market prices are seldom available for trademarks and trade names such as ours, we utilize present value techniques to estimate fair value. Accordingly, management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In performing this analysis, management considers the same types of information as listed below with regard to finite-lived intangible assets. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. In a manner similar to goodwill, future events, such as competition, technological advances, sustained or significant adverse changes in operating results of certain brands, and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Finite-Lived Intangible Assets

As mentioned above, when events or changes in circumstances indicate the carrying value of the assets may not be recoverable, management performs a review to ascertain the impact of events and circumstances on the estimated useful lives and carrying values of our trademarks and trade names.  In connection with this analysis, management:

• Reviews period-to-period sales and profitability by brand;

• Analyzes industry trends and projects brand growth rates;

• Prepares annual sales forecasts;

• Evaluates advertising effectiveness;

• Analyzes gross margins;

• Reviews contractual benefits or limitations;

• Monitors competitors' advertising spend and product innovation;

• Prepares projections to measure brand viability over the estimated useful life of the intangible asset; and

• Considers the regulatory environment, as well as industry litigation.

- 57-

If analysis of any of the aforementioned factors warrants a change in the estimated useful life of the intangible asset, management will reduce the estimated useful life and amortize the carrying value prospectively over the shorter remaining useful life.  Management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life.  In the event that the long-term projections indicate that the carrying value is in excess of the undiscounted cash flows expected to result from the use of the intangible assets, management is required to record an impairment charge.  Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value.  The impairment charge is measured as the excess of the carrying amount of the intangible asset over fair value, as calculated using the discounted cash flow analysis.  Future events, such as competition, technological advances, sustained or significant adverse changes in operating results of certain brands, and reductions in advertising support for our trademarks and trade names, could cause subsequent evaluations to utilize different assumptions.

Impairment Analysis

We estimate the fair value of our intangible assets and goodwill using a discounted cash flow method.  This discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently.  In addition, we considered our market capitalization at September 30, 2014, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. As a result of our analysis, we did not record an impairment charge during the six months ended September 30, 2014. However, sustained or significant future declines in revenue, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair values of specific brands could require us to record a non-cash impairment charge in future periods. Management will continue to assess as necessary individual brands that would potentially be impacted by the indicators described above that might occur in the future, which would trigger consideration for impairment.

The discount rate utilized in the analysis, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation.  Additionally, should the related fair values of goodwill and intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future.  However, no impairment charge was recorded during the six months ended September 30, 2014.

Stock-Based Compensation

The Compensation and Equity topic of the FASB ASC requires us to measure the cost of services to be rendered based on the grant-date fair value of an equity award.  Compensation expense is to be recognized over the period during which an employee is required to provide service in exchange for the award, generally referred to as the requisite service period.  Information utilized in the determination of fair value includes the following:

• Type of instrument (i.e., restricted shares vs. an option, warrant or performance shares);

• Strike price of the instrument;

• Market price of our common stock on the date of grant;

• Discount rates;

• Duration of the instrument; and

• Volatility of our common stock in the public market.

Additionally, management must estimate the expected attrition rate of the recipients to enable it to estimate the amount of non-cash compensation expense to be recorded in our financial statements.  While management uses diligent analysis to estimate the respective variables, a change in assumptions or market conditions, as well as changes in the anticipated attrition rates, could have a significant impact on the future amounts recorded as non-cash compensation expense.  We recorded non-cash compensation expense of $3.4 million and $2.5 million for the six months ended September 30, 2014 and 2013, respectively.

Loss Contingencies

Loss contingencies are recorded as liabilities when it is probable that a liability has been incurred and the amount of such loss is reasonably estimable.  Contingent losses are often resolved over longer periods of time and involve many factors, including:

• Rules and regulations promulgated by regulatory agencies;

• Sufficiency of the evidence in support of our position;

• Anticipated costs to support our position; and

• Likelihood of a positive outcome.

- 58-

Recent Accounting Pronouncements

In August 2014, the FASB issued Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

- 59-

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations.  The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the “safe harbor” provisions of the PSLRA.  Although we believe that our expectations are based on reasonable assumptions, actual results may differ materially from those in the forward-looking statements.

Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q.  Except as required under federal securities laws and the rules and regulations of the SEC, we do not have any intention to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us.  All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

These forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “anticipate,” “expect,” “estimate,” “project,” "strategy," "future," "seek," "may," "would," "will," “will be,” or other similar words and phrases.  Forward-looking statements and our plans and expectations are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, and our business in general is subject to such risks.  For more information, see “Risk Factors” contained in Part I, Item 1A., of our Annual Report on Form 10-K for our fiscal year ended March 31, 2014 and in Part II, Item 1A., of this Quarterly Report on Form 10-Q.  In addition, our expectations or beliefs concerning future events involve risks and uncertainties, including, without limitation:

• The high level of competition in our industry and markets;

• Our ability to increase organic growth via new product introductions or line extensions;

• Our ability to invest successfully in research and development;

• Our dependence on a limited number of customers for a large portion of our sales;

• Changes in inventory management practices by retailers;

• Our ability to grow our international sales;

• General economic conditions affecting sales of our products and their respective markets;

• Business, regulatory and other conditions affecting retailers;

• Changing consumer trends, additional store brand competition or other pricing pressures which may cause us to lower our prices;

• Our dependence on third-party manufacturers to produce the products we sell;

• Price increases for raw materials, labor, energy and transportation costs;

• Disruptions in our distribution center;

• Acquisitions, dispositions or other strategic transactions diverting managerial resources, the incurrence of additional liabilities or integration problems associated with such transactions;

• Actions of government agencies in connection with our products or regulatory matters governing our industry;

• Product liability claims, product recalls and related negative publicity;

• Our ability to protect our intellectual property rights;

• Our dependence on third parties for intellectual property relating to some of the products we sell;

• Our assets being comprised virtually entirely of goodwill and intangibles and possible changes in their value based on adverse operating results;

• Our dependence on key personnel;

• Shortages of supply of sourced goods or interruptions in the manufacturing of our products;

• The costs associated with any claims in litigation or arbitration and any adverse judgments rendered in such litigation or arbitration;

• Our level of indebtedness, and possible inability to service our debt;

• Our ability to obtain additional financing; and

• The restrictions imposed by our financing agreements on our operations.

- 60-

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rates because our 2012 Term Loan and 2012 ABL Revolver are variable rate debt.  Interest rate changes generally do not significantly affect the market value of the 2012 Term Loan and the 2012 ABL Revolver but do affect the amount of our interest payments and, therefore, our future earnings and cash flows, assuming other factors are held constant.  At September 30, 2014, we had variable rate debt of approximately $982.5 million under our 2012 Term Loan and $66.1 million under our ABL Revolver.

Holding other variables constant, including levels of indebtedness, a one percentage point increase in interest rates on our variable rate debt would have had an adverse impact on pre-tax earnings and cash flows for the three and six months ended September 30, 2014 of approximately $5.2 million and $7.7 million, respectively.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company's management, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of September 30, 2014.  Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2014, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes during the quarter ended September 30, 2014 in the Company's internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act, that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

In addition to the risk factors set forth below and the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended March 31, 2014, which could materially affect our business, financial condition or future results. The risks described below and in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations. The information below amends, updates and should be read in conjunction with the risk factors and information disclosed in our Annual Report on Form 10-K for the year ended March 31, 2014.

The high level of competition in our industry, much of which comes from competitors with greater resources, could adversely affect our business, financial condition and results from operations.

The business of selling brand name consumer products in the OTC Healthcare and Household Cleaning categories is highly competitive.  These markets include numerous manufacturers, distributors, marketers and retailers that actively compete for consumers’ business both in the United States and abroad.  Many of these competitors are larger and have substantially greater resources than we do, and may therefore have the ability to spend more aggressively on research and development, advertising and marketing, and to respond more effectively to changing business and economic conditions.  If this were to occur, it could have a material adverse effect on our business, financial condition and results from operations.

We compete for customers’ attention based on a number of factors, including brand recognition, product quality, performance, price and product availability at the retail level.  Advertising, promotion, merchandising and packaging and the timing of new product introductions and line extensions also have a significant impact on consumer buying decisions and, as a result, on our sales. Additionally, the return to the market of previously recalled competitive products could impact our sales. The structure and quality of our sales force, as well as sell-through of our products, affect the continued offering of our products, in-store position, wall display space and inventory levels in retail stores.  If we are unable to maintain our current distribution network, product

- 61-

offerings in retail stores, inventory levels and in-store positioning of our products, our sales and operating results will be adversely affected.  Our markets also are highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.  An increase in the number of product innovations by our competitors or the failure of a new product launch by the Company could have a material adverse effect on our business, financial condition and results from operations.

In addition, competitors may attempt to gain market share by offering products at prices at or below those typically offered by us.  Competitive pricing may require us to reduce prices, which may result in lost sales or a reduction of our profit margins.  Future price adjustments, product changes or new product introductions by our competitors or our inability to react with price adjustments, product changes or new product introductions of our own could result in a loss of market share, which could have a material adverse effect on our business, financial condition and results from operations.

We depend on a limited number of customers with whom we have no long-term agreements for a large portion of our gross sales and the loss of one or more of these customers could reduce our gross sales and have a material adverse effect on our financial condition and results of operations.

For the three and six months ended September 30, 2014, Walmart, which accounted for approximately 17.0% and 18.0%, respectively, of our gross sales, was our only customer that accounted for 10% or more of our sales. We expect that for future periods, our top five and top ten customers, including Walmart, will, in the aggregate, continue to account for a large portion of our sales.  The loss of one or more of our top customers, any significant decrease in sales to these customers based on inventory management or otherwise, or a significant decrease in our retail display space in any of these customers’ stores, could reduce our sales and have a material adverse effect on our financial condition and results from operations.

In addition, our business is based primarily upon individual sales orders.  We typically do not enter into long-term contracts with our customers.  Accordingly, our customers could cease buying products or reduce the number of items they buy from us at any time and for any reason.  The fact that we do not have long-term contracts with our customers means that we have no recourse in the event a customer no longer wants to purchase products from us or reduces the number of items purchased.  If a significant number of our smaller customers, or any of our significant customers, elect not to purchase products from us, our financial condition and results from operations could be adversely affected.

Our annual and quarterly results from operations may fluctuate significantly and could fall below the expectations of securities analysts and investors due to a number of factors, many of which are beyond our control, resulting in a decline in the price of our securities.

Our annual and quarterly results from operations may fluctuate significantly because of numerous factors, including:

• Increases and decreases in quarterly revenues and profitability;

• The timing of when we make acquisitions or introduce new products;

• Our inability to increase the sales of our existing products and expand their distribution;

• The timing of the introduction or return to the market of competitive products and the introduction of store brand products;

• Adverse regulatory actions or market events in the United States or in our international markets;

• Changes in consumer preferences, spending habits and competitive conditions, including the effects of competitors’ operational, promotional or expansion activities;

• Seasonality of our products;

• Fluctuations in commodity prices, product costs, utilities and energy costs, prevailing wage rates, insurance costs and other costs;

• The discontinuation and return of our products from retailers;

• Our ability to recruit, train and retain qualified employees, and the costs associated with those activities;

• Changes in advertising and promotional activities and expansion to new markets;

- 62-

• Negative publicity relating to us and the products we sell;

• Litigation matters;

• Unanticipated increases in infrastructure costs;

• Impairment of goodwill or long-lived assets;

• Changes in interest rates; and

• Changes in accounting, tax, regulatory or other rules applicable to our business.

Our quarterly operating results and revenues may fluctuate as a result of any of these or other factors. Accordingly, results for any one quarter are not necessarily indicative of results to be expected for any other quarter or for any year, and revenues for any particular future period may decrease.  In the future, operating results may fall below the expectations of securities analysts and investors.  In that event, the market price of our outstanding securities could be adversely impacted.

We depend on third-party manufacturers to produce the products we sell.  If we are unable to maintain these manufacturing relationships or fail to enter into additional relationships, as necessary, we may be unable to meet customer demand and our sales and profitability could suffer as a result.

Most of our products are produced by third-party manufacturers.  Our ability to retain our current manufacturing relationships and engage in and successfully transition to new relationships is critical to our ability to deliver quality products to our customers in a timely manner.  Without adequate supplies of quality merchandise, sales would decrease materially and our business would suffer.  In the event that our primary third-party manufacturers are unable or unwilling to ship products to us in a timely manner, we would have to rely on secondary manufacturing relationships or identify and qualify new manufacturing relationships.  We might not be able to identify or qualify such manufacturers for existing or new products in a timely manner, and such manufacturers may not allocate sufficient capacity to us to allow us to meet our commitments to customers.  In addition, identifying alternative manufacturers without adequate lead times may involve additional manufacturing expense, delay in production or product disadvantage in the marketplace.   In general, the consequences of not securing adequate, high quality and timely supplies of merchandise would negatively impact inventory levels and sales, and could have a material adverse effect on our business, financial condition and results from operations.

The manufacturers we use have and may in the future increase the cost of the products we purchase, which could adversely affect our margins in the event we are unable to pass along these increased costs to our customers.  Increased costs could also have a material adverse effect on our financial condition and results from operations.

At September 30, 2014, we had relationships with 101 third-party manufacturers pertaining to our domestic operations.  Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 77.4% of our gross sales for 2014.  The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing these products at any time and for any reason or initiate arbitrary and costly price increases, either of which could have a material adverse effect on our business, financial condition and results from operations.

Our risks associated with doing business internationally increase as we expand our international footprint.

During the three and six months ended September 30, 2014, approximately 9.9% and 9.8%, respectively, of our total revenues were attributable to our international business. As of July 1, 2013, we acquired Care Pharma, which markets and sells healthcare products in Australia. In addition, on April 30, 2014, we acquired Hydralyte in Australia and New Zealand. We generally rely on brokers and distributors for the sale of our products in other foreign countries.  Risks of doing business internationally include:

• Political instability or declining economic conditions in the countries or regions where we operate that adversely affect sales of our products;

• Currency controls that restrict or prohibit the payment of funds or the repatriation of earnings to the United States;

• Fluctuating foreign exchange rates that result in unfavorable increases in the price of our products or cause increases in the cost of certain products purchased from our foreign third-party manufacturers;

- 63-

• Trade restrictions and exchange controls;

• Inability to protect our intellectual property rights in these markets; and

• Increased costs of compliance with general business and tax regulations in these countries or regions.

Our indebtedness could adversely affect our financial condition, and the significant amount of cash we need to service our debt will not be available to reinvest in our business.

At September 30, 2014, our total indebtedness, including current maturities, was approximately $1,698.6 million.

Our indebtedness could:

• Increase our vulnerability to general adverse economic and industry conditions;

• Limit our ability to engage in strategic acquisitions;

• Require us to dedicate a substantial portion of our cash flow from operations toward repayment of our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions and investments and other general corporate purposes;

• Limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;

• Place us at a competitive disadvantage compared to our competitors that have less debt; and

• Limit, among other things, our ability to borrow additional funds on favorable terms or at all.

The terms of the indentures governing the 2012 Senior Notes and the 2013 Senior Notes, and the credit agreement governing the 2012 Term Loans and 2012 ABL Revolver, allow us to issue and incur additional debt only upon satisfaction of the conditions set forth in those respective agreements.  If new debt is added to current debt levels, the related risks described above could increase.

At September 30, 2014, we had $68.9 million of borrowing capacity available under the 2012 ABL Revolver to support our operating activities.

The senior credit facility and the indentures governing the senior notes contain cross-default provisions that could result in the acceleration of all of our indebtedness.

The senior credit facility and the indentures governing the senior notes contain provisions that allow the respective creditors to declare all outstanding borrowings under one agreement to be immediately due and payable as a result of a default under another agreement.  Consequently, under the senior credit facility, failure to make a payment required by the indentures governing the senior notes, among other things, may lead to an event of default under the senior credit facility.  Similarly, an event of default or failure to make a required payment at maturity under the senior credit facility, among other things, may lead to an event of default under the indentures governing the senior notes.  If the debt under the senior credit facility and indentures governing the senior notes were to both be accelerated, the aggregate amount immediately due and payable as of September 30, 2014 would have been approximately $1.7 billion.  We presently do not have sufficient liquidity to repay these borrowings in the event they were to be accelerated, and we may not have sufficient liquidity in the future to do so.  Additionally, we may not be able to borrow money from other lenders to enable us to refinance our indebtedness.  At September 30, 2014, the book value of our current assets was $0.2 billion.  Although the book value of our total assets was $2.7 billion, approximately $2.5 billion was in the form of intangible assets, including goodwill of $0.3 billion, a significant portion of which may not be available to satisfy our creditors in the event our debt is accelerated.

Any failure to comply with the restrictions of the senior credit facility, the indentures governing the senior notes or any other subsequent financing agreements may result in an event of default.  Such default may allow the creditors to accelerate the related debt, as well as any other debt to which the cross-acceleration or cross-default provisions apply.  In addition, the lenders may be able to terminate any commitments they had made to supply us with additional funding.  As a result, any default by us under our credit agreement, indentures governing the senior notes or any other financing agreement could have a material adverse effect on our financial condition.

- 64-

Virtually all of our assets consist of goodwill and intangibles and are subject to impairment risk.

As our financial statements indicate, virtually all of our assets consist of goodwill and intangibles, principally the trademarks, trade names and patents that we have acquired. On an annual basis, and otherwise when there is evidence that events or changes in circumstances indicate that the carrying value of intangible assets might not be recoverable we assess the potential impairment of our goodwill and other intangible assets. Upon any such evaluation, we may be required to record a significant charge in our financial statements, which would negatively impact our financial condition and results of operations. We recorded charges in 2010 and 2009 for impairment of certain of these assets. If any of our brands sustain significant or prolonged declines in performance, we may be required to perform an interim impairment analysis. For example, if the Company’s brand performance is weaker than projections used in valuation calculations, the value of such brands may become impaired. In the event that such analysis would result in the fair value being lower than the carrying value, we would be required to record an impairment charge. Should the value of those assets or other assets become further impaired or our financial condition is materially adversely affected in any way, we would not have tangible assets that could be sold to repay our liabilities.  As a result, our creditors and investors may not be able to recoup the amount of the indebtedness that they have extended to us or the amount they have invested in us.

Interruptions and breaches of computer and communications systems, including computer viruses, “hacking” and “cyber-attacks” could impair our ability to conduct business.

Increased IT security threats and more sophisticated computer crime, including advanced persistent threats, pose a potential risk to the security of our IT systems, networks, and services, as well as the confidentiality, availability, and integrity of our data.  If the IT systems, networks, or service providers we rely upon fail to function properly, or if we suffer a loss or disclosure of business or stakeholder information, due to any number of causes, ranging from catastrophic events to power outages to security breaches, and our business continuity plans do not effectively address these failures on a timely basis, we may suffer interruptions in our ability to manage operations and reputational, competitive and/or business harm, which may adversely impact our results of operations and/or financial condition.

Our information technology systems may be susceptible to disruptions.

We utilize information technology systems to improve the effectiveness of our operations and support our business including systems to support financial reporting and an enterprise resource planning system, which we are currently implementing.  During the implementation process, we could be subject to transaction errors, processing inefficiencies and other business disruptions that could lead to the loss of revenue or inaccuracies in our financial information.  The occurrence of these or other challenges could disrupt our information technology systems and adversely affect our operations.

Changes in our provision for income taxes or adverse outcomes resulting from examination of our income tax returns could adversely affect our results.

Our provision for income taxes is subject to volatility and could be adversely affected by several factors, some of which are outside of our control, including:

• changes in the income allocation methods for state taxes, and the determination of which states or countries have jurisdiction to tax our Company;

• an increase in non-deductible expenses for tax purposes, including certain stock-based compensation, executive compensation and impairment of goodwill;

• transfer pricing adjustments;

• tax assessments resulting from income tax audits or any related tax interest or penalties that could significantly affect our income tax provision for the period in which the settlement takes place;

• a change in our decision to indefinitely reinvest foreign earnings;

• changes in accounting principles; and

• changes in tax laws or related interpretations, accounting standards, regulations, and interpretations in multiple tax jurisdictions in which we operate.

- 65-

Significant judgment is required to determine the recognition and measurement attribute prescribed in FASB ASC 740. As a multinational corporation, we conduct our business in many countries and are subject to taxation in many jurisdictions. The taxation of our business is subject to the application of multiple and sometimes conflicting tax laws and regulations as well as multinational tax conventions. Our effective tax rate is dependent upon the availability of tax credits and carryforwards. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, and the evolution of regulations and court rulings. Consequently, taxing authorities may impose tax assessments or judgments against us that could materially impact our tax liability and/or our effective income tax rate.

In addition, we may be subject to examination of our income tax returns by the Internal Revenue Service and other tax authorities. If tax authorities challenge the relative mix of our U.S. and international income, or successfully assert the jurisdiction to tax our earnings, our future effective income tax rates could be adversely affected.

- 66-

ITEM 6. EXHIBITS

See Exhibit Index immediately following the signature page.

- 67-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		PRESTIGE BRANDS HOLDINGS, INC.
Date:	November 6, 2014	By:	/s/ RONALD M. LOMBARDI
			Ronald M. Lombardi
			Chief Financial Officer
			(Principal Financial Officer and
			Duly Authorized Officer)

- 68-

Exhibit Index

10.1	Executive Employment Agreement, dated as of August 11, 2014, by and between Prestige Brands Holdings, Inc. and Thomas Hochuli.
10.2	Second Amendment to Lease between RA 660 White Plains Road LLC and Prestige Brands, Inc.
10.3	Amendment No. 2, dated as of September 3, 2014, to the Term Loan Credit Agreement (as amended by Amendment No. 1, dated as of February 21, 2013), dated as of January 31, 2012, among Prestige Brands Holdings, Inc., Prestige Brands, Inc., the other Guarantors from time to time party thereto, the lenders from time to time party thereto and Citibank, N.A. as administrative agent (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 3, 2014, and incorporated herein by reference).
10.4	Amendment No. 3, dated as of September 3, 2014, to the ABL Credit Agreement (as amended by that certain Incremental Amendment, dated as of September 12, 2012, and that certain Incremental Amendment, dated as of June 11, 2013), dated as of January 31, 2012, among Prestige Brands Holdings, Inc., Prestige Brands, Inc., the other Guarantors from time to time party thereto, the lenders from time to time party thereto and Citibank, N.A. as administrative agent, L/C issuer and swing line lender (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on September 3, 2014, and incorporated herein by reference).
31.1	Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
31.2	Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
32.1	Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
32.2	Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* XBRL information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement, prospectus or other document to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

- 69-

EX-10.1

Exhibit 10.1

Executive Employment Agreement

1. Employment. Prestige Brands Holdings, Inc. (“Employer”) agrees to employ Thomas Hochuli (“Executive”) and Executive accepts such employment for the period beginning as of August 11, 2014 and ending upon his termination pursuant to Section 1(c) hereof (the “Employment Period”), subject only to the approval of the Prestige Brands Holdings, Inc. Board of Directors (the “Board”).

(a)Position and Duties.

(i)During the Employment Period, Executive shall serve as Vice President – Operations of Employer and shall have the normal duties, responsibilities and authority implied by such position, subject to the power of the Chief Executive Officer of Employer and the Board to expand or limit such duties, responsibilities and authority and to override such actions.

(ii)Executive shall report to the Chief Executive Officer of Employer, and Executive shall devote his best efforts and his full business time and attention to the business and affairs of Employer and its Subsidiaries (as defined below).

(b)Salary, Bonus and Benefits. During the Employment Period, Employer will pay Executive a base salary of $260,000 per annum (the “Annual Base Salary”), paid twice monthly, in accordance with Employer’s normal payroll cycle and procedures. In addition, in fiscal years 2015 and beyond, the Executive shall be eligible for and participate in the Annual Incentive Compensation Plan (the “Annual Bonus”) under which the Executive shall be eligible for an annual Target Bonus payment of 40% of Annual Base Salary, subject to the terms and conditions of the applicable Annual Incentive Compensation Plan and the discretion of the Board; provided, however, any Annual Bonus paid regarding fiscal year 2015 shall be prorated based on the duration of the Executive’s employment with Employer during such fiscal year. Executive shall be eligible to participate in the Long-Term Equity Incentive Plan of Employer (the “Plan”) and receive grants thereunder at the same time as grants are made to the rest of senior management; provided, however, that the Board reserves its discretion to not make an equity grant in any fiscal year. Any equity grant provided under the Plan shall have at the time of grant a value equal to Executive’s Annual Base Salary then in effect at the time of grant; provided, however, at the discretion of the Board, such grant may be modified to have a value equal to no less than 80% or no greater than 120% of Executive’s Annual Base Salary then in effect at the time of grant. In addition, any equity grant provided under the Plan shall automatically vest upon a Change in Control (as defined in the Plan). On the first day of the Employment Period, Executive shall receive an equity grant under the Plan with a value equal to Executive’s Annual Base Salary. During the Employment Period, Executive will be entitled to such other benefits approved by

1

the Board and made available to the senior management of Employer and its Subsidiaries, which shall include vacation time (four weeks per year), flexible spending account, 401(k) Plan (currently 65% match of up to 6% of salary, subject to IRS cap and periodic potential adjustment by the Board), expense reimbursement in accordance with the policies and procedures of Employer, as well as medical, dental, vision, life, long term care and disability insurance (collectively, such insurance plans, the “Welfare Plans”). The Board, on a basis consistent with past practice, shall review the Annual Base Salary of Executive and may increase the Annual Base Salary by such amount as the Board, in its sole discretion, shall deem appropriate; provided, however, Executive shall not be entitled to an increase in Annual Base Salary for fiscal year 2016. The term “Annual Base Salary” as used in this Agreement shall refer to the Annual Base Salary as it may be so increased.

(c)Termination. The Employment Period will continue until (i) Executive’s death, Disability or resignation from employment with Employer and its Subsidiaries or (ii) Employer and its Subsidiaries decide to terminate Executive’s employment with or without Cause (as defined below). If (A) Executive’s employment is terminated without Cause pursuant to clause (ii) above or (B) Executive resigns from employment with Employer and its Subsidiaries for Good Reason, then, subject to Executive’s execution and delivery of a Release in form and substance as set forth below, starting on the sixtieth (60^th) day following Executive’s termination of employment, Employer shall pay to Executive, in equal installments ratably over twelve (12) months (the “Severance Period”) in accordance with the Employer’s normal payroll cycle and procedures, an aggregate amount (the “Severance”) equal to (I) his Annual Base Salary (prior to any material diminution that constitutes Good Reason for Employee’s resignation), plus (II) an amount equal to the average Annual Bonus paid or payable to Executive by Employer for the last three completed fiscal years prior to the date of termination (or if Executive has not completed three (3) fiscal years prior to the date of termination, then the average Annual Bonus paid or payable to Executive by Employer will be determined based on the actual number of completed fiscal years prior to the date of termination). In calculating the average Annual Bonus for purposes of the immediately preceding sentence, in the event Executive’s employment is terminated pursuant to this Section 1(c) during fiscal years 2016 through 2018, Executive’s Annual Bonus payable hereunder shall be calculated using a fiscal year 2015 Annual Bonus payment equal to the amount that Executive would have otherwise received had Executive been employed by Employer during all of fiscal year 2015. If Executive is entitled on the date of termination to coverage under the Welfare Plans, such coverage shall continue for Executive and Executive’s covered dependents for a period ending on the first anniversary of the date of termination at the active employee cost payable by Executive with respect to those costs paid by Executive prior to the date of termination; provided, that this coverage will not count towards the depletion of any continued health care coverage rights that Executive and Executive’s dependents may have pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), and such rights to continued health care coverage under

2

COBRA shall remain available to Executive and Executive’s dependents after the Severance Period; providedfurther, that Executive’s or Executive’s covered dependents’ rights to continued health care coverage pursuant to this Section 1(c) shall terminate at the time Executive or Executive’s covered dependents become covered, as described in COBRA, under another group health plan, and shall also terminate as of the date Employer ceases to provide coverage to its senior executives generally under any such Welfare Plan. Notwithstanding the foregoing, (I) Executive shall not be entitled to receive any payments or benefits pursuant to this Section 1(c) unless Executive has executed and delivered to Employer a general release in form and substance satisfactory to Employer and (II) Executive shall be entitled to receive such payments and benefits only so long as Executive has not breached the provisions of Section 2 or Section 3 hereof. The release described in the foregoing sentence shall not require Executive to release any claims for Severance or benefits under the Welfare Plans as set forth in this Agreement, any vested employee benefits, workers compensation benefits covered by insurance or self-insurance, claims to indemnification to which Executive may be entitled under Employer’s or its Subsidiaries’ certificate(s) of incorporation, by-laws, any indemnification agreement or under any of Employer’s or its Subsidiaries’ directors or officers insurance policy(ies) or applicable law, or equity claims to contribution from Employer or its Subsidiaries or any other Person to which Executive is entitled as a matter of law in respect of any claim made against Executive for an alleged act or omission in Executive’s official capacity and within the scope of Executive’s duties as an officer, director or employee of Employer or its Subsidiaries. Not later than eighteen (18) months following the termination of Executive’s employment, Employer and its Subsidiaries for which the Executive has acted in the capacity of a senior manager, shall sign and deliver to Executive a release of claims that Employer and its Subsidiaries have against Executive; provided that, such release shall not release any claims that Employer and/or its Subsidiaries commenced prior to the date of the release(s), any claims relating to matters actively concealed by Executive, any claims to contribution from Executive to which Employer or its Subsidiaries are entitled as a matter of law or any claims arising out of mistaken indemnification by Employer and/or any of its Subsidiaries. Except as otherwise provided in this Section 1(c) or in the Employer’s employee benefit plans or as otherwise required by applicable law, Executive shall not be entitled to any other salary, compensation or benefits after termination of Executive’s employment with Employer.

(d)Relocation Expenses. Executive will be paid $75,000 in a lump sum as a moving allowance payable within 30 days of commencement of employment. In addition, Employer will pay for the movement of household goods from Pennsylvania to a home located near Employer. Executive will also be reimbursed for reasonable temporary housing for up to 90 days. The moving allowance and relocation expenses shall be subject to 100% recoupment by Employer in the event of a termination of employment by Executive, other than for Good Reason, during the first twenty (24) months of employment.

3

2.Confidential Information.

(a)Obligation to Maintain Confidentiality. Executive acknowledges that the information, observations and data (including trade secrets) obtained by him during the course of his performance under this Agreement concerning the business or affairs of Employer, its Subsidiaries and Affiliates (“Confidential Information”) are the property of Employer, its Subsidiaries and Affiliates, as applicable, including information concerning acquisition opportunities in or reasonably related to Employer’s, its Subsidiaries’ and/or Affiliates’ business or industry of which Executive becomes aware during the Employment Period. Therefore, Executive agrees that he will not disclose to any unauthorized Person or use for his own account (for his commercial advantage or otherwise) any Confidential Information without the Board’s written consent, unless and to the extent that the Confidential Information, (i) becomes generally known to and available for use by the public other than as a result of Executive’s acts or omissions to act, (ii) was known to Executive prior to Executive’s employment with Employer or any of its Subsidiaries or Affiliates or (iii) is required to be disclosed pursuant to any applicable law, court order or other governmental decree. Executive shall deliver to Employer on the date of termination, or at any other time Employer may request, all memoranda, notes, plans, records, reports, computer tapes, printouts and software and other documents and data (and copies thereof) relating to the Confidential Information, Work Product (as defined below) or the business of the Employer, its Subsidiaries and Affiliates (including, without limitation, all acquisition prospects, lists and contact information) which he may then possess or have under his control.

(b)Ownership of Property. Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, processes, programs, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any Confidential Information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) that relate to Employer’s, its Subsidiaries’ and/or Affiliates’ actual or anticipated business, research and development, or existing or future products or services and that are conceived, developed, contributed to, made, or reduced to practice by Executive (either solely or jointly with others) while employed by the Employer, its Subsidiaries and/or Affiliates (including any of the foregoing that constitutes any proprietary information or records) (“Work Product”) belong to the Employer or such Subsidiary or Affiliate and Executive hereby assigns, and agrees to assign, all of the above Work Product to Employer or to such Subsidiary or Affiliate. Any copyrightable work prepared in whole or in part by Executive in the course of his work for any of the foregoing entities shall be deemed a “work made for hire” under the copyright laws, and Employer or such Subsidiary or Affiliate shall own all rights therein. To the extent that any such copyrightable work is not a “work made for hire,” Executive hereby assigns and agrees to assign to Employer or such Subsidiary or Affiliate all right, title, and interest, including without limitation, copyright in and

4

to such copyrightable work. Executive shall promptly disclose such Work Product and copyrightable work to the Board and perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm the Employer’s or such Subsidiary’s or Affiliate’s ownership (including, without limitation, assignments, consents, powers of attorney, and other instruments).

(c) Third Party Information. Executive understands that Employer, its Subsidiaries and Affiliates will receive from third parties confidential or proprietary information (“Third Party Information”), subject to a duty on Employer’s, its Subsidiaries’ and Affiliates’ part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the Employment Period and thereafter, and without in any way limiting the provisions of Section 2(a) above, Executive will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than personnel and consultants of Employer, its Subsidiaries and Affiliates who need to know such information in connection with their work for Employer or any of its Subsidiaries and Affiliates) or use, except in connection with his work for Employer or any of its Subsidiaries and Affiliates, Third Party Information unless expressly authorized by a member of the Board (other than himself if Executive is on the Board) in writing.

(d) Use of Information of Prior Employers. During the Employment Period and thereafter, Executive will not improperly use or disclose any confidential information or trade secrets, if any, of any former employers or any other Person to whom Executive has an obligation of confidentiality, and will not bring onto the premises of Employer or any of its Subsidiaries or Affiliates any unpublished documents or any property belonging to any former employer or any other Person to whom Executive has an obligation of confidentiality unless consented to in writing by the former employer or Person. Executive will use in the performance of his duties only information which is (i) generally known and used by persons with training and experience comparable to Executive’s and which is (x) common knowledge in the industry or (y) otherwise legally in the public domain, (ii) otherwise provided or developed by Employer or any of its Subsidiaries or Affiliates or (iii) in the case of materials, property or information belonging to any former employer or other Person to whom Executive has an obligation of confidentiality, approved for such use in writing by such former employer or Person.

3.     Non-competition and No Solicitation. Executive acknowledges that (i) the course of his employment with Employer he will become familiar with Employer’s, its Subsidiaries’ and Affiliates’ trade secrets and with other confidential information concerning the Employer, its Subsidiaries and Affiliates; and (ii) his services will be of special, unique and extraordinary value to Employer and such Subsidiaries. Therefore, Executive agrees that:

5

(a) Non-competition. During the Employment Period and also during the period commencing on the date of termination of the Employment Period and ending on the first anniversary of the date of termination (the “Severance Period”), he shall not without the express written consent of Employer, anywhere in the United States, directly or indirectly, own, manage, control, participate in, consult with, render services for, or in any manner engage in any business (i) which competes with (a) OTC wart or skin tag treatment products (including, without limitation, salicylic acid or cryogen-based products), (b) dental devices for treatment or management of bruxism, (c) OTC sore throat treatment products (including, without limitation, liquids, lozenges and strips) and cough drops, (d) inter-proximal devices, (e) powdered and liquid cleansers, (f) pediatric OTC medicinal and non-medicinal products, (g) OTC eye and ear care products, (h) denture cleansers or adhesives, (i) motion sickness products (j) OTC analgesic products, (k) OTC feminine hygiene products, or (l) any other business acquired by Employer and its Subsidiaries after the date hereof which represents 5% or more of the consolidated revenues or EBITDA of Employer and its Subsidiaries for the trailing 12 months ending on the last day of the last completed calendar month immediately preceding the date of termination of the Employment Period, or (ii) in which Employer and/or its Subsidiaries have conducted discussions or have requested and received information relating to the acquisition of such business by such Person (x) within one year prior to the date of termination and (y) during the Severance Period, if any. Nothing herein shall prohibit Executive from (i) consulting with, being employed by, or rendering services for a company which operates a business unit engaged in the activities described in subsection (a)(i)(a) - (j) of this Section 3; provided, that Executive is not employed in and has no involvement with such competing business unit; or (ii) being a passive owner of not more than 2% of the outstanding stock of any class of a corporation that is publicly traded, so long as Executive has no active participation in the business of such corporation

(b) No solicitation. During the Employment Period and also during the Severance Period, Executive shall not directly or indirectly through another entity (i) induce or attempt to induce any employee of Employer or its Subsidiaries to leave the employ of Employer or its Subsidiaries, or in any way interfere with the relationship between Employer or its Subsidiaries and any employee thereof, (ii) hire any person who was an employee of Employer or its Subsidiaries within 180 days after such person ceased to be an employee of Employer or its Subsidiaries; provided, however, that such restriction shall not apply for a particular employee if Employer or its Subsidiaries have provided written consent to such hire, which consent, in the case of any person who was not a key employee of Employer or its Subsidiaries shall not be unreasonably withheld, (iii) induce or attempt to induce any customer, supplier, licensee or other business relation of Employer or its Subsidiaries to cease doing business with Employer or its Subsidiaries or in any way interfere with the relationship between any such customer, supplier, licensee or business relation and Employer or its Subsidiaries or (iv) directly or indirectly acquire or attempt to acquire an interest in any business relating to the business of Employer

6

or its Subsidiaries and with which Employer or its Subsidiaries have conducted discussions or have requested and received information relating to the acquisition of such business by Employer or its Subsidiaries in the two year period immediately preceding the date of termination.

(c)Enforcement. If, at the time of enforcement of Section 2 or this Section 3, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated period, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law. Because Executive’s services are unique and because Executive has access to Confidential Information, the parties hereto agree that money damages would be an inadequate remedy for any breach of this Agreement. Therefore, in the event of a breach or threatened breach of this Agreement, Employer, its Subsidiaries or their successors or assigns may, in addition to other rights and remedies existing in their favor, apply to any court of competent jurisdiction for specific performance and/or injunctive or other relief in order to enforce, or prevent any violations of, the provisions hereof (without posting a bond or other security).

(d)Additional Acknowledgments. Executive acknowledges that the provisions of this Section 3 are in consideration of: (i) employment with the Employer, (ii) the prospective issuance of securities by Employer pursuant to the Plan and (iii) additional good and valuable consideration as set forth in this Agreement. In addition, Executive agrees and acknowledges that the restrictions contained in Section 2 and this Section 3 do not preclude Executive from earning a livelihood, nor do they unreasonably impose limitations on Executive’s ability to earn a living. In addition, Executive acknowledges (i) that the business of Employer and its Subsidiaries will be conducted throughout the United States, (ii) notwithstanding the state of incorporation or principal office of Employer or any of its Subsidiaries, or any of their respective executives or employees (including the Executive), it is expected that Employer and its Subsidiaries will have business activities and have valuable business relationships within its industry throughout the United States and (iii) as part of his responsibilities, Executive will be traveling throughout the United States in furtherance of Employer’s and/or its Subsidiaries’ business and their relationships. Executive agrees and acknowledges that the potential harm to Employer and its Subsidiaries of the non-enforcement of Section 2 and this Section 3 outweighs any potential harm to Executive of their enforcement by injunction or otherwise. Executive acknowledges that he has carefully read this Agreement and has given careful consideration to the restraints imposed upon Executive by this Agreement, and is in full accord as to their necessity for the reasonable and proper protection of confidential and proprietary information of Employer and its Subsidiaries now existing or to be developed in the future. Executive expressly acknowledges and agrees that each and every restraint imposed

7

by this Agreement is reasonable with respect to subject matter, time period and geographical area.

4.    Miscellaneous.

(a)    Survival. The provisions of Sections 1(c), 2, 3 and 4 shall survive the termination of this Agreement.

(b)    Entire Agreement and Merger. This Agreement sets forth the entire understanding of the parties and merges and supersedes any prior or contemporaneous agreements, whether written or oral, between the parties pertaining to the subject matter hereof.

(c)    Modification. This Agreement may not be modified or terminated orally, and no modification or waiver of any of the provisions hereof shall be binding unless in writing and signed by the party against whom the same is sought to be enforced.

(d)    Waiver. Failure of a party to enforce one or more of the provisions of this Agreement or to require at any time performance of any of the obligations hereof shall not be construed to be a waiver of such provisions by such party nor to in any way affect the validity of this Agreement or such party's right thereafter to enforce any provision of this Agreement, nor to preclude such party from taking any other action at any time which it would legally be entitled to take.

(e)    Successors and Assigns. Neither party shall have the right to assign this Agreement, or any rights or obligations hereunder, without the consent of the other party; provided, however, that upon the sale of all or substantially all of the assets, business and goodwill of Employer to another company, or upon the merger or consolidation of Employer with another company, this Agreement shall inure to the benefit of, and be binding upon, both Executive and the company purchasing such assets, business and goodwill, or surviving such merger or consolidation, as the case may be, in the same manner and to the same extent as though such other company were Employer; and provided, further, that Employer shall have the right to assign this Agreement to any Affiliate or Subsidiary of Employer. Subject to the foregoing, this Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their legal representatives, heirs, successors and permitted assigns.

(f)    Communications. All notices or other communications required or permitted hereunder will be in writing and will be deemed given or delivered when delivered personally, by registered or certified mail or by overnight courier (fare prepaid) addressed as follows:

8

(i)	To Employer:	Prestige Brands Holdings, Inc.
		660 White Plains Road
		Tarrytown, New York 10591
		Attention: Chief Executive Officer

(ii)	With a copy to:	Prestige Brands Holdings, Inc.
		660 White Plains Road
		Tarrytown, New York 10591
		Attention: General Counsel

(iii)	To the Employee:	Thomas Hochuli
		5808 Emily Drive
		Doylestown, PA 18902

or to such address as a party hereto may indicate by a notice delivered to the other party. Notice will be deemed received the same day when delivered personally, five (5) days after mailing when sent by registered or certified mail, and the next business day when delivered by overnight courier. Any party hereto may change its address to which all communications and notices may be sent by addressing notices of such change in the manner provided.

(g)    Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, such invalidity or unenforceability shall not affect the validity and enforceability of the other provisions of this Agreement and the provision held to be invalid or unenforceable shall be enforced as nearly as possible according to its original terms and intent to eliminate such invalidity or unenforceability.

(h)    Governing Law. This Agreement will be governed by, construed and enforced in accordance with the laws of the State of New York, without giving effect to its conflicts of law provisions.

(i)    Arbitration. (a) Except as provided in subsection (b) of this Section 4(i), the following provisions shall apply to disputes between Employer and Executive arising out of or related to either: (i) this Agreement (including any claim that any part of this Agreement is invalid, illegal or otherwise void or voidable), or (ii) the employment relationship that exists between Employer and Executive:

(i) The parties shall first use their reasonable best efforts to discuss and negotiate a resolution of the dispute.

9

(ii) If efforts to negotiate a resolution do not succeed within 5 business days after a written request for negotiation has been made, the dispute shall be resolved timely and exclusively by final and binding arbitration in New York County or Westchester County, New York pursuant to the American Arbitration Association (“AAA”) National Rules for the Resolution of Employment Disputes (the “AAA Rules”). Arbitration must be demanded within ten (10) calendar days after the expiration of the five (5) day period referred to above. The arbitration opinion and award shall be final and binding on the Employer and the Executive and shall be enforceable by any court sitting within New York County or Westchester County, New York. Employer and Executive shall share equally all costs of arbitration excepting their own attorney’s fees unless and to the extent ordered by the arbitrator(s) to pay the attorneys’ fees of the prevailing party.

(iii) The parties recognize that this Section 4(i) means that certain claims will be reviewed and decided only before an impartial arbitrator or panel of arbitrators instead of before a court of law and/or a jury, but desire the many benefits of the arbitration process over court proceedings, including speed of resolution, lower costs and fees, and more flexible rules of evidence. The arbitration or arbitrators duly selected pursuant to the AAA’s Rules shall have the same power and authority to order any remedy for violation of a statute, regulation, or ordinance as a court would have; and shall have the same power to order discovery as a federal district court has under the Federal Rules of Civil Procedure.

(b) The provisions of this Section 4(i) shall not apply to any action by the Employer seeking to enforce its rights arising out of or related to the provisions of Sections 2 and 3 of this Agreement.

(c) This Section 4(i) is intended by the Employer and the Executive to be enforceable under the Federal Arbitration Act (“FAA”). Should it be determined by any court that the FAA does not apply, then this Section 4(i) shall be enforceable under the applicable arbitration statutes of the State of Delaware.

(j)    No Third-Party Beneficiaries. Each of the provisions of this Agreement is for the sole and exclusive benefit of the parties hereto and shall not be deemed for the benefit of any other person or entity.

(k)    Section 409A of the Internal Revenue Code.  (a) Notwithstanding any provisions of this Agreement to the contrary, if the Executive is considered a Specified Executive (as defined below) at termination of employment other than on

10

account of death or Disability, under such procedures as established by the Employer in accordance with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), benefit distributions, other than those that are deemed “separation pay” under the Treas. Reg. §1.409A-1(b)(9), that are made upon termination of employment may not commence earlier than six (6) months after the date of termination. Therefore, in the event this provision is applicable to the Executive, any distribution which would otherwise be paid to the Executive within the first six months following termination shall be accumulated and paid to the Executive in a lump sum on the first day of the seventh month following termination. All subsequent distributions shall be paid in the manner specified. “Specified Executive” means a key employee (as defined in Section 416(i) of the Code without regard to paragraph 5 thereof) of the Employer if any stock of the Employer is publicly traded on an established securities market or otherwise.

(b) With respect to the payment of all benefits under the Agreement, including separation pay and deferred compensation, whether a “termination of employment” takes place is determined based on the facts and circumstances surrounding the termination of the Executive’s employment and whether the Employer and the Executive intended for the Executive to provide significant services for the Employer following such termination. A change in the Executive’s employment status will not be considered a termination of employment if:

(i) the Executive continues to provide services as an employee of the Employer at an annual rate that is twenty percent (20%) or more of the services rendered, on average, during the immediately preceding three full calendar years of employment (or, if employed less than three years, such lesser period) and the annual remuneration for such services is twenty percent (20%) or more of the average annual remuneration earned during the final three full calendar years of employment (or, if less, such lesser period), or

(ii) the Executive continues to provide services to the Employer in a capacity other than as an employee of the Employer at an annual rate that is fifty percent (50%) or more of the services rendered, on average, during the immediately preceding three full calendar years of employment (or if employed less than three years, such lesser period) and the annual remuneration for such services is fifty percent (50%) or more of the average annual remuneration earned during the final three full calendar years of employment (or if less, such lesser period).

For purposes of applying the provisions of Section 409A of the Code, a reference to the Employer shall also be deemed a reference to any affiliate thereof within the

11

contemplation of Sections 414(b) and 414(c) of the Code. For purposes of this Agreement, the definition of “termination of employment” shall apply to all uses of such term, whether capitalized or not.

(l)    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.

(e)[Remainder of page intentionally left blank]

12

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first written above.

PRESTIGE BRANDS HOLDINGS, INC.

By: /s/ Matthew M. Mannelly Name: Matthew M. Mannelly

Title: Chief Executive Officer

By: /s/ Thomas Hochuli

Name: Thomas Hochuli

DEFINITIONS

“Affiliate” means, with respect to any Person, any other Person who directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms “controlled” and “controlling” have meanings correlative thereto.

“Cause” is defined as (i) your willful and continued failure to substantially perform your duties with Employer (other than any such failure resulting from your incapacity due to physical or mental illness) that has not been cured within 10 days after a written demand for substantial performance is delivered to you by the Board, which demand specifically identifies the manner in which the Board believes that you have not substantially performed your duties, (ii) the willful engaging by you in conduct which is demonstrably and materially injurious to Employer or its Affiliates, monetarily or otherwise, (iii) your conviction (or plea of nolo contendere) for any felony or any other crime involving dishonesty, fraud or moral turpitude, (iv) your breach of fiduciary duty to Employer or its Affiliates, (v) any violation of Employer's policies relating to compliance with applicable laws which have a material adverse effect on Employer or its Affiliates or (vi) your breach of any restrictive covenant. For purposes of clauses (i) and (ii) of this definition, no act, or failure to act, on your part shall be deemed "willful" unless done, or omitted to be done, by you not in good faith and without reasonable belief that your act, or failure to act, was in the best interest of Employer.

“Disability” means the Executive: (i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months; or (ii) is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees or directors of the Employer. Medical determination of Disability may be made by either the Social Security Administration or by the provider of an accident or health plan covering employees or directors of the Employer provided that the definition of “disability” applied under such disability insurance program complies with the requirements of the preceding sentence. Upon the request of the plan administrator, the Executive must submit proof to the plan administrator of the Social Security Administration’s or the provider’s determination. For purposes of this Agreement the definition of “Disability” shall apply to all uses of such term, whether capitalized or not.

“Good Reason” means that the Executive terminated his employment with the Employer because, within the twelve (12) month period preceding the Executive’s

termination, one or more of the following conditions arose and the Executive notified the Employer of such condition within 90 days of its occurrence and the Employer did not remedy such condition within 30 days:

(i) a material diminution in the Executive’s base salary as in effect on the date hereof or as the same may be increased from time to time;

(ii) a material diminution in the Executive’s authority, duties, or responsibilities;

(iii) the relocation of the Employer’s headquarters outside a thirty-mile radius of Tarrytown, New York or the Employer’s requiring the Executive to be based at any place other than a location within a thirty-mile radius of Tarrytown, New York, except for reasonably required travel on the Employer’s business; or

(iv) any other action or inaction that constitutes a material breach by the Employer of this Agreement.

“Person” means any person or entity, whether an individual, trustee, corporation, limited liability company, partnership, trust, unincorporated organization, business association, firm, joint venture, governmental authority or similar entity.

“Subsidiary” of any specified Person shall mean any corporation fifty percent (50%) or more of the outstanding capital stock of which, or any partnership, joint venture, limited liability company or other entity fifty percent (50%) or more of the ownership interests of which, is directly or indirectly owned or controlled by such specified Person, or any such corporation, partnership, joint venture, limited liability company, or other entity which may otherwise be controlled, directly or indirectly, by such Person.

EX-10.2

Exhibit 10.2

RA 660 WHITE PLAINS ROAD LLC

c/o RXR Realty LLC

660 White Plains Road

Tarrytown, New York 10591

August 26, 2014

Prestige Brands, Inc.

660 White Plains Road

Tarrytown, New York 10591

Re: First Amendment to Lease, made as of June 30, 2014 (the “First Amendment”), between RA 660 White Plains Road LLC (“Landlord”) and Prestige Brands, Inc. (“Tenant”) for the Lease of certain Demised Premises in the Building located at 660 White Plains Road, Tarrytown, New York

Dear Valued Tenant:

This letter agreement will confirm the understanding and agreement of the parties that each reference in Section 2.2 of the First Amendment to the date “September 1, 2014” shall be deemed to have been deleted and replaced with a corresponding reference to the date “October 1, 2014.”

If the foregoing accurately presents the understanding and agreement of the parties with respect to the subject matter addressed herein, then please countersign and return to Landlord two (2) counterpart originals of this letter agreement at your earliest convenience.

Sincerely,

RA 660 WHITE PLAINS ROAD LLC

By: /s/ Richard J. Conniff

Name: Richard J. Conniff

Title: Authorized Person

ACKNOWLEDGED AND AGREED:

PRESTIGE BRANDS, INC.

By:/s/ Ron Lombardi

Name: Ron Lombardi

Title: CFO

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Matthew M. Mannelly, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Prestige Brands Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:	November 6, 2014	/s/ Matthew M. Mannelly
		Matthew M. Mannelly
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Ronald M. Lombardi, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Prestige Brands Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:	November 6, 2014	/s/ Ronald M. Lombardi
		Ronald M. Lombardi
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew M. Mannelly, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Brands Holdings, Inc. on Form 10-Q for the quarter ended September 30, 2014, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Brands Holdings, Inc.

/s/ Matthew M. Mannelly

Name: Matthew M. Mannelly

Title: Chief Executive Officer

(Principal Executive Officer)

Date: November 6, 2014

EX-32.2

EXHIBIT 32.2

CERTIFICATION

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ronald M. Lombardi, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Brands Holdings, Inc. on Form 10-Q for the quarter ended September 30, 2014, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Brands Holdings, Inc.

/s/ Ronald M. Lombardi

Name: Ronald M. Lombardi

Title: Chief Financial Officer

(Principal Financial Officer)

Date: November 6, 2014

XML

Business Segments (Tables)

6 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our reportable segments.

	Three Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	138,138		$	17,331	$	25,246	$	180,715
Elimination of intersegment revenues	(710		)	—		—		(710		)
Third-party segment revenues	137,428			17,331		25,246		180,005
Other revenues	150			23		1,091		1,264
Total segment revenues	137,578			17,354		26,337		181,269
Cost of sales	52,185			6,595		19,947		78,727
Gross profit	85,393			10,759		6,390		102,542
Advertising and promotion	21,442			3,035		567		25,044
Contribution margin	$	63,951		$	7,724	$	5,823	77,498
Other operating expenses								30,980
Operating income								46,518
Other expense								18,193
Income before income taxes								28,325
Provision for income taxes								11,862
Net income								$	16,463

	Six Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	249,112		$	31,022	$	45,839	$	325,973
Elimination of intersegment revenues	(1,427		)	—		—		(1,427		)
Third-party segment revenues	247,685			31,022		45,839		324,546
Other revenues	327			58		2,040		2,425
Total segment revenues	248,012			31,080		47,879		326,971
Cost of sales	94,526			11,679		36,358		142,563
Gross profit	153,486			19,401		11,521		184,408
Advertising and promotion	37,794			5,375		971		44,140
Contribution margin	$	115,692		$	14,026	$	10,550	140,268
Other operating expenses								50,947
Operating income								89,321
Other expense								32,846
Income before income taxes								56,475
Provision for income taxes								23,280
Net income								$	33,195

	Three Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	132,944		$	9,008	$	24,374	$	166,326
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	132,125			9,008		24,374		165,507
Other revenues	150			7		1,281		1,438
Total segment revenues	132,275			9,015		25,655		166,945
Cost of sales	50,987			4,338		18,398		73,723
Gross profit	81,288			4,677		7,257		93,222
Advertising and promotion	22,547			1,446		554		24,547
Contribution margin	$	58,741		$	3,231	$	6,703	68,675
Other operating expenses								14,913
Operating income								53,762
Other expense								16,439
Income before income taxes								37,323
Provision for income taxes								4,531
Net income								$	32,792

	Six Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	251,880		$	12,422	$	43,666	$	307,968
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	251,061			12,422		43,666		307,149
Other revenues	300			14		1,994		2,308
Total segment revenues	251,361			12,436		45,660		309,457
Cost of sales	94,533			5,803		32,875		133,211
Gross profit	156,828			6,633		12,785		176,246
Advertising and promotion	40,097			1,710		1,421		43,228
Contribution margin	$	116,731		$	4,923	$	11,364	133,018
Other operating expenses								29,815
Operating income								103,203
Other expense								32,344
Income before income taxes								70,859
Provision for income taxes								17,375
Net income								$	53,484

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.

	Three Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,072	$	792	$	—	$	29,864
Cough & Cold	24,771		5,460		—		30,231
Women's Health	9,119		658		—		9,777
Gastrointestinal	20,896		5,598		—		26,494
Eye & Ear Care	21,405		4,028		—		25,433
Dermatologicals	17,459		687		—		18,146
Oral Care	12,934		127		—		13,061
Other OTC	1,922		4		—		1,926
Household Cleaning	—		—		26,337		26,337
Total segment revenues	$	137,578	$	17,354	$	26,337	$	181,269

	Six Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	54,103	$	1,457	$	—	$	55,560
Cough & Cold	44,814		10,259		—		55,073
Women's Health	9,487		1,176				10,663
Gastrointestinal	41,534		8,096		—		49,630
Eye & Ear Care	42,130		8,670		—		50,800
Dermatologicals	29,720		1,229		—		30,949
Oral Care	23,121		189		—		23,310
Other OTC	3,103		4		—		3,107
Household Cleaning	—		—		47,879		47,879
Total segment revenues	$	248,012	$	31,080	$	47,879	$	326,971

	Three Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,343	$	698	$	—	$	30,041
Cough & Cold	28,695		5,023		—		33,718
Women's Health	501		633		—		1,134
Gastrointestinal	21,695		301		—		21,996
Eye & Ear Care	19,378		1,625		—		21,003
Dermatologicals	17,716		605		—		18,321
Oral Care	13,028		130		—		13,158
Other OTC	1,919		—		—		1,919
Household Cleaning	—		—		25,655		25,655
Total segment revenues	$	132,275	$	9,015	$	25,655	$	166,945

	Six Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	57,479	$	727	$	—	$	58,206
Cough & Cold	49,193		6,006		—		55,199
Women's Health	988		633		—		1,621
Gastrointestinal	43,453		312		—		43,765
Eye & Ear Care	39,710		3,885		—		43,595
Dermatologicals	32,347		696		—		33,043
Oral Care	24,114		177		—		24,291
Other OTC	4,077		—		—		4,077
Household Cleaning	—		—		45,660		45,660
Total segment revenues	$	251,361	$	12,436	$	45,660	$	309,457

Allocation of Long-Term Assets to Segments

At September 30, 2014, approximately 95.0% of our consolidated goodwill and intangible assets were located in the United States and approximately 5.0% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	23,193	$	7,389	$	293,993
Intangible assets
Indefinite-lived	1,723,498		97,740		119,820		1,941,058
Finite-lived	196,145		1,449		25,295		222,889
Intangible assets, net	1,919,643		99,189		145,115		2,163,947
Total	$	2,183,054	$	122,382	$	152,504	$	2,457,940

XML

Other Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Payables and Accruals [Abstract]
Accrued marketing costs	$ 16,187	$ 11,812
Accrued compensation costs	5,129	6,232
Accrued broker commissions	851	1,019
Income taxes payable	1,186	1,854
Accrued professional fees	2,344	2,002
Deferred rent	1,109	1,258
Accrued production costs	3,364	1,506
Other accrued liabilities	3,916	763
Total other accrued liabilities	$ 34,086	$ 26,446

XML

Inventories (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 3,929,000	$ 3,099,000
Work in process	3,456,000	0
Finished goods	75,490,000	62,487,000
Inventories	82,875,000	65,586,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4,800,000	$ 1,100,000

XML

Income Taxes (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate	41.90%	12.10%	41.20%	24.50%
One-time benefit due to recent tax law change			$ 9.1
Net operating loss carryforwards	78.2		78.2
Operating loss carryforwards, limitation on use, annual amount	33.6		33.6
Uncertain tax liability	$ 1.2		$ 1.2		$ 1.2

XML

Long-Term Debt (2012 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%
2012 Senior Notes
Debt Instrument [Line Items]
Debt issuance costs capitalized		$ 12,600,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 250,000,000.0
Debt instrument, stated interest rate		8.125%

XML

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues
Net sales	$ 180,005	$ 165,507	$ 324,546	$ 307,149
Other revenues	1,264	1,438	2,425	2,308
Total revenues	181,269	166,945	326,971	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	78,727	73,723	142,563	133,211
Gross profit	102,542	93,222	184,408	176,246
Operating Expenses
Advertising and promotion	25,044	24,547	44,140	43,228
General and administrative	27,128	11,619	44,134	23,253
Depreciation and amortization	3,852	3,294	6,813	6,562
Total operating expenses	56,024	39,460	95,087	73,043
Operating income	46,518	53,762	89,321	103,203
Other (income) expense
Interest income	(15)	(25)	(47)	(28)
Interest expense	18,208	16,464	32,893	32,372
Equity in (income) loss of subsidiaries	0	0	0	0
Total other (income) expense	18,193	16,439	32,846	32,344
Income before income taxes	28,325	37,323	56,475	70,859
Provision for income taxes	11,862	4,531	23,280	17,375
Net income	16,463	32,792	33,195	53,484
Comprehensive income, net of tax:
Currency translation adjustments	(10,830)	1,122	(8,104)	1,123
Total other comprehensive (loss) income	(10,830)	1,122	(8,104)	1,123
Comprehensive income	5,633	33,914	25,091	54,607
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	1,109	891	2,254	2,390
Depreciation and amortization	870	517	1,512	1,034
Total operating expenses	1,979	1,408	3,766	3,424
Operating income	(1,979)	(1,408)	(3,766)	(3,424)
Other (income) expense
Interest income	(12,245)	(12,778)	(24,378)	(24,991)
Interest expense	8,629	8,687	17,177	17,294
Equity in (income) loss of subsidiaries	(17,577)	(30,344)	(33,256)	(50,199)
Total other (income) expense	(21,193)	(34,435)	(40,457)	(57,896)
Income before income taxes	19,214	33,027	36,691	54,472
Provision for income taxes	2,751	235	3,496	988
Net income	16,463	32,792	33,195	53,484
Comprehensive income, net of tax:
Currency translation adjustments	(10,830)	1,122	(8,104)	1,123
Total other comprehensive (loss) income	(10,830)	1,122	(8,104)	1,123
Comprehensive income	5,633	33,914	25,091	54,607
Prestige Brands, Inc., the issuer or the borrower
Revenues
Net sales	27,167	25,237	52,577	49,386
Other revenues	95	67	225	135
Total revenues	27,262	25,304	52,802	49,521
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	10,426	9,338	19,874	18,796
Gross profit	16,836	15,966	32,928	30,725
Operating Expenses
Advertising and promotion	2,699	3,594	5,388	6,924
General and administrative	3,441	1,481	5,914	3,124
Depreciation and amortization	145	143	290	285
Total operating expenses	6,285	5,218	11,592	10,333
Operating income	10,551	10,748	21,336	20,392
Other (income) expense
Interest income	(16,719)	(14,005)	(30,944)	(28,328)
Interest expense	18,208	16,464	32,893	32,372
Equity in (income) loss of subsidiaries	(9,825)	(20,599)	(20,723)	(35,152)
Total other (income) expense	(8,336)	(18,140)	(18,774)	(31,108)
Income before income taxes	18,887	28,888	40,110	51,500
Provision for income taxes	3,262	1,064	6,979	4,151
Net income	15,625	27,824	33,131	47,349
Comprehensive income, net of tax:
Currency translation adjustments	(10,830)	1,122	(8,104)	1,123
Total other comprehensive (loss) income	(10,830)	1,122	(8,104)	1,123
Comprehensive income	4,795	28,946	25,027	48,472
Combined Subsidiary Guarantors
Revenues
Net sales	138,336	132,821	247,234	249,091
Other revenues	1,241	1,431	2,340	2,294
Total revenues	139,577	134,252	249,574	251,385
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	64,812	61,513	115,327	111,502
Gross profit	74,765	72,739	134,247	139,883
Operating Expenses
Advertising and promotion	19,311	19,556	33,377	34,700
General and administrative	20,329	8,358	29,319	16,815
Depreciation and amortization	2,729	2,589	4,818	5,184
Total operating expenses	42,369	30,503	67,514	56,699
Operating income	32,396	42,236	66,733	83,184
Other (income) expense
Interest income	(1,760)	(710)	(2,522)	(710)
Interest expense	20,333	18,093	38,138	36,021
Equity in (income) loss of subsidiaries	(1,870)	(1,189)	(911)	(1,868)
Total other (income) expense	16,703	16,194	34,705	33,443
Income before income taxes	15,693	26,042	32,028	49,741
Provision for income taxes	4,976	2,922	11,202	11,738
Net income	10,717	23,120	20,826	38,003
Comprehensive income, net of tax:
Currency translation adjustments	(10,830)	1,122	(8,104)	1,123
Total other comprehensive (loss) income	(10,830)	1,122	(8,104)	1,123
Comprehensive income	(113)	24,242	12,722	39,126
Combined Non-Guarantor Subsidiaries
Revenues
Net sales	15,212	7,449	26,163	8,672
Other revenues	436	668	838	1,102
Total revenues	15,648	8,117	27,001	9,774
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	5,767	3,600	9,790	4,136
Gross profit	9,881	4,517	17,211	5,638
Operating Expenses
Advertising and promotion	3,034	1,397	5,375	1,604
General and administrative	2,249	889	6,647	924
Depreciation and amortization	108	45	193	59
Total operating expenses	5,391	2,331	12,215	2,587
Operating income	4,490	2,186	4,996	3,051
Other (income) expense
Interest income	(11)	(22)	(40)	(24)
Interest expense	1,758	710	2,522	710
Equity in (income) loss of subsidiaries	0	0	0	0
Total other (income) expense	1,747	688	2,482	686
Income before income taxes	2,743	1,498	2,514	2,365
Provision for income taxes	873	310	1,603	498
Net income	1,870	1,188	911	1,867
Comprehensive income, net of tax:
Currency translation adjustments	(10,830)	1,122	(8,104)	1,123
Total other comprehensive (loss) income	(10,830)	1,122	(8,104)	1,123
Comprehensive income	(8,960)	2,310	(7,193)	2,990
Eliminations
Revenues
Net sales	(710)	0	(1,428)	0
Other revenues	(508)	(728)	(978)	(1,223)
Total revenues	(1,218)	(728)	(2,406)	(1,223)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(2,278)	(728)	(2,428)	(1,223)
Gross profit	1,060	0	22	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	1,060	0	22	0
Other (income) expense
Interest income	30,720	27,490	57,837	54,025
Interest expense	(30,720)	(27,490)	(57,837)	(54,025)
Equity in (income) loss of subsidiaries	29,272	52,132	54,890	87,219
Total other (income) expense	29,272	52,132	54,890	87,219
Income before income taxes	(28,212)	(52,132)	(54,868)	(87,219)
Provision for income taxes	0	0	0	0
Net income	(28,212)	(52,132)	(54,868)	(87,219)
Comprehensive income, net of tax:
Currency translation adjustments	32,490	(3,366)	24,312	(3,369)
Total other comprehensive (loss) income	32,490	(3,366)	24,312	(3,369)
Comprehensive income	$ 4,278	$ (55,498)	$ (30,556)	$ (90,588)

XML

Acquisitions Pro Forma Information (Details) (Insight Pharmaceuticals, USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Insight Pharmaceuticals
Business Acquisition [Line Items]
Revenues	$ 393,140	$ 389,490
Net income	$ 37,957	$ 53,511
Earnings per share:
Basic EPS (in dollars per share)	$ 0.73	$ 1.04
Diluted EPS (in dollars per share)	$ 0.72	$ 1.03

XML

Other Accrued Liabilities (Tables)

6 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Other Accrued Liabilities

Other accrued liabilities consist of the following:

(In thousands)	September 30, 2014		March 31, 2014
Accrued marketing costs	$	16,187	$	11,812
Accrued compensation costs	5,129		6,232
Accrued broker commissions	851		1,019
Income taxes payable	1,186		1,854
Accrued professional fees	2,344		2,002
Deferred rent	1,109		1,258
Accrued production costs	3,364		1,506
Other accrued liabilities	3,916		763
	$	34,086	$	26,446

XML

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	$ 21,748	$ 28,331	$ 26,833	$ 15,670
Accounts receivable, net	98,644	65,050
Inventories	82,875	65,586
Deferred income tax assets	9,171	6,544
Prepaid expenses and other current assets	9,935	11,674
Total current assets	222,373	177,185
Property and equipment, net	12,420	9,597
Goodwill	293,993	190,911
Intangible assets, net	2,163,947	1,394,817
Other long-term assets	32,937	23,153
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,725,670	1,795,663
Current liabilities
Current portion of long term debt	7,200	0
Accounts payable	58,538	48,286
Accrued interest payable	12,086	9,626
Other accrued liabilities	34,086	26,446
Total current liabilities	111,910	84,358
Long-term debt
Principal amount	1,691,400	937,500
Less unamortized discount	(6,289)	(3,086)
Long-term debt, net of unamortized discount	1,685,111	934,414
Deferred income tax liabilities	334,297	213,204
Other long-term liabilities	313	327
Intercompany payables	0	0
Total Liabilities	2,131,631	1,232,303
Stockholders' Equity
Preferred share rights	0
Common stock	524	520
Additional paid-in capital	421,574	414,387
Treasury stock, at cost	(3,034)	(1,431)
Accumulated other comprehensive (loss) income, net of tax	(7,365)	739
Retained earnings (accumulated deficit)	182,340	149,145
Total Stockholders' Equity	594,039	563,360
Total Liabilities and Stockholders' Equity	2,725,670	1,795,663
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	10,465	24,644	23,667	14,720
Accounts receivable, net	7	473
Inventories	0	0
Deferred income tax assets	1,139	260
Prepaid expenses and other current assets	2,841	8,004
Total current assets	14,452	33,381
Property and equipment, net	8,580	8,966
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,203,499	655,146
Investment in subsidiary	1,519,129	1,497,357
Total Assets	2,745,660	2,194,850
Current liabilities
Current portion of long term debt	0
Accounts payable	2,084	4,416
Accrued interest payable	0	0
Other accrued liabilities	6,407	7,728
Total current liabilities	8,491	12,144
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,143,130	1,619,346
Total Liabilities	2,151,621	1,631,490
Stockholders' Equity
Preferred share rights	0
Common stock	524	520
Additional paid-in capital	421,574	414,387
Treasury stock, at cost	(3,034)	(1,431)
Accumulated other comprehensive (loss) income, net of tax	(7,365)	739
Retained earnings (accumulated deficit)	182,340	149,145
Total Stockholders' Equity	594,039	563,360
Total Liabilities and Stockholders' Equity	2,745,660	2,194,850
Prestige Brands, Inc., the issuer or the borrower
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	14,352	14,245
Inventories	9,666	14,357
Deferred income tax assets	823	925
Prepaid expenses and other current assets	354	113
Total current assets	25,195	29,640
Property and equipment, net	90	112
Goodwill	66,007	66,007
Intangible assets, net	192,593	192,861
Other long-term assets	32,937	23,153
Intercompany receivables	2,688,676	1,824,482
Investment in subsidiary	1,213,732	749,947
Total Assets	4,219,230	2,886,202
Current liabilities
Current portion of long term debt	7,200
Accounts payable	9,508	7,658
Accrued interest payable	12,086	9,626
Other accrued liabilities	2,970	2,117
Total current liabilities	31,764	19,401
Long-term debt
Principal amount	1,691,400	937,500
Less unamortized discount	(6,289)	(3,086)
Long-term debt, net of unamortized discount	1,685,111	934,414
Deferred income tax liabilities	58,076	56,827
Other long-term liabilities	0	0
Intercompany payables	995,186	451,497
Total Liabilities	2,770,137	1,462,139
Stockholders' Equity
Preferred share rights	0
Common stock	0	0
Additional paid-in capital	1,280,948	1,280,945
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(7,365)	739
Retained earnings (accumulated deficit)	175,510	142,379
Total Stockholders' Equity	1,449,093	1,424,063
Total Liabilities and Stockholders' Equity	4,219,230	2,886,202
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	5,034	0	0	0
Accounts receivable, net	76,165	45,885
Inventories	67,420	46,309
Deferred income tax assets	6,743	4,914
Prepaid expenses and other current assets	6,023	2,898
Total current assets	161,385	100,006
Property and equipment, net	2,297	226
Goodwill	204,794	101,540
Intangible assets, net	1,871,933	1,169,943
Other long-term assets	0	0
Intercompany receivables	599,886	656,759
Investment in subsidiary	79,877	34,562
Total Assets	2,920,172	2,063,036
Current liabilities
Current portion of long term debt	0
Accounts payable	42,634	33,553
Accrued interest payable	0	0
Other accrued liabilities	20,746	13,443
Total current liabilities	63,380	46,996
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	276,180	156,327
Other long-term liabilities	0	0
Intercompany payables	1,295,207	1,037,105
Total Liabilities	1,634,767	1,240,428
Stockholders' Equity
Preferred share rights	0
Common stock	0	0
Additional paid-in capital	1,131,578	681,503
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(7,365)	739
Retained earnings (accumulated deficit)	161,192	140,366
Total Stockholders' Equity	1,285,405	822,608
Total Liabilities and Stockholders' Equity	2,920,172	2,063,036
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	6,249	3,687	3,166	950
Accounts receivable, net	8,120	4,447
Inventories	6,777	5,930
Deferred income tax assets	466	445
Prepaid expenses and other current assets	717	659
Total current assets	22,329	15,168
Property and equipment, net	1,453	293
Goodwill	23,192	23,364
Intangible assets, net	99,421	32,013
Other long-term assets	0	0
Intercompany receivables	10,045	13,595
Investment in subsidiary	0	0
Total Assets	156,440	84,433
Current liabilities
Current portion of long term debt	0
Accounts payable	4,312	2,659
Accrued interest payable	0	0
Other accrued liabilities	3,963	3,158
Total current liabilities	8,275	5,817
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	41	50
Other long-term liabilities	313	327
Intercompany payables	68,583	42,034
Total Liabilities	77,212	48,228
Stockholders' Equity
Preferred share rights	0
Common stock	0	0
Additional paid-in capital	74,031	23,815
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(7,365)	739
Retained earnings (accumulated deficit)	12,562	11,651
Total Stockholders' Equity	79,228	36,205
Total Liabilities and Stockholders' Equity	156,440	84,433
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories	(988)	(1,010)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(988)	(1,010)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(4,502,106)	(3,149,982)
Investment in subsidiary	(2,812,738)	(2,281,866)
Total Assets	(7,315,832)	(5,432,858)
Current liabilities
Current portion of long term debt	0
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(4,502,106)	(3,149,982)
Total Liabilities	(4,502,106)	(3,149,982)
Stockholders' Equity
Preferred share rights	0
Common stock	0	0
Additional paid-in capital	(2,486,557)	(1,986,263)
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	22,095	(2,217)
Retained earnings (accumulated deficit)	(349,264)	(294,396)
Total Stockholders' Equity	(2,813,726)	(2,282,876)
Total Liabilities and Stockholders' Equity	$ (7,315,832)	$ (5,432,858)

XML

Concentrations of Risk (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 brand	Sep. 30, 2013
Concentration Risk [Line Items]
Number of third-party manufacturers	101	50	101	50
Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	40.60%	41.80%	41.20%	43.00%
Number of highest selling brands comprising group against which concentration risk is measured			5
Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	19.20%	18.00%	20.40%
Number of customers exceeding concentration risk benchmark			1	1
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			77.40%	77.90%
Number of third-party manufacturers with long-term contracts			47	22
Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			21.50%

XML

Long-Term Debt (2013 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 400,000,000.0
Debt instrument, stated interest rate	5.375%
Debt issuance costs capitalized	$ 7,200,000

XML

Business Segments (Assets by Segment) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 293,993	$ 190,911
Indefinite-lived intangibles	1,941,058
Finite-lived intangibles	222,889
Intangible assets, net (excluding goodwill)	2,163,947	1,394,817
Intangible assets, net (including goodwill)	2,457,940
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	263,411	160,157
Indefinite-lived intangibles	1,723,498
Finite-lived intangibles	196,145
Intangible assets, net (excluding goodwill)	1,919,643
Intangible assets, net (including goodwill)	2,183,054
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	23,193	23,365
Indefinite-lived intangibles	97,740
Finite-lived intangibles	1,449
Intangible assets, net (excluding goodwill)	99,189
Intangible assets, net (including goodwill)	122,382
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	7,389	7,389
Indefinite-lived intangibles	119,820
Finite-lived intangibles	25,295
Intangible assets, net (excluding goodwill)	145,115
Intangible assets, net (including goodwill)	$ 152,504

XML

Condensed Consolidating Financial Statements Narrative (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended	6 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Prestige Brands, Inc., the issuer or the borrower
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	$ (48.1)	$ 48.1
Corrections adjustment for cumulative adjustment		1
Prestige Brands Holdings, Inc.
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	0.6	0.6
Eliminations
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	47.5	47.5
Combined Subsidiary Guarantors
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for cumulative adjustment		$ 1

XML

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 sqft	Sep. 30, 2013
Operating Leased Assets [Line Items]
Additional space			15,470
2015 (Remaining six months ending March 31, 2015)	$ 1,203,000		$ 1,203,000
2016	1,923,000		1,923,000
2017	1,849,000		1,849,000
2018	1,856,000		1,856,000
2019	1,864,000		1,864,000
Thereafter	2,465,000		2,465,000
Total future minimum payments due	11,160,000		11,160,000
Rent expense	300,000	500,000	700,000	800,000
Facilities
Operating Leased Assets [Line Items]
2015 (Remaining six months ending March 31, 2015)	859,000		859,000
2016	1,612,000		1,612,000
2017	1,772,000		1,772,000
2018	1,856,000		1,856,000
2019	1,864,000		1,864,000
Thereafter	2,465,000		2,465,000
Total future minimum payments due	10,428,000		10,428,000
Equipment
Operating Leased Assets [Line Items]
2015 (Remaining six months ending March 31, 2015)	344,000		344,000
2016	311,000		311,000
2017	77,000		77,000
2018	0		0
2019	0		0
Thereafter	0		0
Total future minimum payments due	$ 732,000		$ 732,000

XML

Business and Basis of Presentation (Policies)

6 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31^st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three and six months ended September 30, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.

Revision

Revision

We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.

Accounts Receivable

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

Inventories

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.

Deferred Financing Costs

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.

Revenue Recognition

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.  

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

Recently Issued Accounting Standards

In August 2014, the FASB issued Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

XML

Goodwill (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014 business	Sep. 30, 2014 North American OTC Healthcare	Sep. 30, 2014 International OTC Healthcare	Sep. 30, 2014 Household Cleaning	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte
Goodwill [Roll Forward]
Balance — March 31, 2014	$ 190,911	$ 160,157	$ 23,365	$ 7,389	$ 103,255	$ 1,224
Additions	104,478	103,254	1,224	0
Effects of foreign currency exchange rates	(1,396)	0	(1,396)	0
Balance — September 30, 2014	$ 293,993	$ 263,411	$ 23,193	$ 7,389	$ 103,255	$ 1,224
Number of acquisitions	2

XML

Business and Basis of Presentation (Intangible Assets) (Details)	6 Months Ended
	Sep. 30, 2014
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

XML

Business Segments (Revenue by Product) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue from External Customer [Line Items]
Revenues	$ 181,269	$ 166,945	$ 326,971	$ 309,457
Analgesics
Revenue from External Customer [Line Items]
Revenues	29,864	30,041	55,560	58,206
Cough & Cold
Revenue from External Customer [Line Items]
Revenues	30,231	33,718	55,073	55,199
Women's Health
Revenue from External Customer [Line Items]
Revenues	9,777	1,134	10,663	1,621
Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	26,494	21,996	49,630	43,765
Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	25,433	21,003	50,800	43,595
Dermatologicals
Revenue from External Customer [Line Items]
Revenues	18,146	18,321	30,949	33,043
Oral Care
Revenue from External Customer [Line Items]
Revenues	13,061	13,158	23,310	24,291
Other OTC
Revenue from External Customer [Line Items]
Revenues	1,926	1,919	3,107	4,077
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	26,337	25,655	47,879	45,660
North American OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	137,578	132,275	248,012	251,361
North American OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	29,072	29,343	54,103	57,479
North American OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	24,771	28,695	44,814	49,193
North American OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	9,119	501	9,487	988
North American OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	20,896	21,695	41,534	43,453
North American OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	21,405	19,378	42,130	39,710
North American OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	17,459	17,716	29,720	32,347
North American OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	12,934	13,028	23,121	24,114
North American OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	1,922	1,919	3,103	4,077
North American OTC Healthcare | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
International OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	17,354	9,015	31,080	12,436
International OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	792	698	1,457	727
International OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	5,460	5,023	10,259	6,006
International OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	658	633	1,176	633
International OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	5,598	301	8,096	312
International OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	4,028	1,625	8,670	3,885
International OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	687	605	1,229	696
International OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	127	130	189	177
International OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	4	0	4	0
International OTC Healthcare | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	26,337	25,655	47,879	45,660
Household Cleaning | Analgesics
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Women's Health
Revenue from External Customer [Line Items]
Revenues	0	0		0
Household Cleaning | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Oral Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Other OTC
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	$ 26,337	$ 25,655	$ 47,879	$ 45,660

XML

Share-Based Compensation (Tables)

6 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company's restricted shares granted under the Plan is presented below:

Restricted Shares	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Six months ended September 30, 2013
Vested and nonvested at March 31, 2013	421.3		$	11.01
Granted	120.6		30.19
Vested and issued	(54.7	)	8.11
Forfeited	(3.6	)	13.24
Vested and nonvested at September 30, 2013	483.6		16.11
Vested at September 30, 2013	83.1		9.63
Six months ended September 30, 2014:
Vested and nonvested at March 31, 2014	437.5		$	16.76
Granted	104.4		33.30
Vested and issued	(120.7	)	13.34
Forfeited	(14.4	)	20.78
Vested and nonvested at September 30, 2014	406.8		21.88
Vested at September 30, 2014	76.6		11.62

Stock Options, Valuation Assumptions

	Six Months Ended September 30,
	2014			2013
Expected volatility	47.3		%	48.0		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	2.2		%	1.3		%

Stock Option Activity

A summary of option activity under the Plan is as follows:

Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Six months ended September 30, 2013:
Outstanding at March 31, 2013	1,386.4		$	10.43
Granted	227.7		29.94
Exercised	(539.4	)	9.54
Forfeited or expired	(8.0	)	13.24
Outstanding at September 30, 2013	1,066.7		15.02		6.5	$	16,110
Exercisable at September 30, 2013	225.5		11.42		7.7	4,216
Six months ended September 30, 2014:
Outstanding at March 31, 2014	994.9		$	15.24
Granted	307.5		33.50
Exercised	(284.4	)	9.70
Forfeited or expired	(32.5	)	25.61
Outstanding at September 30, 2014	985.5		22.19		8.0	$	10,364
Exercisable at September 30, 2014	416.0		14.31		6.8	7,514

XML

Intangible Assets Narrative (Details) (USD $)	3 Months Ended	6 Months Ended			0 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2014 business	Sep. 30, 2014 Minimum	Sep. 30, 2014 Maximum	Sep. 03, 2014 Insight Pharmaceuticals	Sep. 30, 2014 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte
Finite-Lived Intangible Assets [Line Items]
Number of acquisitions		2
Intangible Assets							$ 724,374,000	$ 73,580,000
Acquired intangible assets sold on acquisition date					17,700,000
Weighted average remaining life for finite-lived intangible assets		14 years 6 months				16 years 1 month 12 days
Amortization of Intangible Assets	$ 2,800,000	$ 5,064,000
Intangible assets, useful lives			3 years	30 years

XML

Share-Based Compensation Restricted Stock Units Activity) (Details) (Restricted Stock Units (RSUs), USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Restricted Stock Units (RSUs)
Shares
Outstanding, beginning of period (in shares)	437,500	421,300
Granted (in shares)	104,400	120,600
Vested and issued (in shares)	120,700	(54,700)
Forfeited (in shares)	(14,400)	(3,600)
Outstanding, end of period (in shares)	406,800	483,600
Vested, end of period (in shares)	76,600	83,100
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 16.76	$ 11.01
Granted, weighted-average grant-date fair value (in USD per share)	$ 33.30	$ 30.19
Vested and issued, weighted-average grant-date fair value (in USD per share)	$ 13.34	$ 8.11
Forfeited, weighted-average grant-date fair value (in USD per share)	$ 20.78	$ 13.24
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$ 21.88	$ 16.11
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 11.62	$ 9.63

XML

Fair Value Measurements (Details) (USD $)	Sep. 30, 2014 Revolving Credit Facility 2012 ABL Revolver Carrying Value	Dec. 17, 2013 Senior Notes 2013 Senior Notes	Sep. 30, 2014 Senior Notes 2013 Senior Notes Carrying Value	Mar. 31, 2014 Senior Notes 2013 Senior Notes Carrying Value	Jan. 31, 2012 Senior Notes 2012 Senior Notes	Sep. 30, 2014 Senior Notes 2012 Senior Notes Carrying Value	Mar. 31, 2014 Senior Notes 2012 Senior Notes Carrying Value	Sep. 30, 2014 Senior Notes Nonrecurring Fair Value, Inputs, Level 2 2013 Senior Notes Market Value	Mar. 31, 2014 Senior Notes Nonrecurring Fair Value, Inputs, Level 2 2013 Senior Notes Market Value	Sep. 30, 2014 Senior Notes Nonrecurring Fair Value, Inputs, Level 2 2012 Senior Notes Market Value	Mar. 31, 2014 Senior Notes Nonrecurring Fair Value, Inputs, Level 2 2012 Senior Notes Market Value	Jan. 31, 2012 Term Loans 2012 Term Loan	Sep. 30, 2014 Term Loans 2012 Term Loan Carrying Value	Mar. 31, 2014 Term Loans 2012 Term Loan Carrying Value	Sep. 30, 2014 Term Loans Nonrecurring Fair Value, Inputs, Level 2 2012 Term Loan Market Value	Mar. 31, 2014 Term Loans Nonrecurring Fair Value, Inputs, Level 2 2012 Term Loan Market Value	Sep. 30, 2014 Term B-2 Amendment 2 2012 Term Loan	Sep. 03, 2014 Term B-2 Amendment 2 2012 Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure			$ 400,000,000	$ 400,000,000		$ 250,000,000	$ 250,000,000	$ 377,000,000	$ 408,500,000	$ 266,900,000	$ 280,600,000		$ 262,500,000	$ 287,500,000	$ 261,200,000	$ 288,900,000
Debt instrument, face amount		400,000,000.0			250,000,000.0							660,000,000.0					720,000,000	720,000,000.0
Debt instrument, fair value disclosure																	718,200,000
Line of credit, fair value disclosure	$ 66,100,000

XML

Accounts Receivable (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 110,119	$ 74,992
Less allowances for discounts, returns and uncollectible accounts	(11,475)	(9,942)
Accounts receivable, net	98,644	65,050
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	107,943	73,632
Other Receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 2,176	$ 1,360

XML

Inventories

6 Months Ended

Sep. 30, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventories consist of the following:

(In thousands)	September 30, 2014		March 31, 2014
Components of Inventories
Packaging and raw materials	$	3,929	$	3,099
Work in process	3,456		—
Finished goods	75,490		62,487
Inventories	$	82,875	$	65,586

Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $4.8 million and $1.1 million at September 30, 2014 and March 31, 2014, respectively, related to obsolete and slow-moving inventory. Following the acquisition of the Hydralyte brand on April 30, 2014, we manufacture certain Hydralyte products in Australia.

XML

Stockholders' Equity (Details) (USD $)			3 Months Ended		6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014 Restricted Shares	Sep. 30, 2013 Restricted Shares	Sep. 30, 2014 Restricted Shares	Sep. 30, 2013 Restricted Shares
Class of Stock [Line Items]
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned	1
Restricted stock repurchased during period, shares			13,924	0	47,664	10,726
Restricted stock acquired, average cost per share					$ 33.63	$ 25.96

XML

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%		100.00%
Term of original maturities, cash equivalents, up to and including			3 months
Shipping, warehousing and handling costs	$ 9.4	$ 9.1	$ 17.1	$ 15.7

XML

Inventories (Tables)

6 Months Ended

Sep. 30, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:

(In thousands)	September 30, 2014		March 31, 2014
Components of Inventories
Packaging and raw materials	$	3,929	$	3,099
Work in process	3,456		—
Finished goods	75,490		62,487
Inventories	$	82,875	$	65,586

XML

Accounts Receivable (Tables)

6 Months Ended

Sep. 30, 2014

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:

(In thousands)	September 30, 2014			March 31, 2014
Components of Accounts Receivable
Trade accounts receivable	$	107,943		$	73,632
Other receivables	2,176			1,360
	110,119			74,992
Less allowances for discounts, returns and uncollectible accounts	(11,475		)	(9,942		)
Accounts receivable, net	$	98,644		$	65,050

XML

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) (USD $)						0 Months Ended		6 Months Ended	3 Months Ended					0 Months Ended		6 Months Ended			0 Months Ended										0 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Dec. 17, 2013	Jan. 31, 2012	Jan. 31, 2012 Term Loan and ABL Revolver 2012	Jan. 31, 2012 Term Loans 2012 Term Loan	Jan. 31, 2012 Term Loans 2012 Term Loan	Sep. 30, 2014 Term Loans 2012 Term Loan	Mar. 31, 2013 Term Loans Amendment 1 2012 Term Loan	Feb. 21, 2013 Term Loans Amendment 1 2012 Term Loan	Sep. 03, 2014 Term Loans Amendment 2 2012 Term Loan	Sep. 30, 2014 Term B-2 Amendment 2 2012 Term Loan	Sep. 03, 2014 Term B-2 Amendment 2 2012 Term Loan	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver	Sep. 30, 2013 Revolving Credit Facility 2012 ABL Revolver	Sep. 30, 2014 Revolving Credit Facility 2012 ABL Revolver	Sep. 03, 2014 Revolving Credit Facility 2012 ABL Revolver Amendment 3	Feb. 21, 2013 LIBOR Term Loans Amendment 1 2012 Term Loan	Sep. 03, 2014 LIBOR Term Loans Amendment 2 2012 Term Loan	Sep. 03, 2014 LIBOR Term B-2 Amendment 2 2012 Term Loan	Jan. 31, 2012 LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Base Rate Term Loans 2012 Term Loan	Jan. 31, 2012 Base Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Base Rate Federal Funds Rate Term Loans 2012 Term Loan	Jan. 31, 2012 Base Rate Federal Funds Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Base Rate LIBOR Term Loans 2012 Term Loan	Jan. 31, 2012 Base Rate LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Minimum LIBOR Term Loans 2012 Term Loan	Jan. 31, 2012 Minimum LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Minimum Base Rate Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Maximum LIBOR Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Maximum Base Rate Revolving Credit Facility 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, face amount							$ 660,000,000.0					$ 720,000,000	$ 720,000,000.0
Debt instrument, maturity term						7 years								5 years
Line of credit facility, maximum borrowing capacity															50,000,000.0		135,000,000
Line of credit facility, increase in borrowing capacity																	85,000,000	40,000,000
Debt instrument, interest rate, increase (decrease)																(0.25%)
Debt instrument, discount, percentage							1.50%
Proceeds from issuance of long-term debt							650,100,000
Debt issuance costs capitalized					20,600,000
Percentage of subsidiary owned			100.00%	100.00%
Debt instrument, basis spread on variable rate																			2.75%	3.125%	3.50%								1.00%
Debt instrument, reference rate floor										1.00%	1.00%		1.00%
Loss on extinguishment of debt									1,400,000
Debt instrument, quarterly payment, percent of original principal amount							0.25%
Debt instrument, step down interest rate																					3.25%
Current portion of long term debt	$ 7,200,000	$ 0
Debt instrument, basis spread on variable rate, fixed component																							2.00%		0.50%	0.50%	1.00%	1.00%
Debt instrument, average interest rate during period								4.90%
Debt instrument, variable rate																						1.75%		0.75%
Debt instrument, conditional variable rate																														2.00%	1.00%	2.25%	1.25%
Line of credit facility, commitment fee percentage															0.50%
Line of credit facility, conditional commitment fee percentage															0.375%
Line of credit facility, interest rate at period end																	3.70%

XML

Acquisitions Allocation of Assets Acquired and Liabilities Assumed(Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Sep. 03, 2014 Insight Pharmaceuticals	Apr. 30, 2014 Hydralyte	Jul. 02, 2013 Care Pharma
Purchase Price
Cash acquired			$ 3,507		$ 1,546
Accounts receivable			25,784		1,658
Inventories			23,559	1,970	2,465
Deferred income tax assets - current			860		283
Prepaids and other current assets			1,407		647
Property, plant and equipment			2,308	1,267	163
Goodwill	293,993	190,911	103,255	1,224	23,122
Intangible Assets			724,374	73,580	31,502
Total assets acquired			885,054	78,041	61,386
Accounts payable			16,079		1,537
Accrued expenses			8,003	38	2,788
Deferred income tax liabilities - long term			107,799
Other long term liabilities				12	300
Total liabilities assumed			131,881	50	4,625
Net assets acquired			$ 753,173	$ 77,991	$ 56,761

XML

Property and Equipment (Tables)

6 Months Ended

Sep. 30, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following:

(In thousands)	September 30, 2014			March 31, 2014
Components of Property and Equipment
Machinery	$	4,245		$	1,927
Computer equipment and software	10,183			8,923
Furniture and fixtures	2,703			1,858
Leasehold improvements	4,823			4,734
	21,954			17,442
Accumulated depreciation	(9,534		)	(7,845		)
Property and equipment, net	$	12,420		$	9,597

XML

Goodwill (Tables)

6 Months Ended

Sep. 30, 2014

Goodwill [Abstract]

Reconciliation of the Activity Affecting Goodwill

A reconciliation of the activity affecting goodwill by reportable segment is as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare			Household Cleaning		Consolidated
Balance — March 31, 2014	$	160,157	$	23,365		$	7,389	$	190,911
Additions	103,254		1,224			—		104,478
Effects of foreign currency exchange rates	—		(1,396		)	—		(1,396		)
Balance — September 30, 2014	$	263,411	$	23,193		$	7,389	$	293,993

XML

Accounts Receivable

6 Months Ended

Sep. 30, 2014

Receivables [Abstract]

Accounts Receivable

Accounts Receivable

Accounts receivable consist of the following:

(In thousands)	September 30, 2014			March 31, 2014
Components of Accounts Receivable
Trade accounts receivable	$	107,943		$	73,632
Other receivables	2,176			1,360
	110,119			74,992
Less allowances for discounts, returns and uncollectible accounts	(11,475		)	(9,942		)
Accounts receivable, net	$	98,644		$	65,050

XML

Intangible Assets (Tables)

6 Months Ended

Sep. 30, 2014

Intangible Assets [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:

(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Totals
Gross Carrying Amounts
Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
Additions	673,180			124,774			797,954
Reductions	—			(17,674		)	(17,674		)
Effects of foreign currency exchange rates	(6,000		)	(95		)	(6,095		)
Balance — September 30, 2014	1,941,058			311,745			2,252,803
Accumulated Amortization
Balance — March 31, 2014	—			83,801			83,801
Additions	—			5,064			5,064
Effects of foreign currency exchange rates	—			(9		)	(9		)
Balance — September 30, 2014	—			88,856			88,856
Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,723,498		$	196,145		$	1,919,643
International OTC Healthcare	97,740			1,449			99,189
Household Cleaning	119,820			25,295			145,115
Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947

Schedule of Expected Amortization Expense

At September 30, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:

(In thousands)
Year Ending March 31,	Amount
2015 (Remaining six months ending March 31, 2015)	$	7,740
2016	15,554
2017	15,554
2018	15,554
2019	15,554
Thereafter	152,933
	$	222,889

XML

Condensed Consolidating Financial Statements (Tables)

6 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	27,167		$	138,336		$	15,212		$	(710	)	$	180,005
Other revenues	—			95			1,241			436			(508		)	1,264
Total revenues	—			27,262			139,577			15,648			(1,218		)	181,269
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,426			64,812			5,767			(2,278		)	78,727
Gross profit	—			16,836			74,765			9,881			1,060			102,542
Operating Expenses
Advertising and promotion	—			2,699			19,311			3,034			—			25,044
General and administrative	1,109			3,441			20,329			2,249			—			27,128
Depreciation and amortization	870			145			2,729			108			—			3,852
Total operating expenses	1,979			6,285			42,369			5,391			—			56,024
Operating income (loss)	(1,979		)	10,551			32,396			4,490			1,060			46,518
Other (income) expense
Interest income	(12,245		)	(16,719		)	(1,760		)	(11		)	30,720			(15		)
Interest expense	8,629			18,208			20,333			1,758			(30,720		)	18,208
Equity in (income) loss of subsidiaries	(17,577		)	(9,825		)	(1,870		)	—			29,272			—
Total other (income) expense	(21,193		)	(8,336		)	16,703			1,747			29,272			18,193
Income before income taxes	19,214			18,887			15,693			2,743			(28,212		)	28,325
Provision for income taxes	2,751			3,262			4,976			873			—			11,862
Net income (loss)	$	16,463		$	15,625		$	10,717		$	1,870		$	(28,212	)	$	16,463
Comprehensive income, net of tax:
Currency translation adjustments	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
Total other comprehensive (loss) income	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
Comprehensive income (loss)	$	5,633		$	4,795		$	(113	)	$	(8,960	)	$	4,278		$	5,633

Condensed Consolidating Statements of Income and Comprehensive Income

Six Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	52,577		$	247,234		$	26,163		$	(1,428	)	$	324,546
Other revenues	—			225			2,340			838			(978		)	2,425
Total revenues	—			52,802			249,574			27,001			(2,406		)	326,971
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			19,874			115,327			9,790			(2,428		)	142,563
Gross profit	—			32,928			134,247			17,211			22			184,408
Operating Expenses
Advertising and promotion	—			5,388			33,377			5,375			—			44,140
General and administrative	2,254			5,914			29,319			6,647			—			44,134
Depreciation and amortization	1,512			290			4,818			193			—			6,813
Total operating expenses	3,766			11,592			67,514			12,215			—			95,087
Operating income (loss)	(3,766		)	21,336			66,733			4,996			22			89,321
Other (income) expense
Interest income	(24,378		)	(30,944		)	(2,522		)	(40		)	57,837			(47		)
Interest expense	17,177			32,893			38,138			2,522			(57,837		)	32,893
Equity in (income) loss of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Total other (income) expense	(40,457		)	(18,774		)	34,705			2,482			54,890			32,846
Income before income taxes	36,691			40,110			32,028			2,514			(54,868		)	56,475
Provision (benefit) for income taxes	3,496			6,979			11,202			1,603			—			23,280
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Comprehensive income, net of tax:
Currency translation adjustments	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Total other comprehensive (loss) income	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Comprehensive income (loss)	$	25,091		$	25,027		$	12,722		$	(7,193	)	$	(30,556	)	$	25,091

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,237		$	132,821		$	7,449		$	—		$	165,507
Other revenues	—			67			1,431			668			(728		)	1,438
Total revenues	—			25,304			134,252			8,117			(728		)	166,945
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
Gross profit	—			15,966			72,739			4,517			—			93,222
Operating Expenses
Advertising and promotion	—			3,594			19,556			1,397			—			24,547
General and administrative	891			1,481			8,358			889			—			11,619
Depreciation and amortization	517			143			2,589			45			—			3,294
Total operating expenses	1,408			5,218			30,503			2,331			—			39,460
Operating income (loss)	(1,408		)	10,748			42,236			2,186			—			53,762
Other (income) expense
Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
Equity in (income) loss of subsidiaries	(30,344		)	(20,599		)	(1,189		)	—			52,132			—
Total other (income) expense	(34,435		)	(18,140		)	16,194			688			52,132			16,439
Income (loss) before income taxes	33,027			28,888			26,042			1,498			(52,132		)	37,323
Provision for income taxes	235			1,064			2,922			310			—			4,531
Net income (loss)	$	32,792		$	27,824		$	23,120		$	1,188		$	(52,132	)	$	32,792
Comprehensive income, net of tax:
Currency translation adjustments	1,122			1,122			1,122			1,122			(3,366		)	1,122
Total other comprehensive income (loss)	1,122			1,122			1,122			1,122			(3,366		)	1,122
Comprehensive income (loss)	$	33,914		$	28,946		$	24,242		$	2,310		$	(55,498	)	$	33,914

Condensed Consolidating Statements of Income and Comprehensive Income

Six Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	49,386		$	249,091		$	8,672		$	—		$	307,149
Other revenues	—			135			2,294			1,102			(1,223		)	2,308
Total revenues	—			49,521			251,385			9,774			(1,223		)	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
Gross profit	—			30,725			139,883			5,638			—			176,246
Operating Expenses
Advertising and promotion	—			6,924			34,700			1,604			—			43,228
General and administrative	2,390			3,124			16,815			924			—			23,253
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Total operating expenses	3,424			10,333			56,699			2,587			—			73,043
Operating income (loss)	(3,424		)	20,392			83,184			3,051			—			103,203
Other (income) expense
Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
Equity in (income) loss of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Total other (income) expense	(57,896		)	(31,108		)	33,443			686			87,219			32,344
Income (loss) before income taxes	54,472			51,500			49,741			2,365			(87,219		)	70,859
Provision for income taxes	988			4,151			11,738			498			—			17,375
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Comprehensive income, net of tax:
Currency translation adjustments	1,123			1,123			1,123			1,123			(3,369		)	1,123
Total other comprehensive income (loss)	1,123			1,123			1,123			1,123			(3,369		)	1,123
Comprehensive income (loss)	$	54,607		$	48,472		$	39,126		$	2,990		$	(90,588	)	$	54,607

Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet

September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
Accounts receivable, net	7			14,352			76,165			8,120			—			98,644
Inventories	—			9,666			67,420			6,777			(988		)	82,875
Deferred income tax assets	1,139			823			6,743			466			—			9,171
Prepaid expenses and other current assets	2,841			354			6,023			717			—			9,935
Total current assets	14,452			25,195			161,385			22,329			(988		)	222,373
Property and equipment, net	8,580			90			2,297			1,453			—			12,420
Goodwill	—			66,007			204,794			23,192			—			293,993
Intangible assets, net	—			192,593			1,871,933			99,421			—			2,163,947
Other long-term assets	—			32,937			—			—			—			32,937
Intercompany receivables	1,203,499			2,688,676			599,886			10,045			(4,502,106		)	—
Investment in subsidiary	1,519,129			1,213,732			79,877			—			(2,812,738		)	—
Total Assets	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
Liabilities and Stockholders' Equity
Current liabilities
Current portion of long term debt	—			7,200			—			—			—			7,200
Accounts payable	2,084			9,508			42,634			4,312			—			58,538
Accrued interest payable	—			12,086			—			—			—			12,086
Other accrued liabilities	6,407			2,970			20,746			3,963			—			34,086
Total current liabilities	8,491			31,764			63,380			8,275			—			111,910
Long-term debt
Principal amount	—			1,691,400			—			—			—			1,691,400
Less unamortized discount	—			(6,289		)	—			—			—			(6,289		)
Long-term debt, net of unamortized discount	—			1,685,111			—			—			—			1,685,111
Deferred income tax liabilities	—			58,076			276,180			41			—			334,297
Other long-term liabilities	—			—			—			313			—			313
Intercompany payables	2,143,130			995,186			1,295,207			68,583			(4,502,106		)	—
Total Liabilities	2,151,621			2,770,137			1,634,767			77,212			(4,502,106		)	2,131,631
Stockholders' Equity
Preferred share rights	—			—			—			—			—			—
Common stock	524			—			—			—			—			524
Additional paid-in capital	421,574			1,280,948			1,131,578			74,031			(2,486,557		)	421,574
Treasury stock, at cost - 254 shares	(3,034		)	—			—			—			—			(3,034		)
Accumulated other comprehensive (loss) income, net of tax	(7,365		)	(7,365		)	(7,365		)	(7,365		)	22,095			(7,365		)
Retained earnings (accumulated deficit)	182,340			175,510			161,192			12,562			(349,264		)	182,340
Total Stockholders' Equity	594,039			1,449,093			1,285,405			79,228			(2,813,726		)	594,039
Total Liabilities and Stockholders' Equity	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670

Condensed Consolidating Balance Sheet

March 31, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185
Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358
Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414
Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows

Six Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,512			290			4,818			195			—			6,815
Deferred income taxes	(879		)	1,351			11,084			(60		)	—			11,496
Amortization of deferred financing costs				2,398												2,398
Stock-based compensation costs	3,403															3,403
Amortization of debt discount				687												687
Loss on sale of assets							—			56						56
Equity in income of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	466			(107		)	(4,496		)	(4,226		)	—			(8,363		)
Inventories	—			4,691			1,857			738			(22		)	7,264
Prepaid expenses and other current assets	5,163			(241		)	(1,718		)	(90		)	—			3,114
Accounts payable	(2,332		)	1,850			(6,997		)	1,832			—			(5,647		)
Accrued liabilities	(1,321		)	3,313			(701		)	1,349			—			2,640
Net cash provided by operating activities	5,951			26,640			23,762			705			—			57,058
Investing Activities
Purchases of property and equipment	(1,127		)				(87		)	(166		)				(1,380		)
Proceeds from the sale of business	—			—			18,500			—			—			18,500
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)				—			(749,666		)
Acquisition of Hydralyte	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net				(809,157		)	731,166			77,991						—
Net cash used in investing activities	(1,127		)	(809,157		)	(87		)	(166		)	—			(810,537		)
Financing Activities
Term loan borrowings				720,000												720,000
Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	2,757			—			—			—			—			2,757
Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
Fair value of shares surrendered as payment of tax withholding	(1,660		)	—			—			—			—			(1,660		)
Intercompany activity, net	(21,187		)	37,489			(18,641		)	2,339			—			—
Net cash provided by (used in) financing activities	(19,003		)	782,517			(18,641		)	2,339			—			747,212
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(316		)	—			(316		)
(Decrease) increase in cash and cash equivalents	(14,179		)	—			5,034			2,562			—			(6,583		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748

Condensed Consolidating Statement of Cash Flows

Six Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Deferred income taxes	(14		)	(642		)	5,011			—			—			4,355
Amortization of deferred financing costs	—			1,975			—			—			—			1,975
Stock-based compensation costs	2,487			—			—			—			—			2,487
Amortization of debt discount	—			798			—			—			—			798
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(112		)	996			(5,323		)	(1,273		)	—			(5,712		)
Inventories	—			(1,975		)	3,073			(277		)	—			821
Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
Net cash provided by operating activities	2,601			12,368			38,806			1,823			—			55,598
Investing Activities
Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
Financing Activities
Term loan repayments	—			(7,500		)	—			—			—			(7,500		)
Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	2,347			36,122			(38,809		)	340			—			—
Net cash provided by (used in) financing activities	8,562			42,847			(38,809		)	340			—			12,940
Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
Increase in cash and cash equivalents	8,947			—			—			2,216			—			11,163
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	23,667		$	—		$	—		$	3,166		$	—		$	26,833

XML

Intangible Assets Expected Amortization Expense (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2015 (Remaining six months ending March 31, 2015)	$ 7,740
2016	15,554
2017	15,554
2018	15,554
2019	15,554
Thereafter	152,933
Intangible assets, net	$ 222,889

XML

Commitments and Contingencies (Long-term Supply Agreement) (Details) (Third-party Manufacturing, USD $) In Thousands, unless otherwise specified	0 Months Ended
	Nov. 01, 2009	Sep. 30, 2014
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2015 (Remaining six months ending March 31, 2015)		$ 549
2016		1,074
2017		1,044
2018		1,013
2019		982
Thereafter		560
Total purchase commitment		$ 5,222

XML

Consolidated Statements of Income and Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues
Net sales	$ 180,005	$ 165,507	$ 324,546	$ 307,149
Other revenues	1,264	1,438	2,425	2,308
Total revenues	181,269	166,945	326,971	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	78,727	73,723	142,563	133,211
Gross profit	102,542	93,222	184,408	176,246
Operating Expenses
Advertising and promotion	25,044	24,547	44,140	43,228
General and administrative	27,128	11,619	44,134	23,253
Depreciation and amortization	3,852	3,294	6,813	6,562
Total operating expenses	56,024	39,460	95,087	73,043
Operating income	46,518	53,762	89,321	103,203
Other (income) expense
Interest income	(15)	(25)	(47)	(28)
Interest expense	18,208	16,464	32,893	32,372
Total other (income) expense	18,193	16,439	32,846	32,344
Income before income taxes	28,325	37,323	56,475	70,859
Provision for income taxes	11,862	4,531	23,280	17,375
Net income	16,463	32,792	33,195	53,484
Earnings per share:
Basic (in USD per share)	$ 0.32	$ 0.64	$ 0.64	$ 1.04
Diluted (in USD per share)	$ 0.31	$ 0.63	$ 0.63	$ 1.03
Weighted average shares outstanding:
Basic (in shares)	52,088	51,463	52,023	51,343
Diluted (in shares)	52,594	52,219	52,564	52,130
Comprehensive income, net of tax:
Currency translation adjustments	(10,830)	1,122	(8,104)	1,123
Total other comprehensive (loss) income	(10,830)	1,122	(8,104)	1,123
Comprehensive income	$ 5,633	$ 33,914	$ 25,091	$ 54,607

XML

Acquisitions Narrative (Details) (USD $)	3 Months Ended		6 Months Ended			0 Months Ended	3 Months Ended	6 Months Ended						6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Sep. 03, 2014 Insight Pharmaceuticals brand	Sep. 30, 2014 Insight Pharmaceuticals	Sep. 30, 2014 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals	Sep. 03, 2014 Insight Pharmaceuticals Intangible assets	Sep. 03, 2014 Insight Pharmaceuticals Inventory	Sep. 03, 2014 Insight Pharmaceuticals Property, plant and equipment	Apr. 30, 2014 Hydralyte	Sep. 30, 2014 Care Pharma	Jul. 02, 2013 Care Pharma
Business Acquisition [Line Items]
Purchase price of acquisition						$ 753,200,000
Number of pharmaceutical brands acquired as a result of acquisition						27
Number of brands sold						1
Non-amortizable intangible assets									599,600,000						29,800,000
Amortizable intangible assets									124,800,000						1,700,000
Purchased amortizable intangible assets, weighted average useful life							16 years 2 months 12 days							15 years 1 month 6 days
Purchased amortizable intangible assets, weighted average remaining period			14 years 6 months				16 years 1 month 12 days							13 years 0 months 22 days
Goodwill	293,993,000		293,993,000		190,911,000				103,255,000				1,224,000		23,122,000
Revenues of acquired business							12,700,000	12,700,000
Net income	16,463,000	32,792,000	33,195,000	53,484,000			2,000,000	3,200,000
Value of assets sold on acquisition date, excluded from purchase price									$ 18,500,000	$ 17,700,000	$ 600,000	$ 200,000

XML

Business and Basis of Presentation

6 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada), and in Australia and certain other international markets.  Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements.

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31^st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three and six months ended September 30, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.

Revision

We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2014 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $9.4 million and $17.1 million for the three and six months ended September 30, 2014, respectively, and $9.1 million and $15.7 million for the three and six months ended September 30, 2013, respectively.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.  

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In August 2014, the FASB issued Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

XML

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,698,600	$ 937,500
Current portion of long-term debt	7,200	0
Principal amount	1,691,400	937,500
Less: unamortized discount	(6,289)	(3,086)
Long-term debt, net of unamortized discount	1,685,111	934,414
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	66,100	0
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	400,000	400,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	250,000	250,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	262,500	287,500
Term Loans | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	$ 720,000	$ 0

XML

Accumulated Other Comprehensive (Loss) Income (Tables)

6 Months Ended

Sep. 30, 2014

Accumulated Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income

The table below presents accumulated other comprehensive (loss) income (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.

AOCI consisted of the following at September 30, 2014 and March 31, 2014:

	September 30,			March 31,
(In thousands)	2014			2014
Components of Accumulated Other Comprehensive (Loss) Income
Cumulative translation adjustment	$	(7,365	)	$	739
Total accumulated other comprehensive (loss) income, net of tax	$	(7,365	)	$	739

XML

Earnings Per Share Antidilutive Securities (Details) (Outstanding Stock Awards) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	0.3	0.2	0.3	0.2

XML

Concentrations of Risk

6 Months Ended

Sep. 30, 2014

Risks and Uncertainties [Abstract]

Concentrations of Risk

Concentrations of Risk

Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products.  We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores.  During the three and six months ended September 30, 2014, approximately 40.6% and 41.2%, respectively, of our total revenues were derived from our five top selling brands.  During the three and six months ended September 30, 2013, approximately 41.8% and 43.0%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 17.0% and 18.0%, respectively, of our gross revenues for the three and six months ended September 30, 2014, and approximately 19.2% and 20.4%, respectively, of our gross revenues for the three and six months ended September 30, 2013. At September 30, 2014, approximately 21.5% of accounts receivable were owed by the same customer.

We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri.  A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost.  We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels.  As a result, any such disruption could have a material adverse effect on our business, sales and profitability.

At September 30, 2014, we had relationships with 101 third-party manufacturers.  Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 77.4% of gross sales for the six months ended September 30, 2014. At September 30, 2013, we had relationships with 50 third-party manufacturers.  Of those, we had long-term contracts with 22 manufacturers that produced items that accounted for approximately 77.9% of gross sales for the six months ended September 30, 2013. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

XML

Earnings Per Share (Tables)

6 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:

	Three Months Ended September 30,				Six Months Ended September 30,
(In thousands, except per share data)	2014		2013		2014		2013
Numerator
Net income	$	16,463	$	32,792	$	33,195	$	53,484
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,088		51,463		52,023		51,343
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	506		756		541		787
Denominator for diluted earnings per share	52,594		52,219		52,564		52,130
Earnings per Common Share:
Basic net earnings per share	$	0.32	$	0.64	$	0.64	$	1.04
Diluted net earnings per share	$	0.31	$	0.63	$	0.63	$	1.03

XML

Condensed Consolidating Financial Statements

6 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

Condensed Consolidating Financial Statements

As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of September 30, 2014 and March 31, 2014, Condensed Consolidating Statements of Income and Comprehensive Income for the three and six months ended September 30, 2014 and 2013, and Condensed Consolidating Statements of Cash Flows for the six months ended September 30, 2014 and 2013. Such consolidating information includes separate columns for:

a)  Prestige Brands Holdings, Inc., the parent,

b)  Prestige Brands, Inc., the issuer or the borrower,

c)  Combined Subsidiary Guarantors,

d)  Combined Non-Guarantor Subsidiaries, and

e)  Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.

In the third quarter of fiscal 2014, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the second quarter of fiscal 2014. This resulted in an understatement of equity in earnings of subsidiaries for Prestige Brands, Inc. of $48.1 million, an overstatement of $0.6 million for Prestige Brands Holdings, Inc. and a net understatement of equity in earnings of subsidiaries for the eliminations of $47.5 million for each of the three and six month periods ended September 30, 2013. These items also resulted in corresponding adjustments to the investments in subsidiaries on the balance sheet as of September 30, 2013 and adjustments to net income (loss) and equity in income of subsidiaries in the statement of cash flows, although net cash provided by operating activities for the six months ended September 30, 2013 remained unchanged. Revisions were also made to increase the cumulative translation adjustment of the Issuer and subsidiary guarantors by approximately $1 million each, with corresponding adjustments to the investment in subsidiaries and stockholders' equity balances.

The Company assessed the materiality of these items on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the revisions were not material to the consolidated financial statements. The Company disclosed the impact of the revisions on previously reported amounts and accordingly revised the Condensed Consolidating Financial Statements relating to the second quarter of fiscal 2014. There were no changes to any of the Company's Consolidated Financial Statements.

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	27,167		$	138,336		$	15,212		$	(710	)	$	180,005
Other revenues	—			95			1,241			436			(508		)	1,264
Total revenues	—			27,262			139,577			15,648			(1,218		)	181,269
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			10,426			64,812			5,767			(2,278		)	78,727
Gross profit	—			16,836			74,765			9,881			1,060			102,542
Operating Expenses
Advertising and promotion	—			2,699			19,311			3,034			—			25,044
General and administrative	1,109			3,441			20,329			2,249			—			27,128
Depreciation and amortization	870			145			2,729			108			—			3,852
Total operating expenses	1,979			6,285			42,369			5,391			—			56,024
Operating income (loss)	(1,979		)	10,551			32,396			4,490			1,060			46,518
Other (income) expense
Interest income	(12,245		)	(16,719		)	(1,760		)	(11		)	30,720			(15		)
Interest expense	8,629			18,208			20,333			1,758			(30,720		)	18,208
Equity in (income) loss of subsidiaries	(17,577		)	(9,825		)	(1,870		)	—			29,272			—
Total other (income) expense	(21,193		)	(8,336		)	16,703			1,747			29,272			18,193
Income before income taxes	19,214			18,887			15,693			2,743			(28,212		)	28,325
Provision for income taxes	2,751			3,262			4,976			873			—			11,862
Net income (loss)	$	16,463		$	15,625		$	10,717		$	1,870		$	(28,212	)	$	16,463
Comprehensive income, net of tax:
Currency translation adjustments	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
Total other comprehensive (loss) income	(10,830		)	(10,830		)	(10,830		)	(10,830		)	32,490			(10,830		)
Comprehensive income (loss)	$	5,633		$	4,795		$	(113	)	$	(8,960	)	$	4,278		$	5,633

Condensed Consolidating Statements of Income and Comprehensive Income

Six Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	52,577		$	247,234		$	26,163		$	(1,428	)	$	324,546
Other revenues	—			225			2,340			838			(978		)	2,425
Total revenues	—			52,802			249,574			27,001			(2,406		)	326,971
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			19,874			115,327			9,790			(2,428		)	142,563
Gross profit	—			32,928			134,247			17,211			22			184,408
Operating Expenses
Advertising and promotion	—			5,388			33,377			5,375			—			44,140
General and administrative	2,254			5,914			29,319			6,647			—			44,134
Depreciation and amortization	1,512			290			4,818			193			—			6,813
Total operating expenses	3,766			11,592			67,514			12,215			—			95,087
Operating income (loss)	(3,766		)	21,336			66,733			4,996			22			89,321
Other (income) expense
Interest income	(24,378		)	(30,944		)	(2,522		)	(40		)	57,837			(47		)
Interest expense	17,177			32,893			38,138			2,522			(57,837		)	32,893
Equity in (income) loss of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Total other (income) expense	(40,457		)	(18,774		)	34,705			2,482			54,890			32,846
Income before income taxes	36,691			40,110			32,028			2,514			(54,868		)	56,475
Provision (benefit) for income taxes	3,496			6,979			11,202			1,603			—			23,280
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Comprehensive income, net of tax:
Currency translation adjustments	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Total other comprehensive (loss) income	(8,104		)	(8,104		)	(8,104		)	(8,104		)	24,312			(8,104		)
Comprehensive income (loss)	$	25,091		$	25,027		$	12,722		$	(7,193	)	$	(30,556	)	$	25,091

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,237		$	132,821		$	7,449		$	—		$	165,507
Other revenues	—			67			1,431			668			(728		)	1,438
Total revenues	—			25,304			134,252			8,117			(728		)	166,945
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,338			61,513			3,600			(728		)	73,723
Gross profit	—			15,966			72,739			4,517			—			93,222
Operating Expenses
Advertising and promotion	—			3,594			19,556			1,397			—			24,547
General and administrative	891			1,481			8,358			889			—			11,619
Depreciation and amortization	517			143			2,589			45			—			3,294
Total operating expenses	1,408			5,218			30,503			2,331			—			39,460
Operating income (loss)	(1,408		)	10,748			42,236			2,186			—			53,762
Other (income) expense
Interest income	(12,778		)	(14,005		)	(710		)	(22		)	27,490			(25		)
Interest expense	8,687			16,464			18,093			710			(27,490		)	16,464
Equity in (income) loss of subsidiaries	(30,344		)	(20,599		)	(1,189		)	—			52,132			—
Total other (income) expense	(34,435		)	(18,140		)	16,194			688			52,132			16,439
Income (loss) before income taxes	33,027			28,888			26,042			1,498			(52,132		)	37,323
Provision for income taxes	235			1,064			2,922			310			—			4,531
Net income (loss)	$	32,792		$	27,824		$	23,120		$	1,188		$	(52,132	)	$	32,792
Comprehensive income, net of tax:
Currency translation adjustments	1,122			1,122			1,122			1,122			(3,366		)	1,122
Total other comprehensive income (loss)	1,122			1,122			1,122			1,122			(3,366		)	1,122
Comprehensive income (loss)	$	33,914		$	28,946		$	24,242		$	2,310		$	(55,498	)	$	33,914

Condensed Consolidating Statements of Income and Comprehensive Income

Six Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	49,386		$	249,091		$	8,672		$	—		$	307,149
Other revenues	—			135			2,294			1,102			(1,223		)	2,308
Total revenues	—			49,521			251,385			9,774			(1,223		)	309,457
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			18,796			111,502			4,136			(1,223		)	133,211
Gross profit	—			30,725			139,883			5,638			—			176,246
Operating Expenses
Advertising and promotion	—			6,924			34,700			1,604			—			43,228
General and administrative	2,390			3,124			16,815			924			—			23,253
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Total operating expenses	3,424			10,333			56,699			2,587			—			73,043
Operating income (loss)	(3,424		)	20,392			83,184			3,051			—			103,203
Other (income) expense
Interest income	(24,991		)	(28,328		)	(710		)	(24		)	54,025			(28		)
Interest expense	17,294			32,372			36,021			710			(54,025		)	32,372
Equity in (income) loss of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Total other (income) expense	(57,896		)	(31,108		)	33,443			686			87,219			32,344
Income (loss) before income taxes	54,472			51,500			49,741			2,365			(87,219		)	70,859
Provision for income taxes	988			4,151			11,738			498			—			17,375
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Comprehensive income, net of tax:
Currency translation adjustments	1,123			1,123			1,123			1,123			(3,369		)	1,123
Total other comprehensive income (loss)	1,123			1,123			1,123			1,123			(3,369		)	1,123
Comprehensive income (loss)	$	54,607		$	48,472		$	39,126		$	2,990		$	(90,588	)	$	54,607

Condensed Consolidating Balance Sheet

September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748
Accounts receivable, net	7			14,352			76,165			8,120			—			98,644
Inventories	—			9,666			67,420			6,777			(988		)	82,875
Deferred income tax assets	1,139			823			6,743			466			—			9,171
Prepaid expenses and other current assets	2,841			354			6,023			717			—			9,935
Total current assets	14,452			25,195			161,385			22,329			(988		)	222,373
Property and equipment, net	8,580			90			2,297			1,453			—			12,420
Goodwill	—			66,007			204,794			23,192			—			293,993
Intangible assets, net	—			192,593			1,871,933			99,421			—			2,163,947
Other long-term assets	—			32,937			—			—			—			32,937
Intercompany receivables	1,203,499			2,688,676			599,886			10,045			(4,502,106		)	—
Investment in subsidiary	1,519,129			1,213,732			79,877			—			(2,812,738		)	—
Total Assets	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670
Liabilities and Stockholders' Equity
Current liabilities
Current portion of long term debt	—			7,200			—			—			—			7,200
Accounts payable	2,084			9,508			42,634			4,312			—			58,538
Accrued interest payable	—			12,086			—			—			—			12,086
Other accrued liabilities	6,407			2,970			20,746			3,963			—			34,086
Total current liabilities	8,491			31,764			63,380			8,275			—			111,910
Long-term debt
Principal amount	—			1,691,400			—			—			—			1,691,400
Less unamortized discount	—			(6,289		)	—			—			—			(6,289		)
Long-term debt, net of unamortized discount	—			1,685,111			—			—			—			1,685,111
Deferred income tax liabilities	—			58,076			276,180			41			—			334,297
Other long-term liabilities	—			—			—			313			—			313
Intercompany payables	2,143,130			995,186			1,295,207			68,583			(4,502,106		)	—
Total Liabilities	2,151,621			2,770,137			1,634,767			77,212			(4,502,106		)	2,131,631
Stockholders' Equity
Preferred share rights	—			—			—			—			—			—
Common stock	524			—			—			—			—			524
Additional paid-in capital	421,574			1,280,948			1,131,578			74,031			(2,486,557		)	421,574
Treasury stock, at cost - 254 shares	(3,034		)	—			—			—			—			(3,034		)
Accumulated other comprehensive (loss) income, net of tax	(7,365		)	(7,365		)	(7,365		)	(7,365		)	22,095			(7,365		)
Retained earnings (accumulated deficit)	182,340			175,510			161,192			12,562			(349,264		)	182,340
Total Stockholders' Equity	594,039			1,449,093			1,285,405			79,228			(2,813,726		)	594,039
Total Liabilities and Stockholders' Equity	$	2,745,660		$	4,219,230		$	2,920,172		$	156,440		$	(7,315,832	)	$	2,725,670

Condensed Consolidating Balance Sheet

March 31, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries		Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—	$	3,687	$	—		$	28,331
Accounts receivable, net	473			14,245			45,885		4,447		—			65,050
Inventories	—			14,357			46,309		5,930		(1,010		)	65,586
Deferred income tax assets	260			925			4,914		445		—			6,544
Prepaid expenses and other current assets	8,004			113			2,898		659		—			11,674
Total current assets	33,381			29,640			100,006		15,168		(1,010		)	177,185
Property and equipment, net	8,966			112			226		293		—			9,597
Goodwill	—			66,007			101,540		23,364		—			190,911
Intangible assets, net	—			192,861			1,169,943		32,013		—			1,394,817
Other long-term assets	—			23,153			—		—		—			23,153
Intercompany receivable	655,146			1,824,482			656,759		13,595		(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562		—		(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553	$	2,659	$	—		$	48,286
Accrued interest payable	—			9,626			—		—		—			9,626
Other accrued liabilities	7,728			2,117			13,443		3,158		—			26,446
Total current liabilities	12,144			19,401			46,996		5,817		—			84,358
Long-term debt
Principal amount	—			937,500			—		—		—			937,500
Less unamortized discount	—			(3,086		)	—		—		—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—		—		—			934,414
Deferred income tax liabilities	—			56,827			156,327		50		—			213,204
Other long-term liabilities	—			—			—		327		—			327
Intercompany payable	1,619,346			451,497			1,037,105		42,034		(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428		48,228		(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—		—		—			520
Additional paid-in capital	414,387			1,280,945			681,503		23,815		(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—		—		—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739		739		(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366		11,651		(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608		36,205		(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036	$	84,433	$	(5,432,858	)	$	1,795,663

Condensed Consolidating Statement of Cash Flows

Six Months Ended September 30, 2014

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	33,195		$	33,131		$	20,826		$	911		$	(54,868	)	$	33,195
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,512			290			4,818			195			—			6,815
Deferred income taxes	(879		)	1,351			11,084			(60		)	—			11,496
Amortization of deferred financing costs				2,398												2,398
Stock-based compensation costs	3,403															3,403
Amortization of debt discount				687												687
Loss on sale of assets							—			56						56
Equity in income of subsidiaries	(33,256		)	(20,723		)	(911		)	—			54,890			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	466			(107		)	(4,496		)	(4,226		)	—			(8,363		)
Inventories	—			4,691			1,857			738			(22		)	7,264
Prepaid expenses and other current assets	5,163			(241		)	(1,718		)	(90		)	—			3,114
Accounts payable	(2,332		)	1,850			(6,997		)	1,832			—			(5,647		)
Accrued liabilities	(1,321		)	3,313			(701		)	1,349			—			2,640
Net cash provided by operating activities	5,951			26,640			23,762			705			—			57,058
Investing Activities
Purchases of property and equipment	(1,127		)				(87		)	(166		)				(1,380		)
Proceeds from the sale of business	—			—			18,500			—			—			18,500
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)				—			(749,666		)
Acquisition of Hydralyte	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net				(809,157		)	731,166			77,991						—
Net cash used in investing activities	(1,127		)	(809,157		)	(87		)	(166		)	—			(810,537		)
Financing Activities
Term loan borrowings				720,000												720,000
Term loan repayments	—			(25,000		)	—			—			—			(25,000		)
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	2,757			—			—			—			—			2,757
Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
Fair value of shares surrendered as payment of tax withholding	(1,660		)	—			—			—			—			(1,660		)
Intercompany activity, net	(21,187		)	37,489			(18,641		)	2,339			—			—
Net cash provided by (used in) financing activities	(19,003		)	782,517			(18,641		)	2,339			—			747,212
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(316		)	—			(316		)
(Decrease) increase in cash and cash equivalents	(14,179		)	—			5,034			2,562			—			(6,583		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	10,465		$	—		$	5,034		$	6,249		$	—		$	21,748

Condensed Consolidating Statement of Cash Flows

Six Months Ended September 30, 2013

(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	53,484		$	47,349		$	38,003		$	1,867		$	(87,219	)	$	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,034			285			5,184			59			—			6,562
Deferred income taxes	(14		)	(642		)	5,011			—			—			4,355
Amortization of deferred financing costs	—			1,975			—			—			—			1,975
Stock-based compensation costs	2,487			—			—			—			—			2,487
Amortization of debt discount	—			798			—			—			—			798
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(50,199		)	(35,152		)	(1,868		)	—			87,219			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(112		)	996			(5,323		)	(1,273		)	—			(5,712		)
Inventories	—			(1,975		)	3,073			(277		)	—			821
Prepaid expenses and other current assets	2,656			(147		)	(787		)	493			404			2,619
Accounts payable	(517		)	(1,296		)	(1,473		)	2,161			—			(1,125		)
Accrued liabilities	(6,218		)	177			(3,011		)	(1,207		)	(404		)	(10,663		)
Net cash provided by operating activities	2,601			12,368			38,806			1,823			—			55,598
Investing Activities
Purchases of property and equipment	(2,216		)	—			—			(103		)	—			(2,319		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,216		)	(55,215		)	3			(103		)	—			(57,531		)
Financing Activities
Term loan repayments	—			(7,500		)	—			—			—			(7,500		)
Repayments under revolving credit agreement	—			(35,500		)	—			—			—			(35,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(275		)	—			—			—			(275		)
Proceeds from exercise of stock options	5,143			—			—			—			—			5,143
Excess tax benefits from share-based awards	1,350			—			—			—			—			1,350
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	2,347			36,122			(38,809		)	340			—			—
Net cash provided by (used in) financing activities	8,562			42,847			(38,809		)	340			—			12,940
Effect of exchange rate changes on cash and cash equivalents	—			—			—			156			—			156
Increase in cash and cash equivalents	8,947			—			—			2,216			—			11,163
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	23,667		$	—		$	—		$	3,166		$	—		$	26,833

XML

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	47.30%	48.00%
Expected dividends	$ 0.00	$ 0.00
Expected term in years	6 years 0 months	6 years 0 months
Risk-free rate	2.20%	1.30%

XML

Acquisitions

6 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Acquisitions

Acquisitions

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed its previously announced acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extends the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading brand in OTC yeast infection treatment. The acquisition also adds brands to the Company's cough/cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.

(In thousands)	September 3, 2014
Cash acquired	$	3,507
Accounts receivable	25,784
Inventories	23,559
Deferred income tax assets - current	860
Prepaids and other current assets	1,407
Property, plant and equipment	2,308
Goodwill	103,255
Intangible Assets	724,374
Total assets acquired	885,054
Accounts payable	16,079
Accrued expenses	8,003
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	131,881
Total purchase price	$	753,173

Based on this analysis, we allocated $599.6 million to non-amortizable intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 16.1 years.

We also recorded goodwill of $103.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. Revenues of the acquired Insight operations for the three and six months ended September 30, 2014 were $12.7 million. Net loss for the three and six months ended September 30, 2014 was $2.0 million. On September 3, 2014 we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.

(In thousands, except per share data)	Six Months Ended September 30, 2014
Revenues	$	393,140
Net income	$	37,957
Earnings per share:
Basic	$	0.73
Diluted	$	0.72

(In thousands, except per share data)	Six Months Ended September 30, 2013
Revenues	$	389,490
Net income	$	53,511
Earnings per share:
Basic	$	1.04
Diluted	$	1.03

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on the balance sheet and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.

(In thousands)	April 30, 2014
Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041
Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also includes a line of brands for children including, Little Allergies, Little Eyes,and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio and are included in our International OTC Healthcare segment.

The Care Pharma acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.

(In thousands)	July 1, 2013
Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income taxes	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386
Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625
Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at September 30, 2014 was 13.1 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Current assets
Cash and cash equivalents	$ 21,748	$ 28,331
Accounts receivable, net	98,644	65,050
Inventories	82,875	65,586
Deferred income tax assets	9,171	6,544
Prepaid expenses and other current assets	9,935	11,674
Total current assets	222,373	177,185
Property and equipment, net	12,420	9,597
Goodwill	293,993	190,911
Intangible assets, net	2,163,947	1,394,817
Other long-term assets	32,937	23,153
Total Assets	2,725,670	1,795,663
Current liabilities
Current portion of long term debt	7,200	0
Accounts payable	58,538	48,286
Accrued interest payable	12,086	9,626
Other accrued liabilities	34,086	26,446
Total current liabilities	111,910	84,358
Long-term debt
Principal amount	1,691,400	937,500
Less unamortized discount	(6,289)	(3,086)
Long-term debt, net of unamortized discount	1,685,111	934,414
Deferred income tax liabilities	334,297	213,204
Other long-term liabilities	313	327
Total Liabilities	2,131,631	1,232,303
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 52,426 shares at September 30, 2014 and 52,021 shares at March 31, 2014	524	520
Additional paid-in capital	421,574	414,387
Treasury stock, at cost - 254 shares at September 30, 2014 and 206 shares at March 31, 2014	(3,034)	(1,431)
Accumulated other comprehensive (loss) income, net of tax	(7,365)	739
Retained earnings	182,340	149,145
Total Stockholders' Equity	594,039	563,360
Total Liabilities and Stockholders' Equity	$ 2,725,670	$ 1,795,663

XML

Accumulated Other Comprehensive (Loss) Income

6 Months Ended

Sep. 30, 2014

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive (Loss) Income

Accumulated Other Comprehensive (Loss) Income

The table below presents accumulated other comprehensive (loss) income (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.

AOCI consisted of the following at September 30, 2014 and March 31, 2014:

	September 30,			March 31,
(In thousands)	2014			2014
Components of Accumulated Other Comprehensive (Loss) Income
Cumulative translation adjustment	$	(7,365	)	$	739
Total accumulated other comprehensive (loss) income, net of tax	$	(7,365	)	$	739

XML

Document and Entity Information	6 Months Ended
	Sep. 30, 2014	Oct. 27, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,172,727

XML

Earnings Per Share

6 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:

	Three Months Ended September 30,				Six Months Ended September 30,
(In thousands, except per share data)	2014		2013		2014		2013
Numerator
Net income	$	16,463	$	32,792	$	33,195	$	53,484
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,088		51,463		52,023		51,343
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	506		756		541		787
Denominator for diluted earnings per share	52,594		52,219		52,564		52,130
Earnings per Common Share:
Basic net earnings per share	$	0.32	$	0.64	$	0.64	$	1.04
Diluted net earnings per share	$	0.31	$	0.63	$	0.63	$	1.03

For the three months ended September 30, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

XML

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating Activities
Net income (loss)	$ 33,195	$ 53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	6,815	6,562
Deferred income taxes	11,496	4,355
Amortization of deferred financing costs	2,398	1,975
Stock-based compensation costs	3,403	2,487
Amortization of debt discount	687	798
Gain (loss) on sale of assets	56	(3)
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(8,363)	(5,712)
Inventories	7,264	821
Prepaid expenses and other current assets	3,114	2,619
Accounts payable	(5,647)	(1,125)
Accrued liabilities	2,640	(10,663)
Net cash provided by operating activities	57,058	55,598
Investing Activities
Purchases of property and equipment	(1,380)	(2,319)
Proceeds from sale of property and equipment	0	3
Proceeds from the sale of business	18,500	0
Acquisition of Insight Pharmaceuticals, less cash acquired	(749,666)	0
Acquisition of Hydralyte	(77,991)	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	(55,215)
Intercompany activity, net	0	0
Net cash provided by (used in) investing activities	(810,537)	(57,531)
Financing Activities
Term loan borrowings	720,000	0
Term loan repayments	(25,000)	(7,500)
Repayments under revolving credit agreement	(58,500)	(35,500)
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	(16,072)	(275)
Proceeds from exercise of stock options	2,757	5,143
Proceeds from restricted stock exercises	57	0
Excess tax benefits from share-based awards	1,030	1,350
Fair value of shares surrendered as payment of tax withholding	(1,660)	(278)
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	747,212	12,940
Effects of exchange rate changes on cash and cash equivalents	(316)	156
(Decrease) Increase in cash and cash equivalents	(6,583)	11,163
Cash and cash equivalents - beginning of period	28,331	15,670
Cash and cash equivalents - end of period	21,748	26,833
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	33,195	53,484
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	1,512	1,034
Deferred income taxes	(879)	(14)
Amortization of deferred financing costs		0
Stock-based compensation costs	3,403	2,487
Amortization of debt discount		0
Gain (loss) on sale of assets		0
Equity in income of subsidiaries	(33,256)	(50,199)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	466	(112)
Inventories	0	0
Prepaid expenses and other current assets	5,163	2,656
Accounts payable	(2,332)	(517)
Accrued liabilities	(1,321)	(6,218)
Net cash provided by operating activities	5,951	2,601
Investing Activities
Purchases of property and equipment	(1,127)	(2,216)
Proceeds from sale of property and equipment		0
Proceeds from the sale of business	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of Hydralyte	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash provided by (used in) investing activities	(1,127)	(2,216)
Financing Activities
Term loan borrowings
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	2,757	5,143
Proceeds from restricted stock exercises	57
Excess tax benefits from share-based awards	1,030	1,350
Fair value of shares surrendered as payment of tax withholding	(1,660)	(278)
Intercompany activity, net	(21,187)	2,347
Net cash provided by (used in) financing activities	(19,003)	8,562
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	(14,179)	8,947
Cash and cash equivalents - beginning of period	24,644	14,720
Cash and cash equivalents - end of period	10,465	23,667
Prestige Brands, Inc., the issuer or the borrower
Operating Activities
Net income (loss)	33,131	47,349
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	290	285
Deferred income taxes	1,351	(642)
Amortization of deferred financing costs	2,398	1,975
Stock-based compensation costs		0
Amortization of debt discount	687	798
Gain (loss) on sale of assets		0
Equity in income of subsidiaries	(20,723)	(35,152)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(107)	996
Inventories	4,691	(1,975)
Prepaid expenses and other current assets	(241)	(147)
Accounts payable	1,850	(1,296)
Accrued liabilities	3,313	177
Net cash provided by operating activities	26,640	12,368
Investing Activities
Purchases of property and equipment		0
Proceeds from sale of property and equipment		0
Proceeds from the sale of business	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of Hydralyte	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net	(809,157)	(55,215)
Net cash provided by (used in) investing activities	(809,157)	(55,215)
Financing Activities
Term loan borrowings	720,000
Term loan repayments	(25,000)	(7,500)
Repayments under revolving credit agreement	(58,500)	(35,500)
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	(16,072)	(275)
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	37,489	36,122
Net cash provided by (used in) financing activities	782,517	42,847
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	20,826	38,003
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,818	5,184
Deferred income taxes	11,084	5,011
Amortization of deferred financing costs		0
Stock-based compensation costs		0
Amortization of debt discount		0
Gain (loss) on sale of assets	0	(3)
Equity in income of subsidiaries	(911)	(1,868)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(4,496)	(5,323)
Inventories	1,857	3,073
Prepaid expenses and other current assets	(1,718)	(787)
Accounts payable	(6,997)	(1,473)
Accrued liabilities	(701)	(3,011)
Net cash provided by operating activities	23,762	38,806
Investing Activities
Purchases of property and equipment	(87)	0
Proceeds from sale of property and equipment		3
Proceeds from the sale of business	18,500
Acquisition of Insight Pharmaceuticals, less cash acquired	(749,666)
Acquisition of Hydralyte	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net	731,166	0
Net cash provided by (used in) investing activities	(87)	3
Financing Activities
Term loan borrowings
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	(18,641)	(38,809)
Net cash provided by (used in) financing activities	(18,641)	(38,809)
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	5,034	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	5,034	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	911	1,867
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	195	59
Deferred income taxes	(60)	0
Amortization of deferred financing costs		0
Stock-based compensation costs		0
Amortization of debt discount		0
Gain (loss) on sale of assets	56	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(4,226)	(1,273)
Inventories	738	(277)
Prepaid expenses and other current assets	(90)	493
Accounts payable	1,832	2,161
Accrued liabilities	1,349	(1,207)
Net cash provided by operating activities	705	1,823
Investing Activities
Purchases of property and equipment	(166)	(103)
Proceeds from sale of property and equipment		0
Proceeds from the sale of business	0
Acquisition of Insight Pharmaceuticals, less cash acquired
Acquisition of Hydralyte	(77,991)
Acquisition of Care Pharmaceuticals, less cash acquired		(55,215)
Intercompany activity, net	77,991	55,215
Net cash provided by (used in) investing activities	(166)	(103)
Financing Activities
Term loan borrowings
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	2,339	340
Net cash provided by (used in) financing activities	2,339	340
Effects of exchange rate changes on cash and cash equivalents	(316)	156
(Decrease) Increase in cash and cash equivalents	2,562	2,216
Cash and cash equivalents - beginning of period	3,687	950
Cash and cash equivalents - end of period	6,249	3,166
Eliminations
Operating Activities
Net income (loss)	(54,868)	(87,219)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	0	0
Deferred income taxes	0	0
Amortization of deferred financing costs		0
Stock-based compensation costs		0
Amortization of debt discount		0
Gain (loss) on sale of assets		0
Equity in income of subsidiaries	54,890	87,219
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0
Inventories	(22)	0
Prepaid expenses and other current assets	0	404
Accounts payable	0	0
Accrued liabilities	0	(404)
Net cash provided by operating activities	0	0
Investing Activities
Purchases of property and equipment		0
Proceeds from sale of property and equipment		0
Proceeds from the sale of business	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of Hydralyte	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net		0
Net cash provided by (used in) investing activities	0	0
Financing Activities
Term loan borrowings
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) Increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$ 0	$ 0

XML

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	52,426,000	52,021,000
Treasury stock, shares	254,000	206,000

XML

Intangible Assets

6 Months Ended

Sep. 30, 2014

Intangible Assets [Abstract]

Intangible Assets

Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:

(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Totals
Gross Carrying Amounts
Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
Additions	673,180			124,774			797,954
Reductions	—			(17,674		)	(17,674		)
Effects of foreign currency exchange rates	(6,000		)	(95		)	(6,095		)
Balance — September 30, 2014	1,941,058			311,745			2,252,803
Accumulated Amortization
Balance — March 31, 2014	—			83,801			83,801
Additions	—			5,064			5,064
Effects of foreign currency exchange rates	—			(9		)	(9		)
Balance — September 30, 2014	—			88,856			88,856
Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947
Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,723,498		$	196,145		$	1,919,643
International OTC Healthcare	97,740			1,449			99,189
Household Cleaning	119,820			25,295			145,115
Intangible assets, net - September 30, 2014	$	1,941,058		$	222,889		$	2,163,947

As discussed in Note 2, we completed two acquisitions during the six months ended September 30, 2014. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014 we sold one of the brands that we acquired from Insight, for which we allocated $17.7 million to the intangible assets.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount.  Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life.  Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.

In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the fourth quarter of fiscal 2014.  We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of September 30, 2014 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the six months ended September 30, 2014.

The weighted average remaining life for finite-lived intangible assets at September 30, 2014 was approximately 14.5 years and the amortization expense for the three and six months ended September 30, 2014 was $2.8 million and $5.1 million, respectively. At September 30, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:

(In thousands)
Year Ending March 31,	Amount
2015 (Remaining six months ending March 31, 2015)	$	7,740
2016	15,554
2017	15,554
2018	15,554
2019	15,554
Thereafter	152,933
	$	222,889

XML

Goodwill

6 Months Ended

Sep. 30, 2014

Goodwill [Abstract]

Goodwill

Goodwill

As described in Note 18 to these Consolidated Financial Statements, we have realigned our reportable segments with how we currently operate, review and evaluate the results of our business. A reconciliation of the activity affecting goodwill by reportable segment is as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare			Household Cleaning		Consolidated
Balance — March 31, 2014	$	160,157	$	23,365		$	7,389	$	190,911
Additions	103,254		1,224			—		104,478
Effects of foreign currency exchange rates	—		(1,396		)	—		(1,396		)
Balance — September 30, 2014	$	263,411	$	23,193		$	7,389	$	293,993

As discussed in Note 2, we completed two acquisitions during the six months ended September 30, 2014. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.3 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.

On an annual basis, during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of the values assigned to goodwill and tests for impairment.

At March 31, 2014, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2014. As of September 30, 2014, there have been no triggering events that would indicate potential impairment of goodwill.

The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value that is utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2014, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

XML

Business Segments

6 Months Ended

Sep. 30, 2014

Segment Reporting [Abstract]

Business Segments

Business Segments

Beginning April 1, 2014, we began managing and reporting certain of our businesses separately and have therefore realigned our reportable segments to align with how we manage and evaluate the results of our business. These reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. The results of our previously reported OTC Healthcare segment is now separated into two reporting segments, the North American OTC Healthcare segment and the International OTC Healthcare segment, largely to reflect our international expansion due to recent acquisitions. Prior year amounts were reclassified to conform to the current reportable segments discussed above. Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our reportable segments.

	Three Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	138,138		$	17,331	$	25,246	$	180,715
Elimination of intersegment revenues	(710		)	—		—		(710		)
Third-party segment revenues	137,428			17,331		25,246		180,005
Other revenues	150			23		1,091		1,264
Total segment revenues	137,578			17,354		26,337		181,269
Cost of sales	52,185			6,595		19,947		78,727
Gross profit	85,393			10,759		6,390		102,542
Advertising and promotion	21,442			3,035		567		25,044
Contribution margin	$	63,951		$	7,724	$	5,823	77,498
Other operating expenses								30,980
Operating income								46,518
Other expense								18,193
Income before income taxes								28,325
Provision for income taxes								11,862
Net income								$	16,463

	Six Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	249,112		$	31,022	$	45,839	$	325,973
Elimination of intersegment revenues	(1,427		)	—		—		(1,427		)
Third-party segment revenues	247,685			31,022		45,839		324,546
Other revenues	327			58		2,040		2,425
Total segment revenues	248,012			31,080		47,879		326,971
Cost of sales	94,526			11,679		36,358		142,563
Gross profit	153,486			19,401		11,521		184,408
Advertising and promotion	37,794			5,375		971		44,140
Contribution margin	$	115,692		$	14,026	$	10,550	140,268
Other operating expenses								50,947
Operating income								89,321
Other expense								32,846
Income before income taxes								56,475
Provision for income taxes								23,280
Net income								$	33,195

	Three Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	132,944		$	9,008	$	24,374	$	166,326
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	132,125			9,008		24,374		165,507
Other revenues	150			7		1,281		1,438
Total segment revenues	132,275			9,015		25,655		166,945
Cost of sales	50,987			4,338		18,398		73,723
Gross profit	81,288			4,677		7,257		93,222
Advertising and promotion	22,547			1,446		554		24,547
Contribution margin	$	58,741		$	3,231	$	6,703	68,675
Other operating expenses								14,913
Operating income								53,762
Other expense								16,439
Income before income taxes								37,323
Provision for income taxes								4,531
Net income								$	32,792

	Six Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues	$	251,880		$	12,422	$	43,666	$	307,968
Elimination of intersegment revenues	(819		)	—		—		(819		)
Third-party segment revenues	251,061			12,422		43,666		307,149
Other revenues	300			14		1,994		2,308
Total segment revenues	251,361			12,436		45,660		309,457
Cost of sales	94,533			5,803		32,875		133,211
Gross profit	156,828			6,633		12,785		176,246
Advertising and promotion	40,097			1,710		1,421		43,228
Contribution margin	$	116,731		$	4,923	$	11,364	133,018
Other operating expenses								29,815
Operating income								103,203
Other expense								32,344
Income before income taxes								70,859
Provision for income taxes								17,375
Net income								$	53,484

The tables below summarize information about our segment revenues from similar product groups.

	Three Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,072	$	792	$	—	$	29,864
Cough & Cold	24,771		5,460		—		30,231
Women's Health	9,119		658		—		9,777
Gastrointestinal	20,896		5,598		—		26,494
Eye & Ear Care	21,405		4,028		—		25,433
Dermatologicals	17,459		687		—		18,146
Oral Care	12,934		127		—		13,061
Other OTC	1,922		4		—		1,926
Household Cleaning	—		—		26,337		26,337
Total segment revenues	$	137,578	$	17,354	$	26,337	$	181,269

	Six Months Ended September 30, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	54,103	$	1,457	$	—	$	55,560
Cough & Cold	44,814		10,259		—		55,073
Women's Health	9,487		1,176				10,663
Gastrointestinal	41,534		8,096		—		49,630
Eye & Ear Care	42,130		8,670		—		50,800
Dermatologicals	29,720		1,229		—		30,949
Oral Care	23,121		189		—		23,310
Other OTC	3,103		4		—		3,107
Household Cleaning	—		—		47,879		47,879
Total segment revenues	$	248,012	$	31,080	$	47,879	$	326,971

	Three Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	29,343	$	698	$	—	$	30,041
Cough & Cold	28,695		5,023		—		33,718
Women's Health	501		633		—		1,134
Gastrointestinal	21,695		301		—		21,996
Eye & Ear Care	19,378		1,625		—		21,003
Dermatologicals	17,716		605		—		18,321
Oral Care	13,028		130		—		13,158
Other OTC	1,919		—		—		1,919
Household Cleaning	—		—		25,655		25,655
Total segment revenues	$	132,275	$	9,015	$	25,655	$	166,945

	Six Months Ended September 30, 2013
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	57,479	$	727	$	—	$	58,206
Cough & Cold	49,193		6,006		—		55,199
Women's Health	988		633		—		1,621
Gastrointestinal	43,453		312		—		43,765
Eye & Ear Care	39,710		3,885		—		43,595
Dermatologicals	32,347		696		—		33,043
Oral Care	24,114		177		—		24,291
Other OTC	4,077		—		—		4,077
Household Cleaning	—		—		45,660		45,660
Total segment revenues	$	251,361	$	12,436	$	45,660	$	309,457

During the three months ended September 30, 2014 and September 30, 2013, approximately 82.7% and 86.9%, respectively of our total segment revenues were from customers in the United States. During the six months ended September 30, 2014 and September 30, 2013, approximately 83.5% and 87.8%, respectively of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended September 30, 2014, our Canada and Australia sales accounted for approximately 7.4% and 8.1%, respectively, of our total segment revenues, while during the three months ended September 30, 2013, approximately 7.2% of our total segment revenues was attributable to sales to Canada. During the six months ended September 30, 2014, our Canada and Australia sales accounted for approximately 6.6% and 7.6%, respectively, of our total segment revenues, while during the six months ended September 30, 2013, approximately 7.6% of our total segment revenues was attributable to sales to Canada.

At September 30, 2014, approximately 95.0% of our consolidated goodwill and intangible assets were located in the United States and approximately 5.0% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:

(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	23,193	$	7,389	$	293,993
Intangible assets
Indefinite-lived	1,723,498		97,740		119,820		1,941,058
Finite-lived	196,145		1,449		25,295		222,889
Intangible assets, net	1,919,643		99,189		145,115		2,163,947
Total	$	2,183,054	$	122,382	$	152,504	$	2,457,940

XML

Share-Based Compensation

6 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. On June 19, 2014, the Board of Directors amended the Plan to provide for the grant of an additional 1.8 million shares of the Company's stock, $0.01 par value, pursuant to the Plan, which amendment the Company's stockholders approved on August 5, 2014.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three and six months ended September 30, 2014, pre-tax share-based compensation costs charged against income were $1.5 million and $3.4 million, respectively, and the related income tax benefit recognized was $0.5 million and $1.2 million, respectively. During the three and six months ended September 30, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $2.5 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.7 million, respectively.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets.  The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan.  The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant, unless specified differently on the date of grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

On May 12, 2014, the Compensation Committee of our Board of Directors granted 96,638 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 75,638 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 21,000 restricted stock units vest 33.3% per year over three years.

The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the six months ended September 30, 2014 and 2013 was $33.30 and $30.19, respectively.

A summary of the Company's restricted shares granted under the Plan is presented below:

Restricted Shares	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Six months ended September 30, 2013
Vested and nonvested at March 31, 2013	421.3		$	11.01
Granted	120.6		30.19
Vested and issued	(54.7	)	8.11
Forfeited	(3.6	)	13.24
Vested and nonvested at September 30, 2013	483.6		16.11
Vested at September 30, 2013	83.1		9.63
Six months ended September 30, 2014:
Vested and nonvested at March 31, 2014	437.5		$	16.76
Granted	104.4		33.30
Vested and issued	(120.7	)	13.34
Forfeited	(14.4	)	20.78
Vested and nonvested at September 30, 2014	406.8		21.88
Vested at September 30, 2014	76.6		11.62

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted.  Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years.  The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies.  We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors.  Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation.  The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding.  The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option.  On May 12, 2014, the Compensation Committee of our Board of Directors granted stock options to acquire 307,490 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $33.50 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

The weighted-average grant-date fair value of the options granted during the six months ended September 30, 2014 and 2013 was $15.93 and $13.94, respectively.

	Six Months Ended September 30,
	2014			2013
Expected volatility	47.3		%	48.0		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.0
Risk-free rate	2.2		%	1.3		%

A summary of option activity under the Plan is as follows:

Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Six months ended September 30, 2013:
Outstanding at March 31, 2013	1,386.4		$	10.43
Granted	227.7		29.94
Exercised	(539.4	)	9.54
Forfeited or expired	(8.0	)	13.24
Outstanding at September 30, 2013	1,066.7		15.02		6.5	$	16,110
Exercisable at September 30, 2013	225.5		11.42		7.7	4,216
Six months ended September 30, 2014:
Outstanding at March 31, 2014	994.9		$	15.24
Granted	307.5		33.50
Exercised	(284.4	)	9.70
Forfeited or expired	(32.5	)	25.61
Outstanding at September 30, 2014	985.5		22.19		8.0	$	10,364
Exercisable at September 30, 2014	416.0		14.31		6.8	7,514

The aggregate intrinsic value of options exercised in the six months ended September 30, 2014 was $7.1 million.

At September 30, 2014, there were $7.4 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest.  We expect to recognize such costs over a weighted-average period of 1.0 year.  The total fair value of options and restricted shares vested during the six months ended September 30, 2014 and 2013 was $4.2 million and $3.2 million, respectively.  For the six months ended September 30, 2014 and 2013, cash received from the exercise of stock options was $2.8 million and $5.1 million, respectively, and we realized $1.8 million and $1.7 million, respectively, in tax benefits from the tax deductions resulting from these option exercises. At September 30, 2014, there were 1.2 million shares available for issuance under the Plan.

XML

Fair Value Measurements

6 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the Term B-1 Loan, Term B-2 Loan, the 2013 Senior Notes, the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At September 30, 2014 and March 31, 2014, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

At September 30, 2014 and March 31, 2014, the carrying value of our 2013 Senior Notes was $400.0 million. The fair value of our 2013 Senior Notes was $377.0 million and $408.5 million at September 30, 2014 and March 31, 2014, respectively.

At September 30, 2014 and March 31, 2014, the carrying value of our 2012 Senior Notes was $250.0 million. The fair value of our 2012 Senior Notes was $266.9 million and $280.6 million at September 30, 2014 and March 31, 2014, respectively.

At September 30, 2014 and March 31, 2014, the carrying value of the Term B-1 Loan was $262.5 million. The fair value of the Term B-1 Loan was $261.2 million and $288.9 million at September 30, 2014 and March 31, 2014, respectively.

At September 30, 2014 the carrying value of the Term B-2 Loan was $720.0 million. The fair value of the Term B-2 Loan was $718.2 million at September 30, 2014. Because the Term B-2 Loan was entered into on September 3, 2014, there were no outstanding loan balances as of March 31, 2014.

At September 30, 2014, the carrying value and fair value of the 2012 ABL Revolver was $66.1 million. There were no outstanding borrowings under the 2012 ABL Revolver at March 31, 2014.

XML

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Debt Disclosure [Abstract]
2015 (remaining six months ending March 31, 2015)	$ 3,600
2016	7,200
2017	73,300
2018	7,200
2019	269,700
Thereafter	1,337,600
Long-term debt, gross	$ 1,698,600	$ 937,500

XML

Other Accrued Liabilities

6 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Other Accrued Liabilities

Other Accrued Liabilities

Other accrued liabilities consist of the following:

(In thousands)	September 30, 2014		March 31, 2014
Accrued marketing costs	$	16,187	$	11,812
Accrued compensation costs	5,129		6,232
Accrued broker commissions	851		1,019
Income taxes payable	1,186		1,854
Accrued professional fees	2,344		2,002
Deferred rent	1,109		1,258
Accrued production costs	3,364		1,506
Other accrued liabilities	3,916		763
	$	34,086	$	26,446

XML

Long-Term Debt

6 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Long-Term Debt

Long-Term Debt

2012 Senior Notes:

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loan"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date.  In addition, Term Loan Amendment No.1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loan") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including but not limited to additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief and (iii) an interest rate on (x) the Term B-1 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin, and (y) the Term B-2 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). Under the Term Loan Amendment No.2, we are required to make quarterly payments each equal to 0.25% of the original principal amount of the Term B-2 Loan, with the balance expected to be due on the seventh anniversary of the closing date. Therefore, we have presented $7.2 million of current portion of long term debt as of September 30, 2014.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%. For the six months ended September 30, 2014, the average interest rate on the 2012 Term Loan was 4.9%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.

On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2014, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 3.7%.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Redemptions and Restrictions:

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At September 30, 2014, we were in compliance with the covenants under our long-term indebtedness.

At September 30, 2014, we had an aggregate of $32.9 million of unamortized debt issuance costs and $6.3 million of unamortized debt discount, the total of which is comprised of $9.4 million related to the 2012 Senior Notes, $6.6 million related to the 2013 Senior Notes, $21.8 million related to the 2012 Term Loan, and $1.4 million related to the 2012 ABL Revolver.

During the six months ended September 30, 2014, we borrowed a net amount of $66.1 million against the 2012 ABL Revolver.

Long-term debt consists of the following, as of the dates indicated:

(In thousands, except percentages)	September 30, 2014			March 31, 2014
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	262,500			287,500
2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	720,000			—
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
	1,698,600			937,500
Current portion of long-term debt	7,200			—
	1,691,400			937,500
Less: unamortized discount	(6,289		)	(3,086		)
Long-term debt, net of unamortized discount	$	1,685,111		$	934,414

As of September 30, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:

(In thousands)
Year Ending March 31,	Amount
2015 (remaining six months ending March 31, 2015)	$	3,600
2016	7,200
2017	73,300
2018	7,200
2019	269,700
Thereafter	1,337,600
	$	1,698,600

XML

Stockholders' Equity

6 Months Ended

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Stockholders' Equity

The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends.  No dividends have been declared or paid on the Company's common stock through September 30, 2014.

During the three and six months ended September 30, 2014, we repurchased 13,924 shares and 47,664 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the three and six months ended September 30, 2013, we repurchased zero shares and 10,726 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the six months ended September 30, 2014 and 2013 were at an average price of $33.63 and $25.96, respectively. All of the repurchased shares have been recorded as treasury stock.

XML

Earnings Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator
Net income	$ 16,463	$ 32,792	$ 33,195	$ 53,484
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	52,088	51,463	52,023	51,343
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)	506	756	541	787
Denominator for diluted earnings per share (in shares)	52,594	52,219	52,564	52,130
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.32	$ 0.64	$ 0.64	$ 1.04
Diluted net earnings per share (in USD per share)	$ 0.31	$ 0.63	$ 0.63	$ 1.03

XML

Share-Based Compensation (Narrative) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended			0 Months Ended		0 Months Ended	6 Months Ended							0 Months Ended	6 Months Ended	0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Aug. 28, 2014 2005 Long-Term Incentive Plan	Aug. 28, 2014 2005 Long-Term Incentive Plan	May 12, 2014 Restricted Shares	Sep. 30, 2014 Restricted Shares	Sep. 30, 2013 Restricted Shares	Sep. 30, 2014 Restricted Shares Minimum	Sep. 30, 2014 Restricted Shares Maximum	Sep. 30, 2014 Stock Options Minimum	Sep. 30, 2014 Stock Options Maximum	Sep. 30, 2014 Employee Restricted Shares	May 12, 2014 Employee Stock Options	Sep. 30, 2014 Director Restricted Shares	May 12, 2014 Group One Restricted Shares	May 12, 2014 Group Two Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan	5,000,000		5,000,000
Share-based compensation arrangement by share-based payment award, number of additional shares authorized						1,800,000
Common stock, par value (in USD per share)	$ 0.01		$ 0.01		$ 0.01		$ 0.01
Share-based compensation costs charged against income	$ 1.5	$ 1.3	$ 3.4	$ 2.5
Tax benefit recognized from share-based compensation expense	0.5	0.3	1.2	0.7
Restricted Shares
Award vesting period								3 years			3 years	5 years	3 years	5 years	3 years	3 years	1 year
Granted in period (in shares)								96,638										75,638	21,000
Percentage of stock units vesting annually								33.30%								33.30%
Granted, weighted-average grant-date fair value (in USD per share)									$ 33.30	$ 30.19
Options, Additional Disclosures:
Award exercisability period, from date of grant														10 years		10 years
Options granted in period																307,490
Options granted, weighted-average grant-date fair value (in USD per share)			$ 15.93	$ 13.94												$ 33.50
Options exercised, aggregate intrinsic value			7.1
Unrecognized compensation costs related to nonvested awards	7.4		7.4
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition			1 year 0 months
Total fair value of vested shares			4.2	3.2
Cash received from exercise of stock options			2.8	5.1
Tax benefit realized from exercise of stock options			$ 1.8	$ 1.7
Shares available for issuance under the Plan	1,200,000		1,200,000

XML

Accumulated Other Comprehensive (Loss) Income (Components of AOCI) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Accumulated Other Comprehensive Income [Abstract]
Cumulative translation adjustment	$ (7,365)	$ 739
Total accumulated other comprehensive (loss) income, net of tax	$ (7,365)	$ 739

XML

Long-Term Debt (Tables)

6 Months Ended

Sep. 30, 2014

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:

(In thousands, except percentages)	September 30, 2014			March 31, 2014
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	262,500			287,500
2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	720,000			—
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
	1,698,600			937,500
Current portion of long-term debt	7,200			—
	1,691,400			937,500
Less: unamortized discount	(6,289		)	(3,086		)
Long-term debt, net of unamortized discount	$	1,685,111		$	934,414

Aggregate Future Principal Payments

As of September 30, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:

(In thousands)
Year Ending March 31,	Amount
2015 (remaining six months ending March 31, 2015)	$	3,600
2016	7,200
2017	73,300
2018	7,200
2019	269,700
Thereafter	1,337,600
	$	1,698,600

XML

Intangible Assets Schedule of Reconciliation of Activity Affecting Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Mar. 31, 2014
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$ 1,941,058	$ 1,941,058
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions	2,800	5,064
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		(9)
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance		1,478,618
Totals, additions		797,954
Totals, reductions		(17,674)
Totals, effects of foreign currency exchange rate		(6,095)
Totals, gross, ending balance	2,252,803	2,252,803
Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, beginning balance		83,801
Intangible assets, accumulated amortization, additions	2,800	5,064
Totals, accumulated amortization, ending balance	88,856	88,856
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	222,889	222,889
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	2,163,947	2,163,947	1,394,817
North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	1,723,498	1,723,498
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	196,145	196,145
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	1,919,643	1,919,643
International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	97,740	97,740
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,449	1,449
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	99,189	99,189
Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	119,820	119,820
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	25,295	25,295
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	145,115	145,115
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		1,273,878
Indefinite-lived Intangible Assets Acquired		673,180
Indefinite Lived Trademarks, reductions		0
Indefinite Lived Trademarks, effects of foreign currency exchange rate		(6,000)
Indefinite Lived Trademarks, ending balance	1,941,058	1,941,058
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks, beginning balance		204,740
Finite Lived Trademarks, additions		124,774
Finite Lived Trademarks, reductions		(17,674)
Finite Lived Trademarks, effects of foreign currency exchange rate		(95)
Finite Lived Trademarks, ending balance	311,745	311,745
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks, accumulated amortization, beginning balance		83,801
Intangible assets, accumulated amortization, additions		5,064
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		(9)
Finite Lived Trademarks, accumulated amortization, ending balance	88,856	88,856
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		5,064
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	$ 222,889	$ 222,889

XML

Commitments and Contingencies

6 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

We are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. We required additional office space as a result of the closing of the acquisition of Insight. Therefore, in the first quarter of fiscal 2015, we amended our existing New York office lease to include an additional 15,470 square feet beginning October 2014 and extended the expiration of the combined lease through September 2020. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases as of September 30, 2014:

(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2015 (Remaining six months ending March 31, 2015)	$	859	$	344	$	1,203
2016	1,612		311		1,923
2017	1,772		77		1,849
2018	1,856		—		1,856
2019	1,864		—		1,864
Thereafter	2,465		—		2,465
	$	10,428	$	732	$	11,160

Rent expense for each of the three months ended September 30, 2014 and 2013 was $0.3 million and $0.5 million, respectively, while rent expense for each of the six months ended September 30, 2014 and 2013 was $0.7 million and $0.8 million, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products.  Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.

(In thousands)
Year Ending March 31,	Amount
2015 (Remaining six months ending March 31, 2015)	$	549
2016	1,074
2017	1,044
2018	1,013
2019	982
Thereafter	560
	$	5,222

XML

Business and Basis of Presentation (Tables)

6 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

XML

Property and Equipment (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Components of Property and Equipment
Property and equipment, gross	$ 21,954,000		$ 21,954,000		$ 17,442,000
Accumulated depreciation	(9,534,000)		(9,534,000)		(7,845,000)
Property and equipment, net	12,420,000		12,420,000		9,597,000
Depreciation	900,000	500,000	1,600,000	1,100,000
Machinery
Components of Property and Equipment
Property and equipment, gross	4,245,000		4,245,000		1,927,000
Computer equipment and software
Components of Property and Equipment
Property and equipment, gross	10,183,000		10,183,000		8,923,000
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,703,000		2,703,000		1,858,000
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 4,823,000		$ 4,823,000		$ 4,734,000

XML

Business and Basis of Presentation (Property and Equipment) (Details)	6 Months Ended
	Sep. 30, 2014
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives		[1]

[1] Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating Activities
Net income	$ 33,195	$ 53,484
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,815	6,562
Deferred income taxes	11,496	4,355
Amortization of deferred financing costs	2,398	1,975
Stock-based compensation costs	3,403	2,487
Amortization of debt discount	687	798
Loss (Gain) on sale or disposal of property and equipment	56	(3)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(8,363)	(5,712)
Inventories	7,264	821
Prepaid expenses and other current assets	3,114	2,619
Accounts payable	(5,647)	(1,125)
Accrued liabilities	2,640	(10,663)
Net cash provided by operating activities	57,058	55,598
Investing Activities
Purchases of property and equipment	(1,380)	(2,319)
Proceeds from the sale of property and equipment	0	3
Proceeds from sale of business	18,500	0
Acquisition of Insight Pharmaceuticals, less cash acquired	(749,666)	0
Acquisition of the Hydralyte brand	(77,991)	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	(55,215)
Net cash provided by (used in) investing activities	(810,537)	(57,531)
Financing Activities
Term loan borrowings	720,000	0
Term loan repayments	(25,000)	(7,500)
Repayments under revolving credit agreement	(58,500)	(35,500)
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	(16,072)	(275)
Proceeds from exercise of stock options	2,757	5,143
Proceeds from restricted stock exercises	57	0
Excess tax benefits from share-based awards	1,030	1,350
Fair value of shares surrendered as payment of tax withholding	(1,660)	(278)
Net cash provided by (used in) financing activities	747,212	12,940
Effects of exchange rate changes on cash and cash equivalents	(316)	156
(Decrease) Increase in cash and cash equivalents	(6,583)	11,163
Cash and cash equivalents - beginning of period	28,331	15,670
Cash and cash equivalents - end of period	21,748	26,833
Interest paid	27,349	29,516
Income taxes paid	$ 4,716	$ 8,468

XML

Property and Equipment

6 Months Ended

Sep. 30, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and Equipment

Property and equipment consist of the following:

(In thousands)	September 30, 2014			March 31, 2014
Components of Property and Equipment
Machinery	$	4,245		$	1,927
Computer equipment and software	10,183			8,923
Furniture and fixtures	2,703			1,858
Leasehold improvements	4,823			4,734
	21,954			17,442
Accumulated depreciation	(9,534		)	(7,845		)
Property and equipment, net	$	12,420		$	9,597

We recorded depreciation expense of $0.9 million and $0.5 million for the three months ended September 30, 2014 and September 30, 2013, respectively, and $1.6 million and $1.1 million for the six months ended September 30, 2014 and September 30, 2013, respectively.

XML

Long-Term Debt (Redemptions and Restrictions) (Details) (USD $)	6 Months Ended											6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Sep. 30, 2014 Senior Notes 2012 Senior Notes	Sep. 30, 2014 Senior Notes 2013 Senior Notes	Sep. 30, 2014 Term Loans 2012 Term Loan	Jan. 31, 2012 Prior to February 1, 2016 Senior Notes 2012 Senior Notes	Jan. 31, 2012 Prior to February 1, 2015 Senior Notes 2012 Senior Notes	Jan. 31, 2012 Upon Change in Control Senior Notes 2012 Senior Notes	Sep. 30, 2014 Prior to December 15, 2016 Senior Notes 2013 Senior Notes	Sep. 30, 2014 On Or After December 15, 2016 Senior Notes 2013 Senior Notes	Sep. 30, 2014 Revolving Credit Facility 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount					101.00%		100.00%	108.125%	101.00%	100.00%	105.375%
Debt instrument, percentage of principal amount eligible for redemption								35.00%		35.00%
Unamortized debt issuance costs	$ 32,900,000
Debt instrument, unamortized discount	6,289,000		3,086,000
Unamortized debt issuance expense and discount				9,400,000	6,600,000	21,800,000						1,400,000
Repayments of long-term debt	$ 25,000,000	$ 7,500,000										$ 66,100,000

XML

Share-Based Compensation (Stock Option Activity) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Shares
Outstanding, beginning of period (in shares)	994,900	1,386,400
Granted (in shares)	307,500	227,700
Exercised (in shares)	(284,400)	(539,400)
Forfeited or expired (in shares)	(32,500)	(8,000)
Outstanding, end of period (in shares)	985,500	1,066,700
Exercisable, end of period (in shares)	416,000	225,500
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 15.24	$ 10.43
Granted, weighted-average exercise price (in USD per share)	$ 33.50	$ 29.94
Exercised, weighted-average exercise price (in USD per share)	$ 9.70	$ 9.54
Forfeited or expired, weighted-average exercise price (in USD per share)	$ 25.61	$ 13.24
Outstanding, end of period, weighted-average exercise price (in USD per share)	$ 22.19	$ 15.02
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 14.31	$ 11.42
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	8 years	6 years 6 months
Exercisable, end of period, weighted-average remaining contractual term	6 years 9 months 18 days	7 years 8 months 12 days
Outstanding, end of period, aggregate intrinsic value	$ 10,364	$ 16,110
Exercisable, end of period, aggregate intrinsic value	$ 7,514	$ 4,216

XML

Acquisitions (Tables)

6 Months Ended

Sep. 30, 2014

Insight Pharmaceuticals

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.

(In thousands)	September 3, 2014
Cash acquired	$	3,507
Accounts receivable	25,784
Inventories	23,559
Deferred income tax assets - current	860
Prepaids and other current assets	1,407
Property, plant and equipment	2,308
Goodwill	103,255
Intangible Assets	724,374
Total assets acquired	885,054
Accounts payable	16,079
Accrued expenses	8,003
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	131,881
Total purchase price	$	753,173

Schedule of Pro Forma Information

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.

(In thousands, except per share data)	Six Months Ended September 30, 2014
Revenues	$	393,140
Net income	$	37,957
Earnings per share:
Basic	$	0.73
Diluted	$	0.72

(In thousands, except per share data)	Six Months Ended September 30, 2013
Revenues	$	389,490
Net income	$	53,511
Earnings per share:
Basic	$	1.04
Diluted	$	1.03

Hydralyte

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.

(In thousands)	April 30, 2014
Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041
Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Care Pharma

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.

(In thousands)	July 1, 2013
Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income taxes	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386
Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625
Net assets acquired	$	56,761

XML

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information, Profit (Loss):
Net sales	$ 180,005	$ 165,507	$ 324,546	$ 307,149
Other revenues	1,264	1,438	2,425	2,308
Total revenues	181,269	166,945	326,971	309,457
Cost of sales	78,727	73,723	142,563	133,211
Gross profit	102,542	93,222	184,408	176,246
Advertising and promotion	25,044	24,547	44,140	43,228
Contribution margin	77,498	68,675	140,268	133,018
Other operating expenses	30,980	14,913	50,947	29,815
Operating income	46,518	53,762	89,321	103,203
Other expense	18,193	16,439	32,846	32,344
Income before income taxes	28,325	37,323	56,475	70,859
Provision for income taxes	11,862	4,531	23,280	17,375
Net income	16,463	32,792	33,195	53,484
Geographic Concentration Risk | Sales
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage		10.00%
Geographic Concentration Risk | Sales | United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	82.70%	86.90%	83.50%	87.80%
Geographic Concentration Risk | Sales | Canada
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	7.40%	7.20%	6.60%	7.60%
Geographic Concentration Risk | Sales | Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage		8.10%	7.60%
Geographic Concentration Risk | Goodwill and Intangible Assets | United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			95.00%
Geographic Concentration Risk | Goodwill and Intangible Assets | Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			5.00%
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	137,428	132,125	247,685	251,061
Other revenues	150	150	327	300
Total revenues	137,578	132,275	248,012	251,361
Cost of sales	52,185	50,987	94,526	94,533
Gross profit	85,393	81,288	153,486	156,828
Advertising and promotion	21,442	22,547	37,794	40,097
Contribution margin	63,951	58,741	115,692	116,731
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	17,331	9,008	31,022	12,422
Other revenues	23	7	58	14
Total revenues	17,354	9,015	31,080	12,436
Cost of sales	6,595	4,338	11,679	5,803
Gross profit	10,759	4,677	19,401	6,633
Advertising and promotion	3,035	1,446	5,375	1,710
Contribution margin	7,724	3,231	14,026	4,923
Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	25,246	24,374	45,839	43,666
Other revenues	1,091	1,281	2,040	1,994
Total revenues	26,337	25,655	47,879	45,660
Cost of sales	19,947	18,398	36,358	32,875
Gross profit	6,390	7,257	11,521	12,785
Advertising and promotion	567	554	971	1,421
Contribution margin	5,823	6,703	10,550	11,364
Operating Segments
Segment Reporting Information, Profit (Loss):
Net sales	180,715	166,326	325,973	307,968
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	138,138	132,944	249,112	251,880
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	17,331	9,008	31,022	12,422
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	25,246	24,374	45,839	43,666
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Net sales	(710)	(819)	(1,427)	(819)
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	(710)	(819)	(1,427)	(819)
Intersegment Eliminations | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	0	0	0	0
Intersegment Eliminations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	$ 0	$ 0	$ 0	$ 0

XML

Commitments and Contingencies (Tables)

6 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases as of September 30, 2014:

(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2015 (Remaining six months ending March 31, 2015)	$	859	$	344	$	1,203
2016	1,612		311		1,923
2017	1,772		77		1,849
2018	1,856		—		1,856
2019	1,864		—		1,864
Thereafter	2,465		—		2,465
	$	10,428	$	732	$	11,160

Unrecorded Unconditional Purchase Obligations Disclosure

Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.

(In thousands)
Year Ending March 31,	Amount
2015 (Remaining six months ending March 31, 2015)	$	549
2016	1,074
2017	1,044
2018	1,013
2019	982
Thereafter	560
	$	5,222

XML

Income Taxes

6 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur.  The effective tax rates used in the calculation of income taxes were 41.9% and 12.1% for the three months ended September 30, 2014 and September 30, 2013, respectively. The effective tax rates used in the calculation of income taxes were 41.2% and 24.5%, for the six months ended September 30, 2014 and September 30, 2013, respectively. The increase in the effective tax rate for the three and six months ended September 30, 2014 was primarily due to the impact of certain non-deductible items related to acquisitions and state tax adjustments and a one-time benefit of $9.1 million to adjust our current and deferred tax balances as of September 30, 2013 for lower state income taxes. This benefit was primarily related to a law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only.

At September 30, 2014, wholly-owned subsidiaries of the Company had net operating loss carryforwards of approximately $78.2 million, which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020.  The net operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire.

We had no change in our uncertain tax liability during the six months ended September 30, 2014. Therefore, the balance in our uncertain tax liability was $1.2 million at September 30, 2014 and March 31, 2014. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense.  We did not incur any material interest or penalties related to income taxes in any of the periods presented.